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ABSTRACT
STOCHASTIC PROGRAMMING AND AGENT-BASED




This dissertation addresses the resource allocation challenges of fighting against
infectious disease outbreaks. The goal of this dissertation is to formulate multi-stage
stochastic programming and agent-based models to address the limitations of
former literature in optimizing resource allocation for preventing and controlling
epidemics and pandemics. In the first study, a multi-stage stochastic programming
compartmental model is presented to integrate the uncertain disease progression
and the logistics of resource allocation to control a highly contagious infectious
disease. The proposed multi-stage stochastic program, which involves various disease
growth scenarios, optimizes the distribution of treatment centers and resources while
minimizing the total expected number of new infections and funerals due to an
epidemic. Two new equity metrics are defined and formulated, namely infection
and capacity equity, to explicitly consider equity for allocating treatment funds and
facilities for fair resource allocation in epidemics control. The multi-stage value of the
stochastic solution (VSS), demonstrating the superiority of the proposed stochastic
programming model over its deterministic counterpart, is studied. The first model
is applied to the Ebola Virus Disease (EVD) case in West Africa, including Guinea,
Sierra Leone, and Liberia. In the following study, the previous model is extended
to a mean-risk multi-stage vaccine allocation model to capture the influence of the
outbreak scenarios with low probability but high impact. The Conditional Value at
Risk (CVaR) measure used in the model enables a trade-off between the weighted
expected loss due to the outbreak and expected risks associated with experiencing
disastrous epidemic scenarios. A method is developed to estimate the migration rate
between each infected region when limited migration data is available. The second
study is applied to the case of EVD in the Democratic Republic of the Congo.
In the third study, a new risk-averse multi-stage stochastic epidemics-ventilator-
logistics compartmental stochastic programming model is developed to address the
resource allocation challenges of mitigating COVID-19. This epidemiological logistics
model involves the uncertainty of untested asymptomatic infections and incorporates
short-term human migration. Disease transmission is also forecasted through deriving
a new formulation of transmission rates that evolve over space and time with respect
to various non-pharmaceutical interventions, such as wearing masks, social distancing,
and lockdown. In the fourth study, a simulation-optimization approach is introduced
to address the vaccination facility location and allocation challenges of the COVID-19
vaccines. A detailed agent-based simulation model of the COVID-19 is extended
and integrated with a new vaccination center and vaccine-allocation optimization
model. The proposed agent-based simulation-optimization framework simulates
the disease transmission first and then minimizes the total number of infections
over all the considered regions by choosing the optimal vaccine center locations
and vaccine allocation to those centers. Specifically, the simulation provides the
number of susceptible and infected individuals in each geographical region for the
current time period as an input into the optimization model. The optimization
model then minimizes the total number of estimated infections and provides the
new vaccine center locations and vaccine allocation decisions for the following time
period. Decisions are made on where to open vaccination centers and how many
people should be vaccinated at each future stage in each region of the considered
geographical location. Then these optimal decision values are imported back into
the simulation model to simulate the number of susceptible and infected individuals
for the subsequent periods. The agent-based simulation-optimization framework is
applied to controlling COVID-19 in the states of New Jersey. The results provide
insights into the optimal vaccine center location and vaccine allocation problem
under varying budgets and vaccine types while foreseeing potential epidemic growth
scenarios over time and spatial locations.
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Xuecheng Yin and İ. Esra Büyüktahtakın, “Risk-Averse Multi-stage Stochastic
Programming to Optimizing Vaccine Allocation and Logistics in Epidemics
Control,” Accepted for publication in IISE Transactions on Healthcare Systems
Engineering, 2021
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Human beings have suffered from epidemic diseases throughout their history. An
epidemic is the rapid spread of an infectious disease that affects a large number of
people. Epidemic diseases can disperse widely in a short time, usually two weeks
or less, such as influenza, meningitis, and cholera, impacting populations either in a
specific area or become a pandemic affecting the lives of millions at a global scale.
The outbreaks ruin the economy and weaken the healthcare systems in the region
where the epidemic locates. The situation can be even worse in impoverished areas
where millions of people do not have an opportunity to receive sufficient treatment.
Thus, the number of deaths and infections in poor regions with the epidemic will be
much higher than that in other regions. Although some countries may have ample
budget to control an outbreak, the shortage of the resource supply during the epidemic
still leads to many deaths, degradation in the quality of human life, and economic
impediments.
Infectious diseases have changed and continue to change the trajectory of
millions of people’s lives in both the short-term and long-term. The country, region,
and the world have more far-reaching impacts, and some are even irreversible. For
example, in 2003, Severe Acute Respiratory Syndrome (SARS) was found to infect
humans in South China. A doctor who was infected with the SARS virus in
Guangdong Province infected many people when he went to Hong Kong in February
2003. The infected people brought SARS to the rest of the world. The statistics show
that the global death toll from SARS is 919, with a fatality rate of nearly 11%. There
are 5,327 cases and 349 deaths in Mainland China; 1,755 cases and 300 deaths in
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Hong Kong; 665 cases and 180 deaths in Taiwan; 251 cases and 41 deaths in Canada;
238 cases and 33 deaths in Singapore; and 63 cases and 5 deaths in Vietnam [Haccp,
2020].
The H1N1 swine flu broke out in the United States in April 2009, and it was the
first outbreak of H1N1 swine flu in a population. The United States is one of the most
developed countries, and its response speed is very rapid. The first sample was found
on April 15, reported to the International Health Organization (WHO) on April 18,
vaccine development began on April 21, and the flue was disclosed to the public on
April 23. On April 25, only 10 days after the first sample was found, WHO declared
that the H1N1 epidemic had become a public health emergency of international
concern. On April 26, 2009, the US government also announced a nationwide public
health emergency, and the Centers for Disease Control and Prevention (CDC) began
to release the national strategic reserve. WHO and the US government attached
great importance to the epidemic. However, the flu epidemic spread rapidly at an
unstoppable rate. About one month after the first sample was discovered, the number
of infections exceeded 10,000 [Sina, 2021].
At the end of 2019, COVID-19 was detected in China, and suddenly, it spread all
over the world. The worldwide spread of COVID-19 caused lots of deaths. Until July
14, 2021, the total number of infections in the world is 188,124,452, and the number
of deaths is 4,053,386 [JHU, 2021]. The pandemic has also had adverse economic
impacts. Globally, more than one-sixth of young people are unemployed due to the
epidemic. Asian Development Bank statistics show that the global economic loss
caused by the epidemic is between 5.8 trillion and 8.8 trillion US dollars [News,
2020]. On the other hand, people who are not infected have suffered from losing their
relatives, and some lost their income due to the indirect economic influence of the
disease.
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Consequently, the high impact of epidemics on human life has motivated
researchers and practitioners to develop new methodologies to prevent and reduce
the effects of infectious diseases. For controlling epidemics, many interventions have
been widely used to treat humans and prevent them from getting infected, such as
contact tracing, isolation, and vaccination.
With the development of vaccines for different epidemics, people can be immune
to the disease, and the health impacts can be significantly reduced. However, for
a newly discovered disease, the production quantity of the treatment resource or
vaccination may not satisfy the high demand in the early period, and it is also difficult
to develop new vaccines. Treatment resources and vaccination supply are almost
always limited. In addition, the uncertainty of the epidemic transmission makes the
resource allocation decision even harder. The resource allocations decisions should be
made ahead of time before knowing the disease’s growth trajectory. Once the disease
transmission is beyond the estimation, the decisions taken in former time periods can
cause a big loss on the number of infections when the resources are limited. Thus,
tackling the resource allocation problem under uncertainty is critical for studying
logistic issues on epidemic control.
1.2 Literature Review
Operations Research (OR) and mathematical modeling methods have been widely
used to determine optimal resource allocation strategies to control an epidemic
disease. Those approaches include simulations [Siettos et al., 2015, Ajelli et al., 2016,
Kurahashi and Terano, 2015, Wells et al., 2015], differential equations [Craft et al.,
2005, Kaplan et al., 2003], network models [Berman and Gavious, 2007, Longini Jr
et al., 2007, Porco et al., 2004, Riley and Ferguson, 2006], resource allocation analysis
[Zaric et al., 2000, Tebbens and Thompson, 2009, Nguyen et al., 2017, Shaw and
Schwartz, 2010], stochastic compartmental models [Lekone and Finkenstädt, 2006,
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Tanner et al., 2008, Funk et al., 2017], and mathematical programming [Coşgun and
Büyüktahtakın, 2018, Büyüktahtakın et al., 2018a, Ren et al., 2013, Tanner et al.,
2008]. The following subsections present a review of the literature in epidemic control
and logistics in major categories and present motivations for this dissertation study.
1.2.1 Simulation, Compartmental, and Network Models
The majority of mathematical models in the epidemiological literature use simulation
methods to study the logistics of controlling epidemics [Meltzer et al., 2014, Dasaklis
et al., 2017, Pandey et al., 2014]. For instance, Rivers et al. [2014] perform simulations
of interventions on Ebola to inform public health efforts. They use existing data
to parameterize an Ebola Virus Disease (EVD) mathematical model that is used to
forecast the progression of the epidemic and the efficacy of several interventions. Their
results suggest that contact tracing and infection control, such as decreasing contact
rates in hospitals and funerals, have a substantial impact on the number of Ebola
cases, but they are not sufficient to halt the spread of the epidemic. On the other
hand, they find that the hypothetical pharmaceutical intervention had a smaller effect
on the forecast trajectory of the epidemic. Siettos et al. [2015] develop an agent-based
simulation model to investigate the dynamics of the Ebola epidemics. The estimated
values of key epidemiological variables are found to be very close to the ones reported
by the WHO Ebola response team. Jalvingh et al. [1999] modify the InterSpread
model for foot-and-mouth (FMD) disease for the case of the classical swine fever
(CSF) to evaluate the impact of control measures by changing the assumptions and
mechanisms for disease spread from FMD to CSF, and including CSF-specific control
measures based on the standard European Union (EU) regulations. They show that
InterSpread was a flexible tool that could be adapted to simulate another disease with
relative ease.
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Several studies have used stochastic compartmental models to analyze different
strategies for controlling epidemic diseases, such as vaccination strategies, behavioral
changes that impact the interaction between different groups, and regional inter-
vention strategies. Lekone and Finkenstädt [2006] use a stochastic discrete-time
approximation to the Susceptible-Exposed-Infectious-Recovered (SEIR) system to
model Ebola epidemics and introduced a Markov Chain Monte Carlo (MCMC)
simulation algorithm for parameter estimation. They find that intervention measures,
such as protective clothing, active surveillance, and community education, have
been successful in controlling the disease, and an earlier onset of the control
intervention could have saved many more lives. Funk et al. [2017] develop a
stochastic compartmental model to analyze the impact of behavior changes on the
elimination of Ebola. They report that the expansion of the Ebola Treatment
Center (ETC) capacity, occasional interruption of transmission, and improvement
in healthcare-seeking behavior contributed to mitigating the epidemic and eventually
stop it. Keeling et al. [2001] present an individual farm-based stochastic model of
the UK foot-and-mouth epidemic. They show that spatial distribution, size, and
species composition of farms influenced the observed pattern and regional variability
of the outbreak. Moreover, they assess the history and possible duration of the
epidemic, the performance of control strategies, such as movement restrictions, and
general implications for disease dynamics in space and time. Onal et al. [2019] present
an integrated simulation-optimization framework, which simulates the growth of an
agricultural epidemic and uses it as an input into the optimization model. The
simulation mimics the growth of an invasive plant over a landscape and multiple years,
while a bio-economic optimization model finds an optimal search and treatment path
to minimize its economic damage to agricultural production. They find that applying
yearly treatment with slow search-and-treatment speed results in the minimum
economic damage under most invasion scenarios.
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Nguyen et al. [2017] use a multi-scale model to explore Ebola vaccination
strategies. They combine a within-host viral dynamics model and a between-host
network model of the Ebola virus infection. Their results suggest that an early,
age-group specific, and high coverage vaccination program is the most beneficial
for controlling the Ebola virus disease. Ball et al. [1997] develop a Susceptible-
InfectedRecovered (SIR) model with both local mixing at the household level and
global mixing at the community level. Their results show that the allocation of
vaccines to those households with the largest number of unvaccinated individuals is
the best strategy for controlling an epidemic, given that the efficiency of the vaccine
is high. Shaw and Schwartz [2010] study vaccine control of disease spread on a new
adaptive network and compare their results with other network models. Their results
suggest that vaccine control is much more effective in their adaptive networks than
in static networks when the vaccination schedule is Poisson distributed.
Kelly et al. [2019a] employ a non-parametrically estimated Hawkes point process
model to generate multiple probabilistic projections of the ongoing 20182019 Ebola
Virus Disease (EVD) outbreak size in the Democratic Republic of the Congo (DRC).
They compare the forecast results with actual outbreak size under thee-, six-, and
nine-week time periods. Their results suggest that the Hawkes point process is an
easily-applied statistical model to predict EVD outbreak trajectories to better inform
decision-making and resource allocation. Dalziel et al. [2018] perform a retrospective
analysis on community deaths during the 2014 − 2016 Ebola epidemic in Sierra
Leone to estimate the number of unreported non-hospitalized cases. Moreover, they
quantify how Ebola reporting rates varied across locations and over time and tested if
variation in reporting rates affected the estimates of disease transmission rates. They
find significant variation in reporting rates among districts and district-specific rates
of increases in reporting over time. Thus, correcting for these reporting variations
improves the accuracy and precision of estimates of transmission patterns.
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Moreover, the literature has often utilized compartmental models with simulations
to study the strategies for controlling the Ebola Virus Disease. For example, Jiang
et al. [2017] construct a mathematical model to devise the optimal EVD eradication
plan. They build a modified epidemic model that takes hospital isolation, Ebola drug,
and vaccine into account and later verify the result with a Monte Carlo Algorithm.
They investigate the numerical spread of Ebola and eradication pathways, further fit
the model against the real total cases data, and calculated infection rate as 1.754.
Their results suggest that Ebola eradication requires systematic thinking, effective
hospital isolation, and effective EVD drug use and vaccination. Mizumoto et al. [2019]
present a quantified effective reproduction number of the ongoing Ebola virus disease
epidemic in the Democratic Republic of the Congo. They use the probability mass
function and cumulative distribution function of the gamma distribution to calculate
the expected number of new incident cases from February 2019 to September 2019.
Moreover, they use the next-generation matrix and Monte Carlo Markov Chain to
forecast the model parameter from September 2019 to October 2019. They suggest
that improving the security situation within the country would reduce the attacks
during the vaccination in the affected health zones and thus would have a positive
impact on the infection control practices. Rachah [2018] presents a deterministic
compartmental model for assessing the impact of isolation to contain the EVD in
Sierra Leone. He uses ordinary differential equations with different isolation strategies
and studied the numerical simulation in several scenarios. According to his results,
the isolation of latent detectable and infectious individuals is the most effective
strategy in curtailing the virus. Hart et al. [2019] consider the variation of symptoms
between different infection stages in the prediction of Ebola epidemics. They compare
the compartmental model that has constant symptoms level to the compartmental
model that accounts for various symptoms during infection and apply the models to
both EVD cases of the 2019 Democratic Republic of Congo (DRC) and 20142016
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Liberia with simulation. According to the results, when the level of surveillance is
increased, the various-symptoms model predicts a smaller number of cases than the
constant-symptoms model. This means that including different levels of symptoms
at different stages of infection in epidemiological models can alter predictions of the
effects of intervention strategies compared with assuming a fixed level of symptoms.
1.2.2 OR Models in Epidemic Resource Allocation
Optimal resource allocation is a core problem in many applications ranging from
epidemic control [Zaric and Brandeau, 2001, Tanner et al., 2008] to agriculture
[Cobuloglu and Büyüktahtakın, 2014, 2015, Kantas et al., 2015], production planning
[Hartman et al., 2010, Büyüktahtakın and Liu, 2016, Büyüktahtakın et al., 2018b],
and asset replacement [Büyüktahtakın et al., 2014b, Büyüktahtakın and Hartman,
2016, des Bordes and Büyüktahtakın, 2017]. Previous mathematical models that
study the epidemic diseases and resource allocation mainly focus on logistics and
operation management to control the disease in optimal ways. For example, Zaric and
Brandeau [2001] present an approximated operation research model for the allocation
of epidemic control resources among a set of interventions. Their results show that
approximations yield reasonable estimates of the objective function values when the
time horizon is on the order of five years or less. On the other hand, their model can
be used as part of effective heuristics for solving large instances of resource allocation.
Ekici et al. [2013] develop a disease spread model to estimate the spread pattern of
the disease and combined it with a facility location and resource allocation network
model for food distribution. They present the estimated number of infections and the
number of meals needed in each census tract for a one-year period.
Considering the capacity of hospitals and logistics issues, Büyüktahtakın et al.
[2018a] develop a new epidemic-logistics mixed-integer programming model of the
epidemic control problem. Their model considers the epidemic spreading over multiple
8
regions and the logistics simultaneously in a spatio-temporal setting. Different from
the classical epidemiological models, the transmission rate between the infected and
treated compartment is not constant but instead depended on the treatment capacity
and the number of infected people receiving treatment. Also, their model considers
the migration between regions to explain how movement patterns contribute to the
further spread of an epidemic. The authors further validate the predictions of the
model by demonstrating the impact of actual interventions. In the sensitivity analysis
of Büyüktahtakın et al. [2018a], the disease transmission rate within the community
is found to be the most critical parameter impacting infected and funerals. Later,
Liu et al. [2019] adapt the epidemics-logistics model of Büyüktahtakın et al. [2018a]
to study the control of the 2009 H1N1 outbreak in China and present similar results
for the H1N1 epidemic.
While the disease transmission rates are highly uncertain, relatively fewer
studies in the OR community take into account the uncertain parameters for resource
allocation in an effort to control the disease. Those OR models that integrate
resource allocation with epidemics control use either stochastic dynamic programming
(SDP) or two-stage stochastic programming [Coşgun and Büyüktahtakın, 2018, Long
et al., 2018, Ren et al., 2013, Yarmand et al., 2014, Tanner et al., 2008]. For
example, Coşgun and Büyüktahtakın [2018] propose SDP and approximate dynamic
programming (ADP) algorithms to optimally allocate the limited intervention budget
for resource allocation to control the human immunodeficiency virus (HIV) disease.
They construct the compartmental model as a Markov decision process to capture the
progression of the disease among the highest risk group and compare the performance
of various ADP algorithms with the SDP. Their results show that the “Dynamic
Proportional” strategy that allocates the budget dynamically over a multi-period
planning period as the uncertainty in disease transmission is revealed gives the
best result among nine different heuristic strategies. Tanner et al. [2008] consider
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parameter uncertainty in a two-stage stochastic mixed-integer programming model
with chance constraints for finding the optimal vaccination policy that could be
applied to a wide class of epidemic models. They consider the seasonal variation
of transmission parameters and estimate the parameter distributions for the worst
season so that the reliability requirement is guaranteed to be satisfied throughout the
entire year.
Long et al. [2018] develop a two-stage model for optimizing the allocation
of Ebola treatment units across multiple geographic regions during the outbreak’s
early phases. They introduce an empirically-estimated coefficient for behavioral
adaptation to changing epidemic conditions in the first stage and applied a heuristic,
a greedy policy, a myopic linear program, and an approximate dynamic programming
algorithm on the second stage. Ren et al. [2013] propose an optimization model to
determine efficient distribution strategies of limited resources over multiple locations
to address a smallpox outbreak. They introduce approximate representations
of disease propagation that are reasonable within parameter ranges and build a
large scale multi-city problem. Their results show that for a multi-city outbreak,
the proposed assignment of resources saves more lives than allocating medicine
proportional to population. Yarmand et al. [2014] develop a simulation model to
capture the epidemic dynamics in a region for different vaccination levels and then
use the simulation output to formulate a two-stage stochastic linear program for a
vaccine allocation problem. Their model solution reduces the number of vaccine doses
required to contain the epidemic and allowed for the redistribution of vaccine doses
more efficiently.
Operations research models have also been widely used in the context of plant
and forestry epidemic diseases, namely invasive species [Büyüktahtakin et al., 2014,
Büyüktahtakın et al., 2011, 2014a, 2015, Bushaj et al., 2020b]. For a detailed survey
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of such methods, we refer the reader to the systematic review paper of Büyüktahtakın
and Haight [2018].
1.2.3 Vaccination Models
Due to the high death rate and difficulties in treating Ebola, vaccination is a widely
used strategy that helps control this disease. Thus, many papers have studied various
vaccination strategies for Ebola control. The majority of those studies formulate the
model based on the uncertainty of the disease transmission or the supply of vaccines.
For instance, Kelly et al. [2019b] use a stochastic branching process model to project
the size and duration of the 2018− 2019 Ebola outbreak in the Democratic Republic
of Congo (DRC) under high (62%), low (44%), and zero (0%) estimates of vaccination
coverage. Then they compare the results with the Thiel-Sen regression model. Their
results show that the stochastic model with suspected cases and high vaccine coverage
predicted total outbreak sizes closest to the true outcome, and a relatively simple
mathematical model that is updated in real time may inform outbreak response teams
with projections of total outbreak size and duration.
Worden et al. [2019] use a stochastic branching process to project the short-term
and long-term course of the 2019 Ebola outbreak in the Democratic Republic of
Congo (DRC). They use negative binomial autoregression and Theil-Sen regression
to estimate short- and long-term projections. Moreover, they use Gotts rule to
estimate a baseline minimum-information projection. The authors conclude that
their model generates more accurate short-term forecasts due to the reliable data
source that provided weekly case counts and the real-time validation of their
models. Also, they estimate that transmission rates were higher than would be
expected under target levels of 62% vaccination coverage. Xie [2019] modifies the
Susceptible-Exposed-Infective-Hospitalized-Funeral-Removed model of Legrand et al.
[2007] to examine disease transmission dynamics after vaccination for the 2014 Ebola
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outbreak in Liberia. The author uses a sensitivity analysis of various epidemic
scenarios to estimate the basic reproduction number and investigated how vaccination
can effectively change the course of the epidemic. He concludes that the ring
vaccination strategy would reduce the transmission rate, and the proposed model
may be used to better understand the spread of Ebola and develop corresponding
strategies.
Brettin et al. [2018] construct a game-theoretic model of the EVD incorporating
individual decisions on vaccination to study the effect of a promising Ebola vaccine
(rVSV-ZEBOV). They adopt a susceptible-vaccinated-exposed-infected-recovered
compartmental model and use differential equations to describe the disease trans-
mission among each compartment. Their results show that Ebola can be eradicated
if voluntary vaccination programs are coupled with focused public education efforts.
Area et al. [2017] introduce vaccination of the susceptible population into a compart-
mental model that includes susceptible, infected, exposed, hospitalized, asymptomatic
but still infectious, dead but not buried, and buried compartments to control the
spread of the disease. They first consider the case where the total number of available
vaccines in a fixed period of time is limited and then analyzed the situation where
there is a limited supply of vaccines at each instant of time for a fixed interval
of time. Finally, they use simulations to compare the models with and without
vaccination. They conclude that vaccination of all susceptible individuals at the
beginning of the outbreak would give the best result for controlling Ebola, and
satisfactory results could be attained if the number of available vaccines meets the
needs of the population.
Wells et al. [2019] present a method that can be applied to identify areas at
risk during outbreaks of emerging and reemerging diseases. They use a spatial model
that incorporates human mobility, poverty, and population density, and assess the
effectiveness of the vaccination. As an example, they apply the maximum likelihood
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approach to fit the model to the 2019 EVD case in the Democratic Republic of Congo
(DRC) from April 5 to May 10. Their results demonstrate that even modest delays
in initiating vaccination would have noticeably degraded the impact of the program.
Chowell et al. [2019] employ an individual-level stochastic transmission model to
evaluate ring and community vaccination strategies for the 2018 − 2019 Democratic
Republic of Congo (DRC) Ebola transmission. Their simulation model incorporates
four different situations, including a proportion of the population that is inaccessible
for effective contact tracing and vaccination efforts, two levels of population mixing
resembling household and community transmission, two types of vaccine doses with
different time periods until immunity, and spatial dependence on transmission rates.
Their results indicate that ring vaccination is an effective intervention to contain
Ebola epidemics at low levels of household inaccessibility when vaccinating contacts
is significantly delayed. Moreover, they find the community vaccination strategies that
supplement a ring vaccination strategy could speed up and enhance the probability
of epidemic containment.
Liu et al. [2008] study the vaccination effects via two Susceptible-Vaccinated-
Infected-Recovered (SVIR) models considering continuous vaccination strategy (CVS)
and pulse vaccination strategy (PVS). Their results suggest that vaccination can help
disease control by decreasing the basic reproduction number under a necessary level
to eliminate the disease successfully. If ignoring the time for the vaccines to obtain
immunity, or the possibility for people to be infected before obtaining immunity,
the disease can always be eradicated by some suitable vaccination strategies. This
may lead to over-evaluating the effect of vaccination. Lee et al. [2010] employ an
agent-based computer simulation model to study the vaccine allocation of 2009 H1N1
in the Washington DC region. They compare different vaccination strategies (children
first and recommended at-risk individual first). Their results support adherence to
the at-risk individual first policy (instead of a children-first policy) for the H1N1
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influenza vaccine when the vaccine is in limited supply. Duijzer et al. [2018] study the
relationship between the herd effect and the vaccination fraction for the seminal SIR
compartmental model and define the dose-optimal vaccine coverage using differential
equations. The results indicate the crucial importance of the dose-optimal coverage
of the vaccine. Focusing on a limited number of populations can make a significant
difference, whereas allocating equally to all populations would be substantially less
effective.
Yarmand et al. [2014] present a two-phase stochastic model to study the optimal
vaccine allocation. They use a simulation to forecast the epidemic dynamics in
each region for different vaccination levels. They also present a Newsvendor model
formulation of the problem, which provides a closed-form solution for the optimal
allocation and tests an easy-to-implement heuristic for vaccine allocation. The
results show that the two-phase vaccination policy potentially results in a lower
attack rate of the disease and a considerable saving in vaccine production and
administration cost. Preciado et al. [2013] use an arbitrary contact network to
distribute vaccination resources throughout the network for epidemic control. They
propose a convex framework to find the cost-optimal distribution of vaccination
resources when different levels of vaccination are allowed. They present a greedy
approach with quality guarantees based on Lagrangian duality and illustrate results
using numerical simulations in a real social network.
1.2.4 OR Models for Fair Resource Allocation
Most resource allocation models on epidemic control compute the optimal solution
without considering fairness in resource allocation. Fair resource allocation has been
studied in the literature, but mainly with different applications. For example, Orgut
et al. [2016] consider a food allocation model with equitable and effective distribution
of donated food under capacity constraints. Davis et al. [2015] develop a multi-period
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linear optimization model for improving geographical equity in kidney allocation while
also respecting transplant system constraints and priorities. Their results show that
enhancing the practice of sharing kidneys may increase geographic equity in kidney
transplantation. Moreover, Lane et al. [2017] give a systematic review of equity in
healthcare resource allocation decision-making. Marsh and Schilling [1994] present
a literature review of various mathematical methods for equity measures in facility-
location decision models. To our knowledge, fairness has not been studied before
within the context of resource allocation for epidemic control over large spatial scales.
1.2.5 Agent-Based Models
Many studies on epidemic control use agent-based simulation models to forecast
the disease transmission and analyze the interventions such as resource allocation
strategies (see, e.g., Müller et al. [2021], Shamil et al. [2021], and Kasaie et al. [2013]).
For example, de Mooij et al. [2021] give a data-driven agent-based simulation model
to address the challenges of modeling social phenomena in the epidemic. The model
incorporates the individual agent’s beliefs, objectives, trust in government, and the
norms imposed by the government to actual data and is applied in the Virginia
state of United States to compare the sensitivity of the COVID-19 outbreak size
to the different normative interventions. Müller et al. [2021] present an approach
that combines transportation modeling with a mechanistic infection model and a
person-centric disease progression model. The model includes various parameters
and is validated against the infection dynamics in Berlin (Germany). Their work
shows that it is possible to build detailed epidemiological simulations from microscopic
mobility models, and the results can be used to inform political decisions. Shamil et al.
[2021] define an agent-based model intending to simulate the disease dynamics and
transmission of COVID-19 among the inhabitants of a city (Ford County and NYC).
They involve the human behavior of different susceptible agents and model how agents
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interact with each other. Their results suggest that contact tracing via smartphones,
with more than 60% of the population owning a smartphone combined with city-wide
lockdown, reduces the effective reproduction number (Rt) below 1 within three weeks
of intervention. Furthermore, contact tracing accompanied with early lockdown can
suppress the epidemic growth of COVID-19 completely with sufficient smartphone
owners. Kasaie et al. [2013] develop an agent-based simulation of a Tuberculosis
epidemic in a single population. They use the parameters from the literature and
consider a hierarchically structured contact network at different levels. They study
the timing of secondary infections from a single source throughout the duration of
the disease. They compare the patterns of transmission among different networks
and discuss implications. In addition, they do the sensitivity analysis of outputs to
illustrate the robustness of the results to variations in the parameter values.
The interventions of disease control have also been incorporated in the agent-
based simulations. For instance, Li et al. [2021] present agent-based simulations to
study the effectiveness of a nationwide vaccine campaign considering different vaccine
efficiencies. The model incorporates the vaccine acceptance rate and different phases
of vaccines to characterize the possible outcomes. The study concludes that vaccines
alone cannot effectively end the pandemic given the current availability estimates and
the adopted vaccination strategy, and thus non-pharmaceutical interventions need to
be continued. Jahn et al. [2021] use a dynamic agent-based population model to
compare different vaccination strategies for different groups. Outcomes are optimized
for an initial number of available vaccines, and optimization is performed deriving a
prioritization sequence to maximize the reduction in total hospitalizations and deaths
compared to no vaccination. They conclude that elderly and vulnerable persons
should be prioritized for vaccination until further vaccines are available. Kerr et al.
[2021] present an agent-based simulation model to estimate COVID-19 transmission
with interventions applied to control the pandemic. The model involves the human
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behaviors and daily activities to simulate the transmission process of the COVID-19
and post different intervention strategies, including testing, treatment, vaccination of
COVID-19. The model is able to provide an accurate estimation of the number of
infections throughout the planning horizon.
Kasaie et al. [2010] develop an agent-based simulation model of epidemics and
study the resource allocation problem by applying response-surface methodology.
They compare the solution of the proposed agent-based simulation model and a
known mathematical solution in an RA example. In addition, they apply the proposed
approach to a more complicated resource allocation problem in which a number of
previous restricting assumptions are relaxed. The results show that the model can
design detailed individual behaviors and their interactions at the microscopic level, so
that the developed models will eventually provide a valid representation of population
dynamics and disease prevalence over the course of time. And the flexibility of
the model can incorporate new assumptions about populations’ characteristics and
disease characteristics. Kasaie and Kelton [2013a] provides an extended discussion of
their former paper on the calibration, analysis, and optimization of an agent-based
simulation model of an epidemic.
The agent-based model is not only used in the epidemic control, but also in
other fields. For instance, Mashhadi et al. [2016] develop an agent-based simulation
(ABS) framework to model the overall product take-back and recovery system. They
consider the Sociodemographic properties of the consumers, attributes of the take-
back programs, specific characteristics of the recovery process, and product life cycle
information. They use a numerical example of an electronic product take-back system
and simulation-based optimization. They notice that the global optima cannot be
guaranteed due to the non-linearity of the problem.
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1.2.6 Simulation-Optimization Models
In recent years, many studies combine simulation and optimization in their own
field. Carson and Maria [1997] review the area of simulation-optimization. They
introduce the basic concept of simulation-optimization and review the methods
and application in this area. In addition, they discuss the corresponding software
tool. April et al. [2003] summarize the most relevant approaches that have been
developed for the purpose of optimizing simulated systems. They concentrate on
the metaheuristic black-box approach used in commercial software. They present an
example of simulation optimization in the context of a simulation model developed
to predict performance and measure risk in a real-world project selection problem.
Xi et al. [2013] develop a simulation-optimization model that determines where to
locate electric vehicle chargers to maximize their use by privately owned electric
vehicles. They explore interactions between the optimization criterion used and
the budget available. The results show that although the optimal location is
sensitive to the specific optimization criterion considered, overall service levels
are less sensitive to the optimization strategy. Nsoesie et al. [2013b] present a
simulation-optimization approach for forecasting the influenza epidemic curve. The
study combines an individual-based model and the Nelder-Mead simplex optimization
method. The results suggest that the peak infected and total infected are also
accurately forecasted for Montgomery County in Virginia within the forecasting
period. Kasaie and Kelton [2013b] propose a simulation-optimization framework
to address a general form of the resource allocation problem on epidemic control.
They discuss implementation steps with application to the control of the influenza
pandemic with several interacting healthcare interventions. Nsoesie et al. [2013a] use
a simulation-optimization approach to forecast influenza epidemics. They combine an
individual-based model and a simple root-finding optimization method for parameter
estimation and forecasting. They use web-based estimates of influenza activity from
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Google Flu Trends (GFT) to forecast seasonal influenza epidemics. The results
indicate that if the overall trend of the epidemic is accurately captured, GFT could be
used for peak forecasts as illustrated, but probably not for forecasting other epidemic
measures such as peak height and attack rate. Ghamizi et al. [2020] propose an
actual data-driven model to enhance epidemiological predictions, which will learn
to fine-tune predictions in different contexts. The model includes deep learning
estimation of the epidemiological parameters and a genetic algorithm component
searching for optimal trade-offs/policies between constraints and objectives. The
results show that the model yields predictions with much lower error rates than pure
epidemiological models.
1.2.7 Literature Focusing on COVID-19 Resource Allocation
Many studies focus on the intervention and its impact on controlling the transmission
of the COVID-19 [Zhang et al., 2020a, Patel et al., 2020, Saldaña et al., 2020,
Ambikapathy and Krishnamurthy, 2020]. Fisman et al. [2020] use a next-generation
matrix approach to estimate the conditions under which masks would reduce the
reproduction number of COVID-19. Their model takes into account the possibility of
assortative mixing, where mask users interact preferentially with other mask users.
They observe that the usage of masks could decrease the reproduction number of
COVID-19 if widely used, and widespread masking may be sufficient to suppress
epidemics when the reproduction number has been brought close to 1 via other
measures. Zhang et al. [2020a] extend a previously established agent-based disease
transmission model and implement non-medical mask-wearing, shelter-in-place, and
case isolation as control measures, and quantify their impact on reducing the attack
rate and adverse clinical outcomes. They find that non-medical mask-wearing by
75% of the population reduced infections, hospitalizations, and deaths by 37.7%. In
addition, sheltering individuals aged 50 to 64 years of age was the most efficient
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strategy. Eikenberry et al. [2020] develop a compartmental model for assessing the
community-wide impact of masks used by the general population. They suggest that
broad adoption of even relatively ineffective face masks may meaningfully reduce
community transmission of COVID-19 and decrease peak hospitalizations and deaths.
Masks are found to be useful with respect to both preventing illness in healthy persons
and preventing asymptomatic transmission.
Optimization Models. Optimization models have also been widely studied
for resource allocation in the fight against COVID-19. Queiroz et al. [2020] provide
a systematic review of various supply chain and logistics approaches for optimizing
the distribution of critical resources amid the COVID-19. To tackle the shortage
of ventilators, Mehrotra et al. [2020] develop a two-stage stochastic programming
model, optimizing ventilator allocation during the pandemic under various demand
scenarios. The authors find that when 60% of the ventilator inventory is allocated to
non-COVID-19 patients, there is no shortfall. In comparison, when 75% of the stock
is allocated to the non-COVID-19 patients, a shortfall in the supply of the ventilators
to the COVID-19 patients occurs. Also, they find that it is essential to ramp up the
production of the ventilators to meet the additional requirements of the ventilators
that might come up during the peak times of the pandemic. Lacasa et al. [2020] come
up with an algorithm for optimizing the allocation of the ventilators and ICU beds
and validate their algorithm during the peak and declining times of the pandemic
based on the data from the United Kingdom and Spain cases.
Bertsimas et al. [2020] develop a four-step approach, combining descriptive,
predictive, and prescriptive analytics and propose an optimization model for the re-
allocation of the ventilators throughout the U.S. during the COVID-19 pandemic.
Blanco et al. [2020] present a two-stage stochastic mixed-integer programming model,
which minimizes the expected non-covered demand, using robust objective functions
of type minmax and maxmin regret. Billingham et al. [2020] present a network
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optimization model to tackle the problem of scarce ventilator distribution. Parker
et al. [2020] develop mixed-integer programming and robust optimization models to
redistribute patients instead of resources, such as ventilators among different hospitals
under demand uncertainty. Govindan et al. [2020] develop a practical decision support
system hinge on the knowledge of the physicians and the fuzzy interference system
(FIS) to help manage the demands of essential hospital services in a healthcare supply
chain, to break down the pandemic propagation chain, and reduce the stress among
the health care workers.
The literature on the optimal allocation of ventilators is not limited to COVID-
19. For example, Zaza et al. [2016] present a conceptual framework that identifies
the steps in planning the distribution of stockpiled mechanical ventilators during
an emergency. Meltzer et al. [2015] develop a spreadsheet model, which estimates
mechanical ventilator demand in the United States during an influenza pandemic.
They estimate a need of 35,000-60,500 additional ventilators to avert 178,000-308,000
deaths in a highly severe pandemic scenario. Huang et al. [2017] introduce a two-
stage method for optimizing stockpiles of mechanical ventilators, which are critical
for treating hospitalized influenza patients in respiratory failure under a pandemic
situation. They also incorporate their model into a web-based decision-support tool
for pandemic preparedness and response.
Vaccine Models. Many articles focus on the vaccine development and
allocation on controlling COVID-19 [Foy et al., 2021, of Sciences Engineering et al.,
2020, Ferranna et al., 2021]. The majority of the vaccine models use the simulation
method to simulate the vaccination results under different intervention strategies
or use the optimization model to generate the optimal vaccine allocation for the
simulation. For instance, Shim [2021] uses an age-structured model to understand the
epidemiological characteristics of COVID-19. The model determines optimal vaccine
allocation for minimizing infections, deaths, and years of life lost while accounting
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for population factors, such as country-specific age distribution and contact structure,
and various levels of vaccine efficacy. The results suggest that a transmission-blocking
vaccine should be prioritized in adults aged between 20 and 49 years old and those
older than 50 years to minimize cumulative incidence and mortality. Leithaeuser
et al. [2020] use mathematical programming for computing an optimal selection of
vaccination sites out of a given set for controlling COVID-19. The model incorporates
the assignments of patients and doctors to facilities, the number of vaccines per site, as
well as maximum travel time. Their results demonstrate that the number of required
physicians can, in most scenarios, be limited to 2,000 in the case of free assignments.
However, when travel distances for the patients are to be minimized, an increased
number of physicians is unavoidable. Rastegar et al. [2021] present an optimization
model for flu vaccine distribution. The model considers the fears of COVID-19 that
have intensified the shortage of flu vaccines in developing countries and utilizes an
equitable objective function to distribute vaccines to high-risk people. The results
demonstrate the applicability of the model proposed in this study for influenza vaccine
distribution during the COVID-19 pandemic.
1.2.8 Mean-Risk Stochastic Programming
Stochastic programming has been widely used in many fields, including but not
limited to healthcare [Yin and Büyüktahtakın, 2021a], agriculture [Cobuloglu and
Büyüktahtakın, 2017], and finance [Birge and Louveaux, 2011]. The expectation is
the most widely-used objective criterion in stochastic programming [Ahmed, 2006].
However, it does not capture the variability in the objective function, in particular,
the situations with high-impact and low-probability. However, when some extreme
cases occur, there could be a big loss when only the expected value over all scenarios
is considered. For example, at the beginning of an epidemic outbreak, disease
characteristics may not be known, and the disease growth could be highly uncertain,
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and thus a large number of infections and losses could happen in shorter time periods
than expected. In order to capture the impact of such events, we will consider a risk
measure in the objective function in addition to the expectation criterion.
Since conditional value-at-risk (CVaR) is a coherent risk measure that can be
used in an optimization model without losing convexity [Rockafellar and Uryasev,
2002], many former studies considered mean-risk models with CVaR in stochastic
programming models [Ahmed, 2006, Rockafellar and Uryasev, 2002, Schultz and
Tiedemann, 2006, Miller and Ruszczyński, 2011]. CVaR-based mean-risk stochastic
programming has been studied in various applications, such as supply chain
management [Alem and Morabito, 2013], reverse logistic network design problem
[Soleimani and Govindan, 2014], water resources allocation [Zhang et al., 2016],
humanitarian relief network [Elçi and Noyan, 2018].
Among the application of mean-CVaR models, Dai et al. [2014] incorporate
the CVaR into a two-stage stochastic model to address the problem of long-term
planning of municipal solid waste management system in the city of Regina, Canada.
While considering the uncertainty of waste-generation rates in the formulation of
the model, they consider a decreasing expansion cost along with the time. Their
results suggest that the model with the mean-CVaR can better quantify the systems’
risk, and it is useful for helping decision maker analyze the trade-offs between cost
and risk. Thus, it would help them identify desired waste management strategies
under complex uncertainties. Soleimani and Govindan [2014] consider a risk-averse
two-stage stochastic programming approach to the design and planning of a reverse
supply chain network. They use CVaR as a risk evaluator and consider return amounts
and prices of second products as two stochastic parameters. Moreover, they compare
the mean-risk model with the risk-neutral model through the mean-risk value of
the stochastic solution (VSS). Their results prove that the model behaves more
conservatively (lower costs) by increasing the weight of the CVaR (λ) in the objective
23
function and decreasing the value of α in CVaR. Also, solving the risk-averse model
is shown to be efficient in obtaining more reliable solutions.
Furthermore, many papers proposed methodology and decomposition algorithms
for mean-CVaR stochastic programming models. For example, Zhang et al. [2016]
consider a risk-averse multi-stage stochastic linear programming model with the
application to the water allocation problem under uncertainty. They incorporate
CVaR into the objective function to control high-risk events, supplementing the mean.
To solve the model, they use a nested L-shaped framework to survey different ways
of decomposing the resulting problem. Their results indicate that separated the
approximations of mean and CVaR related expressions generally work better than
combined approximations, and multicut versions work better than single cut versions
within the nested L-shaped method for the problem they studied. On the other
hand, multicut would lower the optimality gap when a unique VaR representative
variable exists. Moreover, both the risk of water shortage and the cost of most
expensive scenarios are lower under a higher level of risk aversion because it saves
more water and uses less of the water supply source. Elçi and Noyan [2018] develop
a two-stage risk-averse model to address the problem of the threat of hurricanes
in the Southeastern part of the United States. They enforce a joint probability
constraint on the feasibility of the second stage problem, and considered CVaR as
the risk measure. In addition, they employ an exact Benders decomposition-based
branch-and-cut algorithm for solving the model. Their results show that the algorithm
can significantly benefit from parallelization, and it can find better initial first stage
decisions. Noyan [2012] specifies the conditional value-at-risk (CVaR) as a risk
measure and applied the proposed model to disaster management. The author
considers the problem of determining the response facility locations and inventory
levels of the relief supplies at each facility in the presence of uncertainty in demand
and the damage level of the disaster network. To solve the model, two decomposition
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algorithms are constructed based on the generic Benders-decomposition, which are
single-cut and multi-cut. Their results suggest that the proposed problem in the
paper could be solved for different risk parameters, and this would help the decision
makers to evaluate different allocation decisions under uncertainty. Homem-de Mello
and Pagnoncelli [2016] discuss the incorporation of risk measures into multi-stage
stochastic programs. They introduce the expected conditional risk measures and
illustrated the idea of a pension fund problem. Their results show that the expected
conditional risk measures (ECMRs) overcome some issues that arise with other
alternative risk measures for multi-stage stochastic programs, such as the time
consistency.
1.3 Motivation
Former studies above have made outstanding contributions to the epidemic control
and logistics planning literature. However, there still exist research gaps in
decision-making for resource allocation on epidemic control. To begin with, the
majority of the studies use simulations and differential equations to forecast the
transmission of the disease, which is hard to incorporate with the optimization
model. In addition, researchers study the uncertainty of resource allocation problems
using the two-stage models, which are unable to capture the changes in the decision
throughout a planning horizon involving multiple time periods. Moreover, none of
the literature has considered fair resource allocation when the resource is limited.
Last but not least, the current researches on the decisions for epidemic control do not
consider the risk of the realization of the extreme scenarios. Once the realization of
the transmission is significantly different from the estimated values, there will be a
huge loss in the number of infections.
The former epidemic-logistics model presented in Büyüktahtakın et al. [2018a]
has incorporated the logistics of treatment into a disease spread model, which foresees
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the disease growth over a spatial scale, and allocates limited resources to control the
spread of the disease. The mathematical model of Büyüktahtakın et al. [2018a] is
deterministic and assumes expected values for disease transmission rates. However, in
reality, the disease transmission rate could be quite uncertain, changing over time and
space under various scenarios. Thus, a stochastic OR model is necessary to represent
the uncertainty in transmission in a more realistic way. In this dissertation, we address
these shortcomings and the research gaps in the literature by formulating multi-stage
stochastic programming models and simulation-optimization models, which optimizes
the resource allocation for the prevention and control of epidemic outbreaks and
pandemics, such as the Ebola Virus Disease (EVD) and the Coronavirus Disease
2019 (COVID-19). A summary of the research objectives and accomplishments of
this dissertation is discussed in the next section.
1.4 Summary of Research Objectives and Accomplishments
Overall, this dissertation develops multi-stage stochastic models and agent-based
models to address the resource allocation issue that lies at the core of epidemic
control and logistic planning. The first study presents a multi-stage stochastic
model and considers fair resource allocation when the resources are limited, such
as in West Africa. The second study extends the model in the first study to a
mean-risk multi-stage stochastic model to address the risk-aversive resource allocation
problem in the Democratic Republic of the Congo (DRC). The ring vaccination and
short-term migration are also considered in this study. The third study involves the
uncertainty of the proportion of untested asymptomatic infections in the transmission
of COVID-19 and government intervention strategies while providing the optimal
ventilator allocation among New York City regions. The fourth study develops
a simulation-optimization model to optimize the vaccination center locations and
vaccine allocation among the counties in New Jersey. The optimization model imports
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the results from the simulation and generates the optimization results that are used
to be sent back to the simulation. The results presented in this dissertation also lead
to important insights into decision-making and policies in epidemic control.
Each subsection below discusses a summary of research goals and accom-
plishments under each chapter of this dissertation. The detailed research contri-
butions of this dissertation and related insights into healthcare decision-making are
discussed in each chapter, respectively, under a subsection titled “Key Contributions
and Insights.”
1.4.1 A Multi-Stage Stochastic Programming Approach to Epidemic
Control with Equity Considerations
Existing compartmental models in epidemiology are limited in terms of optimizing
the resource allocation to control an epidemic outbreak under disease growth
uncertainty. In Chapter 2, we address this core limitation by presenting a multi-stage
stochastic programming compartmental model, which integrates the uncertain disease
progression and resource allocation to control an infectious disease outbreak. The
proposed multi-stage stochastic program involves various disease growth scenarios
and optimizes the distribution of treatment centers and resources while minimizing
the total expected number of new infections and funerals. We define two new equity
metrics, namely infection and capacity equity, and explicitly consider equity for
allocating treatment funds and facilities over multiple time stages. We also study the
multi-stage value of the stochastic solution (VSS), which demonstrates the superiority
of the proposed stochastic programming model over its deterministic counterpart.
We apply the proposed formulation to control the Ebola Virus Disease (EVD) in
Guinea, Sierra Leone, and Liberia of West Africa to determine the optimal and
fair resource-allocation strategies. Our model balances the proportion of infections
over all regions, even without including the infection equity or prevalence equity
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constraints. Model results also show that allocating treatment resources proportional
to population is sub-optimal, and enforcing such a resource allocation policy might
adversely impact the total number of infections and deaths, and thus resulting
in a high cost that we have to pay for the fairness. Our multi-stage stochastic
epidemic-logistics model is practical and can be adapted to control other infectious
diseases in meta-populations and dynamically evolving situations. The work based
on this chapter is published in Yin and Büyüktahtakın [2021a].
1.4.2 Risk-Averse Multi-Stage Stochastic Programming for Vaccine
Allocation and Treatment Logistics for Epidemic Response
Existing compartmental-logistics models in epidemics control lack methods in optimizing
the allocation of vaccines and treatment resources under a risk-averse objective. In
Chapter 3, we present a mean-risk, multi-stage, stochastic epidemics-vaccination-
logistics model that evaluates various disease growth scenarios under the Conditional
Value-at-Risk (CVaR) risk measure to optimize the distribution of treatment centers,
resources, and vaccines, while minimizing the total expected number of infections,
deaths, and close contacts of infected people under a limited budget. We integrate
a new ring vaccination compartment into a Susceptible-Infected-Treated-Recovered-
Funeral-Burial epidemics-logistics model. Our formulation involves uncertainty both
in the vaccine supply and the disease transmission rate. Here, we also consider the
risk of experiencing scenarios that leads to adverse outcomes in terms of the number
of infected and dead people due to the epidemic. Combining the risk-neutral objective
with a risk measure allows for a trade-off between the weighted expected impact of
the outbreak and the expected risks associated with experiencing extremely disastrous
scenarios. We incorporate human mobility into the model and develop a new method
to estimate the migration rate between each region when data on migration rates is not
available. We apply our multi-stage stochastic mixed-integer programming model to
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the case of controlling the 2018-2020 Ebola Virus Disease (EVD) in the Democratic
Republic of the Congo (DRC). Our results show that increasing the risk-aversion
by emphasizing potentially disastrous outbreak scenarios reduces the expected risk
related to adverse scenarios at the price of the increased expected number of infections
and deaths over all possible scenarios. We also find that isolating and treating infected
individuals are the most efficient ways to slow the transmission of the disease, while
vaccination is supplementary to primary interventions on reducing the number of
infections. Furthermore, our analysis indicates that vaccine acceptance rates affect
the optimal vaccine allocation only at the initial stages of the vaccine rollout under
a tight vaccine supply. The work based on this chapter is published in Yin and
Büyüktahtakın [2021b].
1.4.3 COVID-19: Optimal Allocation of Ventilator Supply under
Uncertainty and Risk
Chapter 4 presents a new risk-averse multi-stage stochastic epidemics-ventilator-
logistics compartmental model to address the resource allocation challenges of
mitigating COVID-19. This epidemiological logistics model involves the uncertainty
of untested asymptomatic infections and incorporates short-term human migration.
Disease transmission is also forecast through a new formulation of transmission
rates that evolve over space and time with respect to various non-pharmaceutical
interventions, such as wearing masks, social distancing, and lockdown. The proposed
multi-stage stochastic model overviews different scenarios on the number of asymp-
tomatic individuals while optimizing the distribution of resources, such as ventilators,
to minimize the total expected number of newly infected and deceased people.
The Conditional Value at Risk (CVaR) is also incorporated into the multi-stage
mean-risk model to allow for a trade-off between the weighted expected loss due to
the outbreak and the expected risks associated with experiencing disastrous pandemic
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scenarios. We apply our multi-stage mean-risk epidemics-ventilator-logistics model
to the case of controlling the COVID-19 in highly-impacted counties of New York
and New Jersey. We calibrate, validate, and test our model using actual infection,
population, and migration data. The results indicate that short-term migration
influences the transmission of the disease significantly. The optimal number of
ventilators allocated to each region depends on various factors, including the number
of initial infections, disease transmission rates, initial ICU capacity, the population
of a geographical location, and the availability of ventilator supply. Our data-driven
modeling framework can be adapted to study the disease transmission dynamics and
logistics of other similar epidemics and pandemics. The work based on this chapter
is under review for publication in Yin et al. [2021].
1.4.4 An Agent-Based Simulation-Optimization Vaccine Center Location
Vaccine Allocation Approach to Controlling COVID-19
In Chapter 5, we introduce a simulation-optimization approach to address the
vaccination facility location and allocation challenges of the COVID-19. We extend an
agent-based model of the COVID-19 by adding two new vaccination compartments,
“Vaccinated 1” and “Vaccinated 2”. The “Vaccinated 1” represents the people
who have taken the first shot of the vaccine and the “Vaccinated 2” means the
people who have taken the second shot of the vaccine. In addition, we formulate
a resource allocation optimization model, which can decide the optimal vaccination
center locations for each type of vaccine and generate the optimal vaccine allocation
strategies in each region considered. We combine the agent-based simulation model
with the vaccination center and vaccine-allocation optimization model into one single
simulation-optimization framework. The simulation model forecasts the number of
susceptible individuals and infections for the current period, and the results are
inputted into the optimization model. The optimization model incorporates the
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available budget, the potential vaccination center locations, as well as the available
vaccines to generate the vaccination center locations and optimal vaccine allocation
decisions for the next period. The generated results will be imported back to the
simulation model to estimate the number of infections in the future. We calibrate,
validate, and test our model against real outbreak data. The results show that
more vaccines with lower costs should be allocated under a limited budget level, and
more vaccines with a higher efficiency should be allocated under an ample budget
level. In addition, the regions that have a high population or initial infections should
receive more vaccines compared with those other with a lower population and initial
infections.
1.4.5 Organization of the Dissertation
This Ph.D. dissertation is organized in chapters that correspond to four journal
papers. Chapter 2 presents a multi-stage stochastic programming model and
considers fair resource allocation for epidemic control when the resources are limited.
Chapter 3 extends the model in the first study to a mean-risk multi-stage stochastic
programming model to address the risk-aversive resource allocation problem for
controlling the Ebola virus disease in the Democratic Republic of the Congo (DRC).
Chapter 4 involves the uncertainty of the proportion of untested asymptomatic
infections in the transmission of COVID-19 and government intervention strategies
while providing the optimal ventilator allocation among New York City regions.
Chapter 5 introduces a simulation-optimization approach to addressing the vacci-
nation facility location and allocation challenges of the COVID-19. Finally, in




A MULTI-STAGE STOCHASTIC PROGRAMMING APPROACH TO
EPIDEMIC RESOURCE ALLOCATION WITH EQUITY
CONSIDERATIONS
2.1 Introduction
An epidemic is the rapid spread of an infectious disease that impacts a large number
of people. Epidemic diseases can disperse widely in a short time period, usually, two
weeks or less, such as influenza, meningitis, and cholera, impacting populations either
in a specific area, or become a pandemic affecting the lives of millions at a global scale,
such as the ongoing the coronavirus pandemic. All over the world, outbreaks continue
to take lives, ruin the economy, and weaken the health-care system. Unfortunately,
the toll is higher in the less-developed countries because millions of people in poor
regions of the world do not have the opportunity to receive sufficient treatment in
case of an outbreak.
Ebola virus disease (EVD) is a prime example of a devastating epidemic. The
EVD, also known as Ebola hemorrhagic fever, is a severe, often fatal illness affecting
humans and other primates [WHO, 2019d]. The 2014-2016 outbreak in West Africa
was the biggest Ebola outbreak in history, causing more than 28,600 cases and 11,325
deaths by the end of June 2016 [CDC, 2019b]. The virus started in Guinea, and
then moved across countries to Sierra Leone and Liberia. The tenth outbreak of
the Ebola virus disease has been ongoing in the Democratic Republic of the Congo
(DRC) since August 2018. The outbreak has started from the northeast region of the
country, centered in the North Kivu and Ituri provinces. More than 3000 cases have
been verified by March 2020 [MSF, 2020], and it is the country’s largest-ever Ebola
outbreak.
There are no specific cure or treatment for Ebola-infected individuals. Multiple
investigational Ebola vaccines have been developed and tested in numerous clinical
32
trials around the world, some of them have been licensed to prevent the Ebola
virus disease [NIH, 2019]. Short term intervention strategies, including quarantine,
isolation, contact tracing, and safe burial, have been helpful to Ebola control.
Moreover, Ebola treatment centers (ETCs), which mainly isolate and treat infected
individuals, play a significant role in controlling the Ebola virus disease.
The optimization problem of allocating resources to control an epidemic, such
as Ebola, is an immense challenge, especially in the regions where available treatment
facilities and funds are scarce. The decision-maker has to make difficult decisions to
allocate limited resources to the right locations and in the right amount for slowing
down the outbreak and minimize its impacts. Due to the insufficiency of intervention
resources, some regions may not receive their fair share of treatment resources,
compared to other regions that are also impacted by the disease. Furthermore, the
EVD can spread from one individual to another through multiple mechanisms, such
as through person-to person-contact or by touching the dead body infected by the
EVD. The rates of disease transmission can change under various conditions and thus
could be highly unpredictable.
Operations Research (OR) and mathematical modeling methods have been
widely used to determine optimal resource allocation strategies to control an epidemic
disease. Those approaches include simulations [Siettos et al., 2015, Ajelli et al., 2016,
Kurahashi and Terano, 2015, Wells et al., 2015], differential equations [Craft et al.,
2005, Kaplan et al., 2003], network models [Berman and Gavious, 2007, Longini Jr
et al., 2007, Porco et al., 2004, Riley and Ferguson, 2006], resource allocation analysis
[Zaric et al., 2000, Tebbens and Thompson, 2009, Nguyen et al., 2017, Shaw and
Schwartz, 2010], and stochastic compartmental models [Lekone and Finkenstädt,
2006, Tanner et al., 2008, Funk et al., 2017, Kibis et al., 2021].
The majority of previous work focuses on analyzing the impact of different
intervention strategies on disease transmission. Most of those studies consider disease
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growth and resource allocation problems separately in different models or enumerate
each resource allocation policy in a simulation model one by one. Moreover, few
studies incorporate fairness in resource allocation optimization models. The former
epidemic-logistics model presented in Büyüktahtakın et al. [2018a] incorporate the
logistics of treatment into a disease spread model, which foresees the disease growth
over a spatial scale, and at the same time allocates limited resources to control the
spread of the disease. Büyüktahtakın et al. [2018a] consider the varying treatment
capacity based on a limited budget. The mathematical model of Büyüktahtakın et al.
[2018a] is deterministic and assume expected values for disease transmission rates.
However, in reality, the disease transmission rate could be quite uncertain, changing
over time and space under various scenarios. Thus, a stochastic OR model is necessary
to represent the uncertainty in transmission in a more realistic way. Moreover, the
majority of the OR models do not consider equity and fairness in resource allocation,
resulting in solutions that may provide few or no resources to some regions impacted
by the disease, especially when resources are quite limited.
The objective of this chapter is to develop a multi-stage stochastic programming
extension of the deterministic epidemic-logistics model of Büyüktahtakın et al. [2018a]
with equity considerations and present realistic insights into controlling the EVD
under disease transmission uncertainty. Considering different budget levels and
various tightness of the equity constraints, we analyze the optimal resource allocation
strategies in a meta-population over three countries in West Africa. In our paper,
the stochastic program incorporates various scenarios of disease transmission rates
through person-to-person contact, thus capturing the uncertainty and variability
in the infection transmission rate better compared to its deterministic counterpart.
The objective function of our multi-stage stochastic programming epidemic-logistics
model is to minimize the expected number of new infections and deceased individuals
overall scenarios, all time periods, and all regions considered. We study the Value of
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the Stochastic Solution (VSS), a well-known stochastic programming measure that
compares the efficiency of the deterministic and the stochastic models. Furthermore,
we introduce two new equity metrics for fair resource allocation in epidemics control
and analyze the impact of various budget distribution strategies on the number of
infected people and deceased individuals under each of these equity metrics.
2.1.1 Key Contributions and Insights
Former stochastic programming approaches on epidemic control involved a time
domain with only two periods. Furthermore, there is a need for analyzing the
equity and efficiency tradeoff in a mathematical programming formulation when
allotting resources for controlling infectious diseases. Our approach contributes to
the epidemiology and OR literature in the following ways.
Modeling Contributions. Firstly, to the best of our knowledge, our study presents
the first multi-stage stochastic programming (SP) model for infectious disease control,
considering the uncertainty in the disease transmission parameter. Multi-stage SP is
superior over two-stage SP models because disease transmission dynamically changes
over multiple time stages. Our stochastic programming approach is also preferable to
probabilistic sensitivity analysis, which considers a single scenario at a time and also to
robust optimization (RO), which could provide highly conservative results by focusing
on the worst-set of outcomes in a hostile environment [Defourny et al., 2012]. Due
to the temporal and spatial dimensions considered in our resource allocation model,
multi-stage SP is also computationally more amenable to dynamic programming,
which cannot tackle such a high-dimensional problem.
Second, we present the multi-stage VSS, which shows that the proposed
stochastic programming model is superior to its deterministic counterpart.
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Third, we introduce and formulate two new equity metrics and incorporate
equity measures as a constraint in the mathematical formulation to balance efficiency
and equity for fair resource allocation in epidemics control. To our knowledge, this
study is the first one that models equity in a multi-stage stochastic programming
formulation. Our multi-stage model provides an advantage of adjusting the level
of equity over time with respect to evolving disease dynamics, as opposed to using
a standard equity measure, which is not updated over time. Furthermore, unlike
former work, we address equity in both establishing treatment centers and allocating
treatment resources over metapopulations and multiple periods using mathematical
optimization.
The infection equity constraint is also easier to implement than using standard
equity metrics, such as the absolute difference between regional prevalence (cases
per population in a region) and the overall prevalence (cases per population over all
regions), because the absolute gap value using the prevalence metric could be tiny
and difficult to adjust compared with the absolute gap value defined by the infection
equity constraint. Furthermore, computational results imply that our model balances
the proportion of infections in each region, even without including the infection equity
or prevalence equity constraint.
Fourth, while we tailor our epidemics-logistics stochastic programming modeling
framework for the EVD, it can be adapted to study different diseases to determine
the optimal and fair resource-allocation strategies among various regions and multiple
planning periods to curb the spread of an epidemic.
Applied Contributions and Policy Insights: Our mathematical model could be
used as a decision support tool to aid policymakers in understanding disease dynamics
and making the most effective decisions to fight epidemics under uncertainty. In
particular, our model could be used by the stakeholders in epidemic control (e.g.,
governments, UN entities, non-profit organizations) to determine the optimal location
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and timing of ETCs opened and treatment resources allocated to minimize the total
expected infections and deaths over metapopulations in multiple locations and over
multiple time periods.
Our model provides significant insights into the control of the Ebola Virus
Disease in West Africa that would not be possible with existing models and methods in
infectious disease control. Our multi-stage stochastic program foresees various disease
growth scenarios to optimize resource allocation, as opposed to solving the problem
for an average scenario and myopically for one stage at a time with fixed periodic
budgets, which could provide sub-optimal solutions and thus less effective resource
allocation. Specifically, our study provides the following several policy insights and
recommendations to decision-makers:
(i) Our analysis emphasizes that quick response, such as allocating treatment
centers and resources in the early stages of the epidemic, is critical for
minimizing the total number of infected individuals and deaths related to the
disease.
(ii) The value of the stochastic solution demonstrates that the optimal timing and
location of resource allocation vary with respect to the disease transmission
scenario, and thus possible disease growth scenarios should be considered when
planning for an epidemic instead of considering a single scenario of the expected
value.
(iii) Our results show that the infection level (“the number of infected people in a
region” / “the total number of infected people” - “population in a region” /
“total population”) is a key factor for resource allocation.
(iv) Our analysis suggests that the region with the highest infection level has the
priority to receive the majority of the resources at the beginning of the time
horizon to minimize the number of infections and funerals.
(v) Model results also show that allocating treatment resources proportional to
population is sub-optimal.
(vi) While equitable resource allocation is important in decision-making, too much
focus on the equity of resource allocation might adversely impact the total
number of infections and deaths and thus resulting in a high cost that we have
to pay for fairness. Therefore, decision makers are advised to be cautious about
enforcing fairness when allocating resources to multiple regions.
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2.2 Problem Formulation
This section gives the formulation of a multi-stage stochastic programming model,
including the compartmental model, description of the scenario tree, formulation,
equity constraints, and their explanation.
2.2.1 Notation
Model notations that are used throughout the rest of Chapter 2 are presented in
Tables 2.1–2.5 below.
Table 2.1 Sets and Indices
Notation Description
J Set of time periods, J = {0, ..., J}.
A Set of ETC types, A = {1, ..., A}.
R Set of regions, R = {1, ..., R}.
Mr Set of all surrounding regions of region r.
Ω Set of scenarios, Ω = {1, ...,Ω}.
j Index for time period where j ∈ J .
r Index for region where r ∈ R.
a Index defining type of ETC, where a ∈ A.
ω Index for scenario where ω ∈ Ω.
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Table 2.2 Transition Parameters Describing the Rate of Movement between Disease
Compartments
Notation Description
λ1,r Disease fatality rate without treatment in region r.
λ2,r Disease fatality rate while receiving treatment in region r.
λ3,r Disease survival rate without treatment in region r.
λ4,r Disease survival rate with treatment in region r.
λ5,r Safe burial rate of Ebola-related dead bodies in region r.
χω1,r Transmission rate per person due to community interaction in region r
under scenario ω.
χ2,r Transition rate per person during traditional funeral ceremony in region r.
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Table 2.3 Other Parameters
Notation Description
b1j,r Unit cost of treatment for an infected individual in region r at end of
period j.
b2j,r Unit cost of safe burial for a dead body in region r at end of period j.
gaj,r Fixed cost of establishing type a ETC in region r at end of period j.
ka Capacity (number of beds) of type a ETC.
ur The population in region r.
∆ Total available budget for treatment.
πr Initial number of susceptible individuals in region r.
$r Initial number of infected individuals in region r.
θr Initial number of treated individuals in region r.
ϑr Initial number of recovered individuals in region r.
υr Initial number of unburied dead bodies (funerals) in region r.
τr Initial number of buried dead bodies (safe burials) in region r.
ςr Initial treatment capacity in terms of number of ETC beds in region r.
αl→r Migration rate of susceptible individuals from surrounding regions l ∈Mr
to region r.
φl→r Migration rate of infected individuals from surrounding regions l ∈Mr
to region r.
νr→l Migration rate of susceptible individuals from region r to surrounding
regions l ∈Mr.
ρr→l Migration rate of infected individuals from region r to surrounding
regions l ∈Mr.
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Table 2.4 State Variables
Notation Description
Sωj,r Number of susceptible individuals in region r at end of period j under
scenario ω.
Iωj,r Number of infected individuals in region r at end of period j under
scenario ω.
Tωj,r Number of individuals receiving treatment in region r at end of period j
under scenario ω.
Rωj,r Number of recovered individuals in region r at end of period j
under scenario ω.
Fωj,r Number of deceased individuals due to the epidemic in region r at end of
period j under scenario ω.
Bωj,r Number of buried individuals in region r at end of period j
under scenario ω.
Ŝωj,r Number of susceptible individuals migrating into region r at end of period j
under scenario ω.
S̃ωj,r Number of susceptible individuals emigrating from region r at end of
period j under scenario ω.
Îωj,r Number of infected individuals migrating into region r at end of period j
under scenario ω.
Ĩωj,r Number of infected individuals emigrating from region r at end of period j
under scenario ω.
41
Table 2.5 Decision Variables
Notation Description
Cωj,r Total capacity (number of beds) of established ETCs in region r at end of
period j under scenario ω.
I
ω
j,r Number of infected individuals hospitalized (and quarantined) in region r
at end of period j under scenario ω.
yωaj,r Number of type a ETCs established in region r at end of period j
under scenario ω.
2.2.2 Compartmental Disease Model Description
Figure 2.1 One-step disease compartmental model.
Figure 2.1 shows the transmission dynamics of the Ebola Virus Disease (EVD) in
a region r of a country located in West Africa. The disease spreads among the
susceptible population (S), by either person-to-person contact at a periodic rate of
χω1,r under scenario ω or through touching Ebola-related dead bodies that are not
yet buried during traditional funerals at a periodic rate of χ2,r. Thus, susceptible
individuals (S) are infected and become infected (I) with a rate of χω1,r as a function
of I and with a rate of χ2,r as a function of funerals (F), who represent deceased
but unburied people. Without treatment, some of the infected individuals in the
compartment (I) will die and move to the funeral (F) compartment with the rate of
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λ1,r, while some of the infected individuals will recover with a rate of λ3,r, moving
into the recovered compartment (R). However, the number of individuals that will
be hospitalized for treatment (T) is based on the treatment capacity variable Cωj,r,
which gives the total available number of beds in the ETCs in region r under scenario
ω in period j. Thus, there is no constant transition rate from I to T . Meanwhile,
individuals who did not receive treatment will remain in the community and continue
to spread the disease. In treated compartment (T), some of the individuals will
recover with a periodic rate of λ4,r, and a fraction of them will die with a periodic
rate of λ2,r. The deceased individuals in the funeral compartment are safely buried at
a rate of λ5,r, moving into the buried compartment (B). Thus, we assume that every
death (F) leads to a safe burial (B). In order to describe the migration of susceptible
and infected individuals within a given country, we define (αl→r, υr→l) as the rates
of migration of susceptible individuals into and out of region r, respectively, and
(ψl→r, ρr→l) as the rates of migration of infected individuals into and out of region
r, respectively. The multi-stage stochastic programming epidemic-logistics model is
defined in detail in the next section.
The latent period for the EVD is highly variable, changing from 2 to 21 days
[WHO, 2020c]. In our model, we assume that each time stage represents two weeks, in
which an infected but asymptomatic individual can become symptomatic and infect
others. For this reason, and to avoid computational complexity, we do not include an
explicit latent compartment in the model; instead, we fit those individuals within the
infected compartment. Similarly, the Ebola modeling literature focusing on logistics
usually omit the latent period to avoid further computational complexity (see, e.g.,
Büyüktahtakın et al. [2018a], Long et al. [2018]).
43
2.2.3 Uncertainty Representation and Scenario Tree Generation Scheme
It is beyond the scope of this work to introduce a new methodology for multi-period
scenario tree generation; we refer the reader to Heitsch and Römisch [2009], Leövey
and Römisch [2015], and Pflug and Pichler [2015] for different approaches to generate
scenario trees. To generate the scenario tree for our case, we follow a similar approach
presented in the study of Alonso-Ayuso et al. [2018]. Here, we focus on the most
uncertain parameter: the community transmission rate based on former research
stating that transmission rates impact the infections and deaths the most among all
different input parameters based on sensitivity analysis [Büyüktahtakın et al., 2018a].
We model the future uncertainties regarding the progression of the disease by




ω = 1. We assume that the uncertain community transmission rate
follows a normal distribution. The data regarding the distribution of the community
transmission rate parameter is not available. Thus, we use the lower and upper bounds
on the transmission rate in the community based on the data gathered from literature
(Table 2.6) to generate the normal distribution function for the transmission rate
parameter at time zero. The upper and lower bounds, thus the distribution functions
for the uncertain parameter, are specified for each country and are different at each
node of the scenario tree. Accordingly, the mean µnr is defined for each region r ∈ R
and node n ∈ N . The lower bound and upper bound are considered as the value
of 0.001- and 0.999-quantiles of the normal distribution, respectively. The standard
deviation σr is defined according to a normal distribution using the initial lower and
upper bounds provided for each region r ∈ R. Also, we use Qh to represent the value
of the h-quantile of the normal distribution.
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Table 2.6 The Range (Lower and Upper Bounds), Mean, and Standard Deviation
of Community Transmission Rate in Each Country
Region Rate Range Mean Standard Deviation
Guinea [0.24, 0.84] 0.54 0.10
Sierra Leone [0.24, 0.88] 0.66 0.07
Liberia [0.24, 0.64] 0.44 0.07
Source: [Althaus, 2014, Towers et al., 2014]
Figure 2.2 Scenario tree generation example for Guinea, where each circle, denoted
by n, n := {0, . . . , 12}, represents a node of the scenario tree.
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As shown in an example scenario tree in Figure 2.2, a particular scenario could
give the community transmission rates (χω1,r) into the future for the next two stages
in all considered regions. In our model, we consider three realizations for each node
of the scenario tree, namely as low, medium, and high. The low and high realizations
have a probability of 0.3, and the medium realization has a probability of 0.4. Each
path from the root node to the leaf node of the scenario tree represents a scenario ω.
In the example shown in Figure 2.2, we have two stages, and thus 32 = 9 scenarios. In
addition, two scenarios are inseparable at stage j if they share the same scenario path
up to that stage. This implication is modeled using non-anticipativity constraints, as
described in Appendix A.1. For example, for scenarios ω1 to ω9, the decision at node
0 should be the same as we do not know the values of the uncertain parameters at
stage 0. Similarly, for scenarios ω1 to ω3, the decision at node 1 should be the same
because these scenarios cannot be differentiated at stage 1 due to uncertainty.
The probability of a scenario ω, pω, is calculated as the multiplication of
probabilities on the scenario path. For example, the probability of scenario ω1, which
corresponds to a low realization in the first and second stages, is 0.09, while the
probability of scenario ω9, which corresponds to a medium realization in the first
stage and a high realization in the second stage, is 0.12.
For each node n ∈ N in the scenario tree, the low realization value of the





ξnr ≤ Q0.30) = Q0.15), the medium realization is given by the value of the 0.50-quantile
(µnr,medium = E(ξ
n
r |Q0.30 ≤ ξnr ≤ Q0.70) = Q0.50), and the high realization is equal to
the value of the 0.85-quantile of the normal distribution (µnr,high = E(ξ
n
r |Q0.70 ≤ ξnr ≤
Q0.999) = Q0.85). In our example, at node 0 the normal distribution of the uncertain
community transmission rate parameter in Guinea has µ0r = 0.54 and σ
0
r = 0.10. The
low, medium, and high realizations of the uncertain parameter at nodes 0 and 1 are
given in Table 2.7 below.
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Table 2.7 The 0.15-, 0.50-, 0.85-Quantiles of the Normal Distribution of the
Random Variable ξnr at Nodes 0 and 1 of the Scenario Tree in Figure 2.2
Low Medium High
node 0: Q0.15=0.44 Q0.50=0.54 Q0.85=0.64
node 1: Q0.15=0.26 Q0.50=0.44 Q0.85=0.62
The normal distribution of community transmission rate associated with nodes
1, 2, and 3 at stage 1 have a mean of Q0.15 = 0.44, Q0.50 = 0.54, and Q0.85 = 0.64,
respectively. While scenarios ω1, ω2, and ω3 at stage 1 has a single realization value of
0.54 for the random parameter at node 1, the realizations of scenarios ω1, ω2, and ω3
at stage 2 correspond to nodes 4, 5, and 6, with a mean of Q0.15 = 0.26, Q0.50 = 0.44,
and Q0.85 = 0.62, respectively.
2.2.4 Model Features and Assumptions
In this study, we have considered six regions, each consisting of multiple districts, in
the three countries most affected by the 2014-16 EVD. West Africa is poor and the
budget for the Ebola treatment comes from an international consortium of partners,
including governments, international financial Institutions, regional organizations,
and private foundations [United Nations, 2020]. Those funding is either directly
provided to the affected governments or the United Nations (UN) entities. In this
chapter, we took the perspective of the UN entities, such as the World Health
Organization (WHO), where the total funding is collected centrally and allocated
among those three countries to optimize the use of treatment resources and the
donated funding.
The actual capacity of ETCs varies from 20 to 200 operational beds [WHO,
2020d]; however, we used 50 and 100-bed ETCs in our model to reduce the
computational complexity. It is essential to differentiate the small and large ETCs
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in the model because each ETC type has a different setup cost, which impacts the
optimal allocation of resources. We assume that each Ebola patient will receive the
same treatment in either a large or small capacity ETC. The treatment capacity
parameter is cumulative and only reflects total ETC beds.
Furthermore, the cost of burying dead bodies safely is shown to be minor
compared to the ETC and treatment cost [WHO, 2020b, Büyüktahtakın et al., 2018a].
In addition, changing the burial rate into a variable that is optimized in the model
would have complicated the model considerably, and so we only focus on adjusting
the variable values of treatment resources. Thus, we assume that the burial rate is
constant, and burials and treatment are operated separately using different budgets.
2.2.5 Model Formulation
Following the convention of Büyüktahtakın et al. [2018a], the multi-stage stochastic








pω((Iωj+1,r − Iωj,r) + F ωj+1,r) (2.1a)
s.t. Sω0,r = πr, I
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0,r = θr, R
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0,r = ϑr,
F ω0,r = υr, B
ω
0,r = τr, C
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j,r − Ĩωj,r + χω1,rIωj,r + χ2,rF ωj,r − (λ1,r + λ3,r)Iωj,r − I
ω
j,r,
j ∈ J \ {J}, r ∈ R, ∀ω ∈ Ω, (2.1d)




j,r − (λ2,r + λ4,r)T ωj,r,








j ∈ J \ {J}, r ∈ R, ∀ω ∈ Ω, (2.1f)






j,r − λ5,rF ωj,r,
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amj,r + C0,r, j ∈ J \ J, r ∈ R, ∀ω ∈ Ω, (2.1n)
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j ∈ J, r ∈ R, ∀ω ∈ Ω, (2.1p)
yωaj,r ∈ {0, 1, 2, . . .}; yωaj,r ≤ Iωj,r,
a ∈ A, j ∈ J \ {J}, r ∈ R, ∀ω ∈ Ω, (2.1q)
yωat(n),r − yan,r = 0, I
ω
t(n),r − In,r = 0, Cωt(n),r − Cn,r = 0,
a ∈ A,∀ω ∈ β(n), ∀n ∈ N, (2.1r)
The objective function (2.1a) minimizes the total expected number of newly
infected individuals plus funerals over all scenarios, in all regions throughout
the planning horizon. Constraints (2.1b) represent the number of individuals in
susceptible, infected, treated, recovered, funeral, and buried compartments and the
total ETC capacity, respectively, in each region r at the beginning of the planning
horizon. Equations (2.1c)–(2.1h) represent the dynamics of the population in each
disease compartment, as shown in Figure 2.1. Specifically, constraint (2.1c) implies
that the number of susceptible individuals in region r at the end of period j+1 under
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scenario ω is equal to the number of susceptible individuals from the previous year
plus the number of susceptible individuals who immigrate into region r minus the
number of susceptible individuals who emigrate from region r and minus the number
of newly infected individuals at the end of period j under scenario ω. Constraint (2.1d)
gives the number of infected individuals at the end of period j + 1 in region r under
scenario ω, which is equal to the number of infected individuals from the previous year
plus immigrated infected individuals minus emigrated infected individuals, plus newly
infected individuals and minus individuals who recovered, died, or were accepted
for treatment at the end of period j under scenario ω. Constraint (2.1e) describes
the total number of treated individuals in region r at the end of time period j + 1
under scenario ω, which is equal to the number of treated individuals at the end of
period j plus infected individuals who accepted treatment based on the availability
of beds minus treated individuals who died or recovered. Constraint (2.1f) ensures
that the cumulative number of recovered individuals in region r at the end of the
period j + 1 under scenario ω is equal to the number of recovered individuals from
the previous year plus newly recovered individuals. Constraint (2.1g) defines the
total number of unburied funerals in region r at the end of time period j + 1 under
scenario ω, which is equal to the infected and treated individuals who moved to
the funeral compartment minus the buried dead bodies. Constraint (2.1h) gives the
cumulative number of buried dead bodies at the end of the period j under scenario ω.
Constraints (2.1i)–(2.1l) present the number of immigrated and emigrated individuals
in susceptible and infected compartments. Specifically, constraints (2.1i) and (2.1j)
give the number of susceptible and infected individuals who immigrated into region
r from region l ∈ Mr under scenario ω. Constraints (2.1k) and (2.1l) represent the
number of susceptible and infected individuals, who emigrated from region r into
neighboring region l ∈Mr under scenario ω. Constraints (2.1m)–(2.1o) represent the
restrictions regarding logistics and operation management. Specifically, constraint
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(2.1m) denotes the budget limitation on the sum of the fixed costs of opening ETCs
and the variable cost of treating infected individuals over all regions r in all periods j
under scenario ω. Constraint (2.1n) shows the total capacity in region r at the end of
period j under scenario ω. Constraint (2.1o) ensures that the number of hospitalized
individuals is limited by the number of available beds in ETCs in region r. In
particular, the number of hospitalized individuals (I) is equal to the minimum of the
number of infected individuals and the capacity available at established ETCs after
considering currently hospitalized individuals in ETCs. Constraints (2.1p) present
non-negativity restrictions on the number of susceptible, infected, treated, funeral,
buried, and recovered individuals, respectively, under scenario ω. Constraints (2.1q)
denote the integer requirements on the number of type-n ETCs to be opened in region
r at the end of period j under scenario ω. In addition, if the number of infected
individuals is less than 1 in a region r, the value of the integer variable corresponding
to opening an n-bed ETC is forced to be zero, and thus no ETC will be opened in
that region. Constraints (2.1r) represent nonanticipativity restrictions, which state
that if two scenarios share the same path up to stage j, the corresponding decisions
should be the same, as described in Appendix A.1.
2.2.6 Equity of ETC and Treatment Resources Distribution
Equitable resource allocation has long been studied in health-care resource allocation
decision-making [Lane et al., 2017]. Some examples include equity in facility
location [Marsh and Schilling, 1994, Ares et al., 2016], organ allocation for kidney
transplantation [Su and Zenios, 2006, Bertsimas et al., 2013], vaccine coverage
[Enayati and Özaltın, 2020], and health-care fleet management [McCoy and Lee,
2014].
In the health-care sector, an equity metric compares two or more populations
based on the service or utility the health system provides to the different populations.
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The comparison of various populations could be based on the health status,
distribution of resources, expenditures, utilization, and access [Goddard and Smith,
2001, Culyer and Wagstaff, 1993].
While it is essential to clearly define equity to be used for fair resource allocation,
there is no universal consensus on the definition and measurement of equity in public
health decision making [Stone, 2002]. Lane et al. [2017] find a large disparity in the
description of equity in health care resource allocation based on their review of the
related literature.
Among numerous definitions of equity, Young [1995] defines three equity
concepts on resource allocation: parity (claimants should be treated equally), propor-
tionality (goods should be divided in proportion to differences among claimants), and
priority (the person with the greatest claim to the good should get it). Savas [1978]
describes equity as fairness, impartiality, or equality of service. Culyer [2001] discusses
utilitarian principles dictating that resources should be allocated in such a way as to
maximize the overall health and wellbeing of a society, and egalitarian principles
dictating that all people are equal and that inequalities between groups should be
removed. McCoy and Lee [2014] use utilitarian, proportionally fair, and egalitarian
principals to incorporate equity into optimal resource allocations.
Marsh and Schilling [1994] present a list of 20 equity measures within the context
of facility location. Among the most commonly-used equity measures are the sum
of absolute deviations (SAD), the mean absolute deviation (MAD), the minimum
effect (ME), and the Gini coefficient (GC). Love-Koh et al. [2020] categorize methods
used to define equity measures into five: 1) gap measures, regression-based measures,
Lorenz and concentration curves, measures incorporating inequality aversion, and
health-related social welfare. The equity measures defined by absolute and relative
gaps are commonly used by international agencies, such as the WHO, to distribute
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resources, such as vaccines and medical treatment, between population groups in low-
and middle-income countries [Casey et al., 2017].
Equitable resource allocation has also been studied considering the tradeoff
between the efficiency and equity in resource allocation for infectious diseases, such
as HIV and influenza (e.g., Mbah and Gilligan [2011], Zaric and Brandeau [2007],
Kaplan and Merson [2002], Enayati and Özaltın [2020]). For example, Earnshaw
et al. [2007] develop a linear programming planning tool to help policymakers
understand the effectiveness of different allocations of HIV prevention funds under
fairness constraints. Enayati and Özaltın [2020] propose an equity constraint in
a mathematical program to help public health authorities consider fairness when
making vaccine distribution decisions. In a food allocation problem, Orgut et al.
[2016] present a deterministic linear programming model to optimize the allocation
of donated food, considering objectives of both equity and effectiveness.
Similar to these works, we will follow an approach that would balance the
efficiency and equity in epidemics resource allocation. Specifically, we will focus on
equity over meta-populations and multiple spatial dimensions. We define our equity
measures within the context of proportionality and priority, as described in Young
[1995]. Our formulations of equity are gap-based, combining absolute and relative
gaps. Our approach is seeking a balance between utilitarian and egalitarian objectives
studied in Culyer and Wagstaff [1993] and McCoy and Lee [2014] by determining a
resource allocation strategy that will minimize total infections and deaths but at the
same time incorporates equality dimensions as a constraint. Unlike former work, we
address equity in the resource allocation for both treatment centers and treatment
resources using mathematical optimization.
Our definition of equity is similar to the descriptions of Mbah and Gilligan
[2011], who defines social equity as the equal opportunity for infected individuals to
access treatment, Marsh and Schilling [1994], who define equity within the context of
53
facility location, and Orgut et al. [2016] who study equity in the fair allocation of food.
Specifically, we define equity as the case where each region and country receives its
fair share of the ETCs and medical treatment resources during an epidemic outbreak.
The majority of studies on fair resource allocation define the equity as a
one-period metric, which does not change over time. In our multi-stage stochastic
programming model, the equity standard is adjusted over time with respect to the
changing disease dynamics throughout the planning horizon, increasing the efficiency
of the resource allocation. To the best of our knowledge, our study is the first to
model the fair resource allocation using a multi-stage stochastic programming model.
Infection Equity Constraint In the first formulation, we will address the
objective of equity by limiting the absolute deviation between a regions relative
number of infections and its relative population with respect to all regions, while
effectiveness corresponds to minimizing the expected number of infections and deaths.
In this equity measure, namely infection equity constraint, we consider priority
concerning the proportions of infections and enforce resource allocation to limit the
proportion of infections with respect to the population for each region. The infection
















| ≤ k (2.2)
The infection equity constraint (2.2) gives a bound on the total number of infections
in each region relative to the total infections in all regions. Specifically, constraint
(2.2) implies that the absolute value of the number of infected individuals in region
r divided by the total number of infected individuals over all regions minus the ratio
of the population of region r, ur, over the total population over all regions should be
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less than or equal to a specific value k.
Because the EVD case fatality rate is high [50% on average [WHO, 2020c]]
and the EVD is highly contagious, having the lowest infections system-wide will lead
to the lowest mortality for the EVD. Thus, we consider the number of infections
instead of deaths as the main parameter for resource allocation in our equity metric.
The number of infections in constraint (2) could also be adjusted to the number of
fatalities.
Capacity Equity Constraint In the second formulation, we will formulate equity
by limiting the absolute deviation between the proportion of treatment capacity
established in a region and proportion of the population in a region relative to all
regions while again, effectiveness corresponds to minimizing expected deaths and
infections. The capacity equity constraint enforces allocating resources considering
















| ≤ k, (2.3)
Similarly, we define the capacity equity constraint (2.3) to bound the absolute
value of the difference between the proportion of the capacity at region r over the total
capacity with the proportion of the population at region r over the total population
with a predefined parameter k.
Prevalence Equity Constraint We also study a widely-used equity metric, known
as prevalence [Lasry et al., 2008, Kedziora et al., 2019]. Here, we define the prevalence
equity constraint to limit the absolute difference between the regional prevalence
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(cases per population in a region) and the country prevalence (cases per population


















| ≤ k (2.4)
The prevalence equity constraint (2.4) bounds the proportion of infections in
each region relative to the proportion of infections in all regions.
2.2.7 Mixed-Integer Linear Program (MIP) Model
In the mathematical formulation (2.1), we have two types of non-linearity. The first
non-linear equation corresponds to the capacity-availability constraint (2.1o), and
the second corresponds to the equity constraints (2.2) and (2.3) (see Appendix A.2
for linearization of (2.1o), (2.2), and (2.3)). The non-linear multi-stage stochastic
programming epidemiclogistics model (2.1) is converted into an equivalent MIP
formulation by replacing the non-linear capacity availability constraint (2.1o) with
constraints (A.3), (A.4a)-(A.4d) and (A.5a)-(A.5d), the non-linear infection equity
constraint (2.2) with constraints (A.7a) and (A.7b), and the non-linear capacity equity
constraint (2.3) with constraints (A.8a) and (A.8b), as given in Appendix A.2.
We apply the MIP model to a case study involving the control of the 20142015
Ebola outbreak in the three most-affected West African countries, Guinea, Sierra
Leone, and Liberia. The details of the 20142015 Ebola outbreak data used as an input
into the mathematical model, including population and migration data, resource cost
data, and epidemiological data are presented in Appendix A.3.
The MIP model is solved using CPLEX 12.7 on a desktop computer running
with Intel i7 CPU and 64.0 GB of memory. A time limitation of 7,200 CPU seconds
was imposed for solving the test instances without equity constraints, while the time
limit is increased to 72,000 CPU seconds for the instances with equity constraints
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due to their computational difficulty. The multi-stage stochastic model is solved over
eight stages for the base case with each stage representing a 2-week period, thus for
a total of the 16-week planning horizon. Since we consider three outcomes on each
branch of the scenario tree, we solve for 38 = 6561 scenarios in the mathematical
model.
2.3 Results
In this section, we present computational results for the multi-stage stochastic MIP
model presented in Section 2.2 for the considered case study instance in West Africa.
Our goal in this section is to provide insights into the optimal and fair resource
allocation for controlling the Ebola disease outbreak under the uncertainty of disease
transmission.
2.3.1 Model Validation
In this subsection, we validate our model against the real outbreak data [WHO, 2016]
in terms of the cumulative number of infections from August 30, 2014, to December
19, 2014. The values of parameters used in the model are obtained from the literature
[Camacho et al., 2014, WHO E. R. Team, 2014, WHO, 2020c].
We fix the number of ETCs at each stage according to the number and timing of
the ETCs established in reality [Büyüktahtakın et al., 2018a]. For instance, according
to the outbreak data, one 50-bed ETC was established on September 15, 2014, in
northern Liberia, and so the value of the related variable is fixed to one in stage one
in the model. Once the ETCs are fixed in the model based on their opening time and
the capacity throughout the planning horizon, the model is solved and validated by
comparing the predicted number of infections with the real outbreak data given in
the WHO database [WHO, 2016].
57
According to the visual comparison of the predicted results and real outbreak
data in Figure 2.3, our model provides a good fit for the cumulative number of infected
individuals in Guinea, Sierra Leone, and Liberia during the considered time period.
In addition, we apply the paired t-test to analyze the difference between the pairs of
weekly predicted cases and the actual data. As shown in Table 2.8, all p-values are
greater than 0.05, indicating that our model provides statistically similar results to
the real outbreak data from August 30, 2014, to December 19, 2014.
Figure 2.3 Comparison of predicted cases with real outbreak data for cumulative
infections in Guinea, Liberia, and Sierra Leone.
Table 2.8 Statistical Analysis to Compare Bi-weekly Predicted Cases and Real
Outbreak Data
Country Mean Two-tailed paired t-test
Outbreak Predicted t-stat t-critical p-value
Guinea 221.0 266.8 0.41 1.89 0.65
Infections Sierra Leone 866.3 910.1 0.65 0.73
Liberia 471.1 534.5 0.45 0.67
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2.3.2 The Value of Stochastic Solution (VSS)
To demonstrate the value of using a stochastic program over a deterministic (expected
value) model, we use a standard measure in stochastic programming, known as the
value of stochastic solution (VSS) [Birge, 1982]. The VSS gives the expected gain
from solving a stochastic model over its deterministic counterpart, in which random
parameters are replaced by their expected values.
Two-Stage VSS WS is the wait-and-see problem objective value, which is the
expected value of using the optimal solution for each scenario. EEV is the expected
result of using the solution of the deterministic model (EV), which replaces all
uncertain parameters by their expected values, and RP is the optimal value of our
stochastic programming model, i.e., the minimization recourse problem. Then the
following inequalities are satisfied for the minimization problems [Madansky, 1960]:
WS ≤ RP ≤ EEV
The VSS can then be formulated as follows:
V SS = EEV −RP
A large value of the VSS implies that incorporating uncertainty is important to
represent the problem realistically, and the solution of the deterministic problem
is not “so good.” On the other hand, if the VSS value is small, replacing uncertain
parameters with their expected values might be a good choice.
Multi-Stage VSS For the multi-stage problem, the value of the stochastic solution
is introduced as a chain of values V SSt for t = 1, . . . , T , where T is the final period
of the planning horizon [Escudero et al., 2007]. In order to calculate the V SSt, the
solution up to stage t−1 of the associated deterministic model is fixed in the stochastic
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model resulting in the EEVt value, and RP value is subtracted from EEVt. Consider
a stochastic model, which only contains decision variables x and recourse variables y,
and let (x̂t, ŷt) be the optimal solution of the corresponding EV model. The EEVt
can then be formulated as:
EEVt : RP model
s.t. xω1 = x̂1 ∀ω ∈ Ω,
· · ·
xωt−1 = x̂t−1 ∀ω ∈ Ω.
The V SSt for each t = 1, . . . , T is then given as:
V SSt = EEVt −RP
As an example, we calculate the V SSt for an 8-stage problem for t = 1, . . . , 4.
Since EEV1 = RP , the value of the V SS1 is zero. We solve the model under a $24M
budget and present the results in Table 2.9 below.
Table 2.9 V SSt Values up to Four Stages for the 8-Stage Problem with EEVt
Values
V SS1(RP ) V SS2 V SS3 V SS4
0 41 65 69
The RP value for the 8-stage problem is 2207 individuals. The V SSt value is
increasing as the stage t increases, thus a multi-stage stochastic model is needed to
obtain a better result compared to the deterministic problem. We notice that under
the $24M budget level, the model allocates almost all the ETCs in the first stage.
Thus, the V SSt value will not change significantly when t ≥ 3. For varying budget
cases or disease dynamics, we expect that the model will allocate ETCs in the stages
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following the first stage, and thus the V SSt values may become larger than the values
in this instance. The results for solving the 8-stage model highlight the importance
of using a multi-stage stochastic model for the epidemic-logistics problem over its
deterministic counterpart.
2.3.3 Analysis of Budget Allocation
The columns of Table 2.10 present results for each Budget level ($12M, $24M, and
$48M), each Country and Region, Stage-1 Budget allocated, Total Budget
allocated, Stage-1 ETC (50/100) representing the number of 50- and 100-bed
ETCs allocated in the first stage of the planning horizon, and Total ETC (50/100)
indicating the total number of 50- and 100-bed ETCs allocated throughout the
planning horizon. Here, expected values of the optimal budget and the number of
ETCs allocated at the first stage and throughout the planning horizon over 6561
scenarios are presented for each budget level. Correspondingly, the expected values
of the total number of infections and funerals for different budget levels are presented
in Figure 2.6. The CPU time used to solve the model is 7230s for the $12M budget,
7232s for the $24M budget, and 7228s for the $48M budget. The optimality gaps for
all the cases are 0.1%.
The fifth column of Table 2.10 and Figure 2.4 show the allocation of the total
budget among three different countries. Due to the high initial number of infected
individuals, Sierra Leone gets the most budget allocation under all different budget
levels. Although the transmission rate of Guinea is higher than Liberia, the second
highest budget goes to Liberia under the $48M budget case because the initial state
of the infection in this country is high, and thus, the allocated budget will provide a
more significant impact on Liberia compared to Guinea when the budget is ample.
According to the results of ETC allocation at all budget levels, most of the beds
are allocated in the first period (stage-1) of the planning horizon under tight budget
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cases, as shown in Table 2.10. Figure 2.5 shows the total capacity allocation under
different budget levels.
Figure 2.6 shows the total number of infections and funerals in those three
countries under different budget levels. According to the result under the $0M budget
level, the case in which no intervention action is taken, the number of infections and
funerals in Sierra Leone would be extremely large if we do not take any intervention
action. As shown in Figure 2.6, the total number of infections and funerals in all
three countries, especially in Liberia and Sierra Leone, drops significantly from $12M
to $48M budget level.
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Table 2.10 Budget and Bed Allocated under Different Budget Levels
Budget Country Region Stage-1 Total Stage-1 Total
($M) Budget Budget ETC ETC
($M) ($M) (50/100) (50/100)
12
Guinea
UG 0.06 0.13 1/1 1/1
MG 0.01 0.02 1/0 1/0
LG 0.03 0.06 1/0 1/0
Sierra Leone S 4.33 11.67 1/4 1/4
Liberia
NL 0.04 0.09 1/1 1/1
SL 0.01 0.03 1/1 1/1
Total 4.47 11.99 6/7 6/7
24
Guinea
UG 0.72 1.83 1/1 1/1
MG 0.52 1.21 1/0 1/1
LG 0.62 1.53 1/1 1/1
Sierra Leone S 5.35 15.50 1/5 1/5
Liberia
NL 0.83 2.31 1/1 1/1
SL 0.57 1.60 1/1 1/1
Total 8.62 23.98 6/9 6/10
48
Guinea
UG 1.11 2.52 1/1 1/1
MG 0.91 1.91 1/1 1/1
LG 1.01 2.32 1/1 1/1
Sierra Leone S 6.85 18.89 4/5 5/5
Liberia
NL 3.94 10.42 3/3 3/3
SL 2.40 6.03 2/2 2/2
Total 16.22 42.09 12/13 13/13
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Figure 2.4 Total budget allocation under different budget levels.
Figure 2.5 Total capacity allocation under different budget levels.
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Figure 2.6 Total number of infections and funerals under different budget levels.
The results presented in this subsection represent the expected values over all
scenarios. To perform a more detailed analysis, we picked 5 (five) out of 6561 scenarios
and analyzed the corresponding results in the next subsection.
2.3.4 Analysis of Different Scenarios
In this subsection, we present results regarding the budget, and ETC allocation as well
as the corresponding total number of infections and funerals for five specific scenarios
under a budget level of $24M. Those four different scenarios are defined as follows.
The first scenario is the “All Low” case that corresponds to the low realization of the
uncertain community disease transmission rate from stages 1 to 8, the second scenario
is the “All Medium” case that corresponds to the medium realization of the uncertain
community disease transmission rate from stages 1 to 8, the third scenario is the “All
High” case that represents the high realization of the community disease transmission
rate from stages 1 to 8, the fourth scenario is the “Low-High” case that stands for
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the low realization of the disease transmission rate from stages 1 to 4 followed by
its high realization from stages 5 to 8, and the fifth scenario is the “High-Low” case
that represents the high realization of the community disease transmission rate from
stages 1 to 4 followed by a low transmission rate from stages 5 to 8. According to
the results, we divided scenarios into two groups except for the “All Medium” case;
the first one is called the better group, including “All Low” and “Low-High” cases,
on the other hand, the second group is called the worse group, encompassing “All
High” and “High-Low” cases. Similar to Table 2.10, Table 2.11 presents results for
each Scenario defined above under the $24M budget level.
The first-stage budget allocation is presented in the fourth column of Table
2.11, while the total budget is presented in both the fifth column of Table 2.11 and
Figure 2.7. In terms of bed allocation, all the regions have the same number of bed
allocation for stage-1 and for the total stages under all scenarios. This result implies
that it is optimal to open treatment centers early in all the locations, in particular,
in the initial stages.
Figure 2.8 represents the total capacity allocation under different scenarios.
According to the results, the total capacity allocated under the worse scenario group is
higher than the capacity allocated for the better group. This result implies that under
the worse scenario group, more budget is allocated to build new Ebola treatment
centers. In addition, as shown in Figure 2.9, the total number of new infections and
funerals under the “High-Low” case is much higher than the corresponding number
under the “Low-High” case. Thus, a scenario where the disease starts with a low
transmission rate and then progresses fast is better than a scenario in which the
disease progression is fast and then slows down. This may be because diseases that
initially progress less aggressively give us more time to get prepared, establish the
ETCs and treatment resources, and thus reduce the number of infections immediately.
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Table 2.11 Budget and Bed Allocated under Different Scenarios
Scenario Country Region Stage-1 Total Total




UG 0.60 1.15 2/0
MG 0.60 1.02 2/0
LG 0.60 1.13 2/0
Sierra Leone S 5.39 12.44 0/5
Liberia
NL 2.15 5.46 0/2
SL 1.08 2.79 0/2
Total 10.41 24.00 6/9
All Medium
Guinea
UG 0.60 1.64 2/0
MG 0.60 1.43 2/0
LG 0.60 1.64 2/0
Sierra Leone S 5.39 16.13 0/5
Liberia
NL 0 0 0/0
SL 1.08 3.16 0/2
Total 8.26 24.00 6/7
All High
Guinea
UG 1.08 2.75 0/2
MG 0.60 1.51 2/0
LG 1.08 2.23 0/2
Sierra Leone S 7.06 17.51 2/7
Liberia
NL 0 0 0/0
SL 0 0 0/0
Total 9.82 24.00 4/11
Low-High
Guinea
UG 0.60 1.44 2/0
MG 0.60 1.18 2/0
LG 0.60 1.34 2/0
Sierra Leone S 4.31 12.02 0/5
Liberia
NL 1.68 4.91 2/2
SL 1.08 3.11 0/2
Total 8.86 24.00 8/9
High-Low
Guinea
UG 1.08 2.44 0/2
MG 0.60 1.29 2/0
LG 1.08 2.23 0/2
Sierra Leone S 6.46 15.47 0/7
Liberia
NL 1.08 2.56 0/2
SL 0 0 0/0
Total 10.29 24.00 2/13
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Figure 2.7 Total budget allocation under different scenarios.
Figure 2.8 Total capacity allocation under different scenarios.
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Figure 2.9 Total number of new infections and funerals under different scenarios.
The results above indicate that if the budget is tight or the disease moves fast,
some countries or regions may not get the ETC allocation or treatment. For example,
under the “All High” scenario, no budget is allocated to Liberia. Therefore, in the
next subsection, we introduce the equity constraint to remedy the problem of not
allocating any ETCs or treatment resources to a single country or some of the regions
of a country.
2.3.5 Impacts of Equity Considerations
In this subsection, we present results by adding each of the three equity constraints
(2.2), (2.3), and (2.4), as introduced in Subsection 2.2.6, separately into the
linearized multi-stage stochastic programming epidemic-logistics model (2.1). Equity
constraints impose a bound on the total number of infections in each region and thus
enforcing that each region considered in West Africa receives a more equitable share
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of resources, including ETCs and treatment funds, while minimizing the total number
of infections and deaths.
According to the results, imposing the infection equity constraint (2.2) or the
prevalence equity constraint (2.4) does not significantly change the optimal budget
allocation or the total number of new infections and funerals (see Appendix A.4
for detailed results). Without introducing the infection equity constraint into the
mathematical model (2.1), the absolute value of the difference between the infection
ratio and the population ratio in Guinea, Sierra Leone, and Liberia is 0.42, 0.04,
and 0.38, respectively, based on the optimal solution value similar to the k values
considered here. This result implies that our model balances the total number
of infections in each region with its population and population, even without the
infection equity constraint.
Similar to the infection equity case, we introduce the capacity equity constraint
(2.3) into the multi-stage stochastic programming epidemic-logistics model (2.1) for
an 8-stage instance with the $24M budget level under different values of k. Table
2.12 represents the run time specifics regarding the mathematical model (2.1) with
the capacity equity constraint (2.3), while Figures 2.10 and 2.11 present the budget
allocation and the total number of infections and funerals over the three considered
countries for varying k values. When k is larger than 0.4, we observe no significant
change in the results. However, a small k value can impact the results significantly.
For example, when k = 0.05, all three regions have a similar budget allocation. If k
increases from 0.05 to 0.2, the total number of infections and funerals in Guinea is
slightly increased, but it is decreased when k is further increased. Thus, allocating the
majority of resources to Guinea may not be necessary, and some of those resources
would be wasted. As we relax the equity capacity constraint by increasing the k
value from 0.05 to 0.4 and above, we observe a significant drop in the number of
infected individuals and funerals in Sierra Leone. The total number of infected people
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and funerals over all three countries is the largest (12,769) when the capacity equity
constraint is strictly enforced, and it is the smallest (10,995) when the capacity equity
constraint is relaxed. This result implies that enforcing a tight equity constraint might
adversely impact the total number of infections and deaths, and thus resulting in a
high cost that we have to pay for fairness.
Table 2.12 Model Run Specifics with the Capacity Equity Constraint (2.3)





A large k value
7,232 0
(no-equity-constraint case)
Figure 2.10 Optimal budget allocation under different k values for an 8-stage
problem with $24M budget.
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Figure 2.11 Total number of new infections and funerals under different k values
for an 8-stage problem with $24M budget.
2.4 Discussion and Future Research Directions
In this chapter, we extended the epidemic-logistics model of Büyüktahtakın et al.
[2018a] to study an epidemic control problem in a large-scale population where
the transmission rate of the disease is uncertain. To our knowledge, this is the
first multi-stage stochastic epidemic-logistic model that takes into account both
the uncertain disease growth and equitable resource allocation simultaneously. We
consider various disease progression scenarios resulted from the realization of the
community transmission rates. Our objective is to minimize the total expected
number of infected individuals and funerals over all scenarios, all periods, and all
regions considered. We study the value of the stochastic solution and introduce the
equity constraints to analyze the fair resource allocation among different countries
and multiple regions of a country. Our multi-stage VSS analysis suggests that
the stochastic model considerably improves the solution of the deterministic model,
and the consideration of uncertainty in a multi-stage disease-transmission model is
necessary.
We define the infection level as the difference between the ratio of the number
of infected people in a region to the total number of infected people over all regions
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and the ratio of the population in a region to the total population over all regions.
Under tight budget levels, most of the budget would be allocated to the region that
has the highest initial infection level, while other regions would receive ETCs and
treatment resources according to their infection level as the available budget increases.
This indicates that the initial infection level is a key factor in resource allocation.
Additionally, more 100-bed ETCs would be allocated to the country that has a high
infection level since more capacity will be needed to treat infected people while saving
from the fixed cost of opening new ETCs.
According to the results, our model allocated most of ETCs in the first stage to
provide a quick response to the epidemic and reduce a large number of unnecessary
infections and funerals. Our results showed that the number of untreated infections
dropped quickly when early actions were taken with a sufficiently large budget, and
the disease was controlled much faster than the report date of the World Health
Organization (WHO). The uncertainty in disease transmission is a critical factor that
makes it challenging to manage an outbreak in a real-life situation. To be more
specific, the transmission rate might suddenly become high after a latent period, and
the existing resources may not be sufficient to handle such unexpected situations.
Consequently, a large number of unisolated and untreated individuals could stay in
the community and continue to spread the disease, as in the case of the current
outbreak of Coronavirus (COVID-19) disease [WHO, 2020e]. Thus, the preparedness
and early action to handle the uncertain disease transmission are crucial, and we
would rather “the beds waiting for people” than “people waiting for the beds.” Our
findings are consistent with several other articles that also report the importance
of early action for epidemic control [Lekone and Finkenstädt, 2006, Jacobsen et al.,
2016, Siedner et al., 2015]. The lessons learned from the EVD control in West Africa
by WHO and Centers for Disease Control and Prevention (CDC) also indicate that
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an early action will have a significant improvement in slowing down an epidemic and
eventually stopping it [CDC, 2019b, WHO, 2020c].
Different than the former literature, the solutions of our multi-stage stochastic
programming model show that the optimal timing of the resource allocation might
vary if we have a relatively ample budget. For instance, in both $24M and $48M
budget levels, some resources were allocated throughout the planning horizon in some
locations, such as Guinea and Sierra Leone. This is because we have more budget to
take action when the transmission of the disease gets worse. This result shows that
the timing of the resource allocation should be decided dynamically and based on the
predicted disease growth scenario and budget, and thus implying the superiority of a
multi-stage stochastic programming model over a two-stage or static model again.
We analyze five specific disease growth scenarios and study resource allocation
strategies under each scenario. Under the scenarios in which the disease moves faster,
more number of ETCs are allocated compared to the scenarios in which the disease
moves slower to treat more people. In addition, if the disease moves faster, the
majority of the capacity is allocated to the region that has the highest initial infection
level. If the disease consistently moves at a slow rate, the treatment capacity is
allocated more equally among regions to help fight against the disease. In the “Low-
High” case, in which the disease moves in a slow rate first and then starts to be
more aggressive in the following time stages, the model allocates budget immediately
to the regions with a high infection level and knocks down the number of infected
individuals to low values, which will lessen the impacts of a high disease transmission
rate later in the planning horizon. Because an initially slow-moving disease gives us
more time to get prepared to control the disease spread, the “Low High” case can be
considered as a better scenario compared to the “High-Low” case.
We introduced the infection and capacity equity constraints separately into our
model to analyze the impact of enforcing fairness in resource allocation. Solutions
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obtained with the infection equity constraint imply that the original optimal solution
balances the resource allocation among multiple regions in a similar fashion to the
infection equity constraint. Thus, our model takes into account the ratio of infection
to the total infection level as well as the ratio of the population to the total population
level over all three countries while making the resource allocation decision.
When a tight capacity equity constraint is enforced, the budget is allocated
equally to the three regions. However, in this case, some of the budget may be
wasted, and no obvious effects are brought out by providing additional capacity to
a region based solely on its population. This result shows that allocating treatment
resources proportional to population is sub-optimal, which is also consistent with the
findings of Ren et al. [2013]. When the capacity equity constraint is relaxed, the
number of infections and funerals in Guinea and Liberia is slightly changed, but this
number decreased significantly for Sierra Leone, and the total three countries. For
both tight and ample budget cases, the total number of infections and funerals is much
higher when the capacity equity constraint is strictly forced, resulting in a heavy price
we would have to pay for perfect equity in resource allocation. This result implies
that the decision maker should be cautious about enforcing fairness when allocating
resources to multiple regions.
There are several important future research directions that arise out of this
study. For example, the impact of vaccinations currently used to prevent the spread
of the disease could be analyzed in a future study. The influence of vaccination is
group-specific, and thus susceptible individuals can be divided into different groups
according to their age, sex, race, and health status. Due to the lack of available data,
the transmission rate from susceptible individuals to infected individuals would be
more difficult to predict under vaccination. Furthermore, different kinds of vaccines
used, the amount of vaccine allocated to each region, and the time when vaccination
becomes accessible might impact the disease transmission rate significantly. Our
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model could be extended by adding a compartmental class named as “vaccinated” to
study the various dimensions of vaccination.
Moreover, our multi-stage stochastic program only includes the expectation
criterion in the objective function when it compares random variables to find the best
decisions. Thus, our study provides a risk-neutral approach. In a future extension
of this work, risk measures, such as Conditional Value at Risk (CV aR), could be




RISK-AVERSE MULTI-STAGE STOCHASTIC PROGRAMMING TO
OPTIMIZING VACCINE ALLOCATION AND TREATMENT
LOGISTICS FOR EFFECTIVE EPIDEMIC RESPONSE
3.1 Introduction
Epidemics and pandemics have devastated humanity throughout its existence. One
recent example is the Coronavirus (COVID-19), which has spread all over the world
since its first detection in China at the end of 2019, causing over 33 million cases and
1 million deaths as of October 2020 [JHU, 2021]. The COVID-19 has also resulted in
large economic losses, and the associated damage continues to escalate. For example,
due to the pandemic, 400 million full-time jobs were lost across the world [CNBC,
2020], and consumer spending so far decreased by more than one trillion dollars only
in the U.S. [Routley, 2020]. Another example is the 2014-16 Ebola Virus Disease
(EVD), one of the deadliest viral infections, causing more than ten thousand deaths in
West Africa. Other recent examples include the Severe Acute Respiratory Syndrome
(SARS), which affected 26 countries since its discovery in South China in 2003, and the
novel swine-origin influenza A (H1N1) virus that spread fast in the human population
since its first appearance in 2009, causing tens of millions of cases and 12,469 deaths
only in the U.S. [CDC, 2016, WHO, 2019b, CDC, 2019a]. Such viral diseases causing
lower respiratory infections, such as pneumonia, have remained among the top causes
of death globally including stroke and cancer [WHO, 2021b, Hasan et al., 2019].
Effective and timely allocation of limited resources, such as medical treatment
and vaccination, plays a crucial role in alleviating the ravaging impacts of infectious
disease outbreaks on the human population. This problem has attracted much
attention from academics and practitioners. The vast majority of the research
literature involves simulations and differential equations [Siettos et al., 2015, Ajelli
et al., 2016, Craft et al., 2005, Kaplan et al., 2003] to estimate the transmission of
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the disease and tackle the epidemic resource allocation problem. Other studies use
network models and stochastic compartmental models to analyze various strategies
on the control of an epidemic [Berman and Gavious, 2007, Longini Jr et al., 2007,
Porco et al., 2004, Riley and Ferguson, 2006, Lekone and Finkenstädt, 2006, Tanner
et al., 2008, Funk et al., 2017] as well as resource allocation analysis [Zaric et al.,
2000, Tebbens and Thompson, 2009, Nguyen et al., 2017, Shaw and Schwartz, 2010].
Previous operations research models that study the epidemic diseases and
resource allocation mainly focused on the logistics and operation management to
control the disease in optimal ways [Zaric and Brandeau, 2001, Büyüktahtakın et al.,
2018a, Ekici et al., 2013, Liu et al., 2019, Queiroz et al., 2020]. Only a few of those
OR studies that integrate resource allocation with epidemics control consider the
uncertain parameters for resource allocation to control the disease. Those mainly
use stochastic and approximate dynamic programming [Coşgun and Büyüktahtakın,
2018, Long et al., 2018] and two-stage stochastic programming [Ren et al., 2013,
Yarmand et al., 2014, Tanner et al., 2008]. Because the growth of an infectious
disease dynamically changes over time, Yin and Büyüktahtakın [2021a] present a
multi-stage stochastic programming model to capture the dynamics of an evolving
disease for effective epidemic control under the uncertainty of disease transmission.
Multi-stage stochastic programs typically minimize an expectation criterion,
which calculates the expected cost of all possible scenarios, each of which is mapped
with a certain probability of occurrence. The expectation is the most widely-used
objective criterion in stochastic programming [Ahmed, 2006]. However, it does
not capture the variability in possible scenarios that could arise, in particular, the
situations with high impact and low probability. If some extreme scenarios occur,
there could be a significant loss when only the expected value is considered in resource
allocation decision-making. For example, in a disastrous epidemic outbreak situation,
non-repetitive decisions made at the beginning of the horizon, such as the placement
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of treatment facilities, may result in capacity shortages and unmet demand under
the realization of a severe disease spread scenario. At the beginning of an epidemic
outbreak, disease characteristics, such as the infection or disease transmission rate,
may be unknown, and the disease growth could be highly uncertain due to the lack
of data. Thus a large number of infections and losses could happen in shorter time
periods than expected, as in the case of COVID-19 [Lazzerini and Putoto, 2020,
Li et al., 2020]. The former epidemics control multi-stage stochastic programming
model of Yin and Büyüktahtakın [2021a] only considered an expectation criterion in
the objective function. To alleviate the adverse impacts of experiencing a disastrous
disease transmission scenario, we consider a risk measure in the objective function in
addition to the expectation criterion.
Conditional value-at-risk (CVaR) is a coherent risk measure that can be
used in an optimization model without losing convexity [Rockafellar and Uryasev,
2002]. Therefore, many previous studies considered mean-risk models with CVaR
in stochastic programming models [Ahmed, 2006, Rockafellar and Uryasev, 2002,
Schultz and Tiedemann, 2006, Miller and Ruszczyński, 2011]. CVaR-based mean-risk
stochastic programming has been studied in various applications, such as supply chain
management [Alem and Morabito, 2013], reverse logistic network design problem
[Soleimani and Govindan, 2014], solid waste management system [Dai et al., 2014],
water resources allocation [Zhang et al., 2016], and forestry invasive species control
planning [Bushaj et al., 2020a].
In this chapter, we address the problem of building a mean-CVaR, multi-stage,
stochastic mixed-integer programming epidemics-vaccination-logistics model. Our
model evaluates various scenarios regarding the disease growth and the vaccine
availability to optimize the distribution of treatment centers and vaccines while
minimizing the total expected number of infections, funerals, and close contacts of
infected people under a limited budget. Here, we consider the risk of experiencing
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scenarios that lead to adverse outcomes in terms of the number of infected and dead
people due to the epidemic. Combining the risk-neutral objective with a risk measure
allows for a trade-off between the weighted expected impact of the outbreak and the
expected risks associated with experiencing extremely disastrous scenarios.
For a newly-discovered disease, the invention of a new vaccine is difficult and
typically takes a long time. Even if there is an approved vaccine available, its
production will be short compared to the high demand in the early period of the
outbreak, and thus the availability of the vaccines will be limited. In this study, we
address the optimal distribution of limited vaccine supply in addition to the allocation
of treatment resources to control an epidemic outbreak under the uncertainty in the
vaccine supply and the transmission rate.
To incorporate human mobility within multiple regions of a country, we present
a new formulation to estimate migration rates among various locations. We apply
our model to the case of controlling the 2018-2020 EVD in the Democratic Republic
of the Congo (DRC). We provide insights into the optimal resource allocation among
different regions of DRC in a multi-period planning horizon with and without risk. We
also analyze how risk-aversion affects decision-making, such as the budget allocated
to treatment and vaccination and the number of infections and deaths, compared to
the risk-neutral problem.
3.1.1 Key Contributions and Insights
Former studies on the logistics of epidemics have omitted the risk of experiencing
extreme scenarios when formulating a stochastic optimization model. A risk-neutral
stochastic programming approach, which does not consider variability in possible
scenario outcomes, may perform poorly when there are outliers in the distribution
of the scenarios. Also, existing mathematical programming studies on epidemic
control have not incorporated vaccine allocation into a compartmental-logistics model.
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Furthermore, due to the lack of data, the rates of migration among multiple regions of
DRC are not known. The population is quite mobile within regions and countries in
Africa [Flahaux and De Haas, 2016]. Thus, movement rates are difficult to estimate.
In this chapter, we address those aforementioned limitations existing in both
the epidemiological modeling and healthcare operations research literature. Below,
we present the modeling and applied contributions with key recommendations to
decision makers.
Modeling Contributions. First, to our knowledge, we present the first risk-averse
multi-stage stochastic programming model presented in the research field of infectious
disease control. Different than the former literature, we formulate the uncertainty
in the transmission rate from the close contacts of infected people to the infections
compartment and the uncertainty in total vaccines available as two dependent random
variables in a multi-stage stochastic scenario tree. We then incorporate a nested
CVAR risk measure into the objective function of the formulation while defining
risk-related constraints to alleviate the risk of experiencing scenarios that lead to
adverse outcomes in terms of the number of infected and dead people due to the
epidemic. We also provide insights on how the expected impact and expected risk
in terms of deaths and infections change as the decision maker shifts from being
risk-neutral to risk-averse at varying risk levels.
Second, we address the optimal allocation of vaccines to multiple regions within
a country in addition to the allocation of Ebola Treatment Centers (ETCs) and
treatment resources to control an epidemic outbreak in a multi-stage stochastic
mean-risk model. Specifically, we have extended the Susceptible-Infected-Treated-
Recovered-Funeral-Burial epidemics-logistics model of Büyüktahtakın et al. [2018a]
into an epidemic-vaccination-logistics model by incorporating new ring vaccination
compartment under uncertainty and risk.
81
Third, we develop a new formulation to estimate the migration rates between
regions of a country and integrate the impacts of human mobility into our epidemic-
vaccination-logistics model. Thus, our mathematical model captures the influence of
human movement on the transmission of the disease.
Fourth, our risk-averse epidemic-vaccination-logistics model is general and thus
could be adopted to study other epidemic diseases, such as influenza and H1N1, as
well as pandemics, such as the COVID-19.
Applied Contributions and Key Recommendations to Decision Makers.
We implement our multi-stage stochastic mean-risk model to study the case of the
2018-2020 EVD in the DRC. We collect and synthesize epidemiological, population,
and economic data of Ebola infections in the provinces of DRC and organize them
into regional data, using WHO Ebola situation reports [WHO, 2021a, 2020a]. We
perform computational experiments to analyze the impact of treatment budget, risk
parameters, uncertain vaccine availability, and vaccine acceptance and effectiveness
rates on the allocation of resources, such as ETC and vaccines, during an epidemic.
We drive several insights into the optimal resource allocation under various risk levels
that the decision maker is willing to take for controlling an infectious disease. As such,
our mathematical model could be used as a decision support tool to aid policymakers
in determining the optimal risk-averse treatment and vaccine-allocation policies.
Based on our results, we provide the following recommendations to inform the
resource allocation decision making under an epidemic situation:
(i) Regions with a high initial infection level (“the number of infected people in
a region” / “the total number of infected people” - “population in a region” /
“total population over all regions”) get the majority of the resources. While the
ETCs and treatment budget are mainly allocated to highly infected locations,
the model allocates a budget for vaccination to most locations to prevent the
disease’s spread. Our findings also suggest using the budget for vaccination
in regions where the disease has just started, while in regions with high initial
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infections, the model gives priority to build new ETCs and treat infected people
over vaccination.
(ii) The potential risk associated with regions with low or zero initial infection levels
should also be taken into account when making resource allocation decisions.
For instance, a non-infected region nearby a highly-infected location may also be
severely affected by the disease due to human mobility among multiple regions.
Thus, as the risk-averseness level increases, the budget allocated to areas with
the highest initial infection level is decreased by moving the ETC and treatment
budget to neighboring locations under the risk of getting infections.
(iii) A risk-averse decision-maker should expect a possible increase in the number
of infections and deaths while trying to mitigate disastrous outbreak scenarios.
Being risk-averse also increases the expected cost of treatment and vaccination.
(iv) For the considered case of the EVD in DRC, isolating and treating infected
individuals are the most efficient ways to slow the disease’s transmission. When
the supplied vaccines are available but limited, the vaccination is supplementary
to the primary interventions on reducing the number of infections.
(v) While vaccination is supplementary, its delay could cause an exponential
increase in the number of infections and deaths, even under the main inter-
vention measures, such as treatment and isolation. In particular, vaccination
at earlier stages of an epidemic would also help control the disease faster than
immunization at later stages. Thus, if available, vaccination should be applied
as early as possible for effective epidemic response.
(vi) The number of vaccines supplied to Upper North Kivu and Middle North Kivu,
the two most-impacted regions of DRC, has a complementary relationship.
When the vaccine acceptance rate is fixed, the number of vaccines provided
to these two regions only sightly fluctuates under different vaccine effectiveness
rates. Also, the more effective the vaccine is, the fewer vaccines are needed in
highly-impacted areas so that some remaining vaccines could be used in regions
with lower infection.
(vii) When the vaccine effectiveness rate is fixed, vaccine acceptance rates affect
vaccine allocation at the initial stages of the vaccine rollout. Under a very
low vaccine acceptance rate, available vaccines are moved from highly impacted
locations to less affected areas. However, vaccine acceptance rates do not impact
the total number of vaccines distributed throughout the planning horizon under
a limited vaccine supply.
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3.2 Multi-Stage Risk and Time Consistency
Let FZ(·) be the cumulative distribution function of a random variable Z. The α-
quantile of the distribution, infη{η ∈ R : FZ(η) ≥ α}, is defined as the value-at-risk
(VaR) at the confidence level α ∈ [0, 1) and denoted by VaRα(Z).
The mean excess loss or tail VaR, at level α, is called conditional value-at-risk
(CVaR), defined as CVaRα(Z) = E(Z | Z ≥ VaRα(Z)). Specifically, CVaR is the
conditional expected value that exceeds the VaR at the confidence level α. For a
minimization problem, VaRα is the α-quantile of the cost distribution, and it provides
an upper bound on the cost that is exceeded only with a small probability of 1− α.
On the other hand, CVaRα measures an expectation of the cost that is more than
VaRα, the α-quantile of the distribution of costs. The conditional value-at-risk can






where (a)+ := max(a, 0) for any a ∈ R.




{E(f(x, ω)) + λCVaRα(f(x, ω))}, (3.1)
where E(f(x, ω)) represents the expected cost function of the scenarios ω ∈ Ω,
CVaRα represents the conditional value-at-risk at α ∈ [0, 1), and λ ∈ [0, 1] is a
non-negative coefficient of the risk part. The risk preference parameter λ is the
weight of the risk term in the objective function (3.1), and can be adjusted for a
trade-off between optimizing an expectation value [E(f(x, ω))] and the level of risk
taken [CVaRα(f(x, ω))]. The larger the λ, more risk-averse the decision maker is.
The α parameter, on the other hand, gives the confidence level on the perceived
risky scenarios that exceed the maximum acceptable loss, VaRα. As α increases, the
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probability of exceeding the VaRα reduces, and thus the decision maker becomes more
risk averse. The parameter α ∈ [0, 1) is typically set to a high value, e.g., 0.95. The
parameters λ and α are set by the user to adjust the level of risk averseness and do
not have a direct relationship.
Time Consistency. When modeling a risk-averse multi-stage stochastic program,
time consistency is considered as a critical issue. Time consistency implies that if
you solve a multi-stage stochastic programming model today and find solutions for
each node of a tree, you should get the same solution if you resolve the problem
tomorrow when you are given the information that is observed and decided today. For
a multi-stage stochastic model, risk measures can be applied at every stage additively
or to the complete scenario path or in a nested form similar to dynamic programming.
The nested risk measures are shown to satisfy the time consistency of multi-stage
stochastic programs in the study of [Homem-de Mello and Pagnoncelli, 2016].
We consider a nested risk measure, expected conditional value-at-risk (E-CVaR),
as defined in Homem-de Mello and Pagnoncelli [2016]. The E-CVaR can be linearized
and formulated as a linear stochastic programming model. In the next section, we
will utilize the E-CVaR as a risk measure to formulate our mean-risk multi-stage
stochastic epidemics-vaccination-logistics model.
3.3 Problem Formulation
This section presents the compartmental model description and the mean-risk
formulation of the multi-stage stochastic epidemics-vaccination-logistics model.
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3.3.1 Notation
In this subsection, we describe the model notation that will be used throughout the
rest of this chapter.
Sets and indices:
J : Set of time periods, J = {0, ..., J}.
A : Set of ETC types, A = {1, ..., A}.
R : Set of regions, R = {1, ..., R}.
Mr : Set of all surrounding regions of region r.
Ω : Set of scenarios, Ω = {1, ...,Ω}.
j : Index for time period, where j ∈ J .
r : Index for region where r ∈ R.
a : Index defining type of ETC, where a ∈ A.
ω : Index for scenario, where ω ∈ Ω.
Transition parameters used to describe the rate of movement between disease
compartments:
χ1,r :Disease fatality rate without treatment in region r.
χ2,r :Disease fatality rate while receiving treatment in region r.
χ3,r :Disease survival rate without treatment in region r.
χ4,r :Disease survival rate with treatment in region r.
χ5,r :Safe burial rate of Ebola-related dead bodies in region r.
σr :Transmission rate per person in general community
due to community interaction in region r.
θω1,r :Transmission rate per person of close contacts due to
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interaction with infected individuals in region r under scenario ω.
θ2,r :Transmission rate per person of close contacts during a traditional funeral
ceremony in region r.
f :Vaccine acceptance rate.
βr :Vaccine effectiveness rate.
εr :Transmission rate per person from successfully vaccinated V (immune)
to general community S (not immune anymore) in region r.
Other parameters:
bj,r :Unit cost of treatment for an infected individual in region r at the end of
period j.
gaj,r :Fixed cost of establishing type a ETC in region r at the end of period j.
ka :Capacity (number of beds) of type a ETC.
ur :The population in region r.
ej,r :Unit cost per vaccine in region r at the end of period j.
∆ :Total available budget for treatment.
πr :Initial number of susceptible individuals in general community in region r.
φr :Initial number of close contacts of infected people in region r.
ϕr :Initial number of vaccinated individuals in region r.
$r :Initial number of infected individuals in region r.
κr :Initial number of treated individuals in region r.
ϑr :Initial number of recovered individuals in region r.
υr :Initial number of unburied dead bodies in region r.
τr :Initial number of buried dead bodies (funerals) in region r.
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ςr :Initial treatment capacity in terms of the number of ETC beds in region r.
il→r :Migration rate of infected individuals from surrounding regions l ∈Mr to
region r.
hl→r :Migration rate of close contacts from surrounding regions l ∈Mr to region r.
ir→l :Migration rate of infected individuals from region r to surrounding
regions l ∈Mr.
hr→l :Migration rate of close contacts from region r to surrounding regions l ∈Mr.
dωj,r :Binary variable for linearization in region r at the end of period j under
scenario ω.
Uωj,r :Auxiliary variable to be substituted with (C
ω
j,r − T ωj,r)dωj,r
in region r at the end of period j under scenario ω.
W ωj,r :Auxiliary variable to be substituted with I
ω
j,r(1− dωj,r)
in region r at the end of period j under scenario ω.
QLB :Lower bound for C
ω
j,r − T ωj,r.
QUB :Upper bound for C
ω
j,r − T ωj,r.
ILB :Lower bound for I
ω
j,r.
IUB :Upper bound for I
ω
j,r.
Gωj :Number of total supplied vaccines at the end of period j under scenario ω.
q :Average number of close contacts per each infected individual.
State variables:
Sωj,r :Number of susceptible individuals in general community
in region r at the end of period j under scenario ω.
Hωj,r :Number of close contacts of infected people
in region r at the end of period j under scenario ω.
V ωj,r :Number of successfully vaccinated individuals, who are fully immunized to
disease, in region r at the end of period j under scenario ω.
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Iωj,r :Number of infected individuals in region r at the end of period j under
scenario ω.
T ωj,r :Number of individuals receiving treatment in region r at the end of period j
under scenario ω.
Rωj,r :Number of recovered individuals in region r at the end of period j under
scenario ω.
F ωj,r :Number of deceased individuals due to the epidemic in region r at the
end of period j under scenario ω.
Bωj,r :Number of buried individuals in region r at the end of period j under
scenario ω.
Ĥωj,r :Number of close contacts of infected people migrating into
region r at the end of period j under scenario ω.
H̃ωj,r :Number of close contacts of infected people emigrating
from region r at the end of period j under scenario ω.
Îωj,r :Number of infected individuals migrating into region r
at the end of period j under scenario ω.
Ĩωj,r :Number of infected individuals emigrating from region r at the end of
period j under scenario ω.
Decision variables:
Cωj,r :Total capacity (number of beds) in ETCs to be established in region r at
the end of period j under scenario ω.
I
ω
j,r :Number of infected individuals hospitalized (and quarantined) in region r
at the end of period j under scenario ω.
yωaj,r :Number of type a ETCs established in region r at the end of period j
under scenario ω.




α :Confidence level of value-at-risk, where α ∈ [0, 1).
λ :Non-negative risk preference parameter or mean-risk trade-off coefficient.
Risk variables:
ηωj :Value at risk at the confidence level α for each stage j
under scenario ω.
zωj :Value exceeding the value-at-risk at the confidence level α (η
ω
j ) at stage j
under scenario ω.
Sets and Parameters related to non-anticipativity:
N :Set of nodes in the scenario tree.
n :The serial number of nodes in the stochastic decision tree.
β(n) :Set of scenarios that pass through node n ∈ N .
t(n) :The corresponding stage that node n marked in the decision tree.
3.3.2 Compartmental Disease Model Description
Figure 3.1 One-Step disease compartmental model.
Figure 3.1 shows the transmission dynamics of the EVD in a region r located
in DRC for each period j. The disease spreads among susceptible individuals (S) as
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well as close contacts of infected (H), by either person-to-person contact at a periodic
rate of θω1,r under scenario ω or through touching Ebola-related dead bodies that are
not yet buried during traditional funerals at a periodic rate of θ2,r in region r. Thus,
once close contacts (H) or susceptible individuals (S) become infected, they move to
the infected (I) compartment. However, individuals in the general community (S) are
infected with a lower rate of σr compared to close contacts (H).
Here, we focus on modeling the ring vaccination, where only close contacts with
infected people can be vaccinated. The quantity of vaccines allocated to region r
under scenario ω at the end of period j under scenario ω is defined by the variable
Oωj,r. Given the effectiveness rate of vaccination, βr, there will be βrO
ω
j,r people who
are moving from the (H) to (V) compartment in each period j, where (V) represents
the successfully vaccinated individuals, who become fully immunized by vaccination.
Next, due to the time effect, successfully vaccinated individuals (V) become no longer
immune to the disease over time and move to the general community (S) with a
rate of εr in region r. When the number of infected people increases, the close
contacts of infected people will also increase. Thus, the dotted arrow from the general
community (S) to close contacts (H) represent the movement of people from (S) to
(H) as (I) increases. Furthermore, since people are getting vaccinated, the number






j,r, where q is the average number of close contacts for each
infected individual. The term
θω1,r
q
shows the proportion of close contacts that would
be infected for each infected individual, and because βrO
ω
j,r represents the number of





j,r gives the number of close contacts saved by the vaccination.
Without treatment, some of the infected individuals in the compartment (I)
will die and move to the funeral (F) compartment with the rate of χ1,r, while some
of the infected individuals will recover with a rate of χ3,r, moving into the recovered
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compartment (R). However, the number of individuals hospitalized for treatment (T)
is based on the treatment capacity variable Cωj,r, which gives the available number of
beds in the ETCs in region r under scenario ω in period j. Thus, there is no constant
transition rate from I to T. Meanwhile, individuals who did not receive treatment
will remain in the community and spread the disease. In treated compartment (T),
some individuals will recover with a periodic rate of χ4,r, and a fraction of them will
die with a periodic rate of χ2,r. The deceased individuals in the funeral compartment
are safely buried at a rate of χ5,r, moving into the buried compartment (B).
To describe the migration of infected individuals and close contacts within a
given country, we define il→r and ir→l as the rates of migration of infected individuals
into and out of region r, as shown in dotted arrows going in and out of compartment
(I). Similarly, we define hl→r and hr→l as the rates of migration of close contacts of
infected people (H) into and out of region r.
3.3.3 Uncertainty and Model Assumptions
Modeling Uncertainty. In this chapter, we used a discrete set of scenarios ω ∈ Ω to
model the uncertainties related to the disease–the uncertainty in the transmission rate
from the close contacts of the infected individuals to infections and the uncertainty




pω = 1. We assume that the uncertainty of the transmission rate
is highly dependent on the availability of vaccine supply. If the vaccine supply is
high, we observe a low transmission rate from close contacts to infections, and if
the vaccine supply is low, we will have a high transmission rate instead. For our
multi-stage stochastic model, we have two branches in each node of the scenario tree,
representing the two possible realizations in each stage j: low and high transmission
rates θω1,r corresponding to the high and low levels of vaccines supplied at time j under
scenario ω, Gωj . The case study values of the uncertain transmission and the vaccine
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availability parameters under two realizations at each branch of the scenario tree are
presented in Table B.7 in Appendix B.1.4.
Assumptions on Model, Data, and Parameters. The transmission of the
EVD is affected by many factors, including damaged public health infrastructures,
cultural beliefs, behavioral practices, and violent events frequently happening in DRC
[Wannier et al., 2019, WHO, 2015]. Due to these issues, data to calibrate some of
the model parameters is either lacking or inaccurate. Data parameters, such as the
transmission rate and the probability of scenarios, are quite difficult to estimate.
Therefore, we make assumptions about some of the parameters used in the model
formulation.
First, in our current model, each infected individual is assumed to have 100
close contacts, including direct close contacts and their close contacts (i.e., contacts
of contacts) [CDC, 2015, Doshi et al., 2020]. Those close contacts (e.g., household
and health care workers) are considered as the high-risk group to be infected. In
contrast, the susceptible people in the general community are considered in the lower
risk group compared to infected people’s close contacts. Due to the nature of the ring
vaccination, we assume that only the close contacts of infected people will get the
vaccination.
Second, in our model, each node of the scenario tree has two realizations of
the transmission rate and vaccine availability, as low and high. Former research has
shown that violent events happening in DRC contribute to the increased transmission
of EVD [Wannier et al., 2019]. During our planning horizon of 15 weeks, from June
25, 2019, to October 8, 2019, seven violent events were reported [Dickey, 2018].
Considering the likelihood of a violent event happening in each period, we assign
a probability of 0.5 to each potential outcome (low and high) of disease transmission
in our scenario tree in each time period. Disease transmission rates under no violent
events are reported to vary between 0.81 and 1.08 [Wannier et al., 2019]. Thus, we
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use a low transmission rate of 0.948 for North Kivu and 0.84 for Ituri based on the
estimations reported in Camacho et al. [2014] and Wannier et al. [2019]. The mean
value of the transmission rate in DRC is 1.11 [Wannier et al., 2019], and the highest
transmission rate in history is 1.83 [Chowell et al., 2004]. In between those two values
of transmission rates in DRC, we consider a high transmission rate of 1.422 for North
Kivu and adjust it proportionally to a high transmission rate of 1.26 for Ituri based
on the ratios of low transmission rates in both locations. Similar to their impacts on
transmission rates, we assume that violent events lead to a low vaccine supply upper
bound due to hindered humanitarian operations and lowered access to the infected
population. Third, the transmission rate defined in our model represents how many
new infections can be generated from the existed infected individuals through a certain
time period. Under the situation of a small population, this value will be influenced
by the total number of susceptible individuals since the total number of infected
individuals will approach the maximum of population. However, our implementation
regions have a large amount of population, it will not be influenced by the total
number of susceptible individuals since the number of infections will never reach
the total number of susceptible individuals under the interventions. In addition, the
dependent relationship between general community and the number of newly infected
individuals will cause a non-linear issue in the optimization model. Thus, the number
of newly infected individuals in our model is independent with the general community
size. Finally, current Ebola vaccines are shown to provide immunization for at least
two years with high and stable levels of antibodies to the Ebola Zaire Virus in the
blood of volunteers who are vaccinated [WHO, 2021a, Branswell, 2018]. Thus, we
assume that recovered individuals will not get infected again within four months of
vaccination or recovering from the disease, which is nearly the planning horizon we
consider in our study.
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3.3.4 Model Formulation
Using the notation defined in Appendix 3.3.1, the mean-risk multi-stage stochastic




















s.t. Sω0,r = πr, I
ω
0,r = $r, T
ω
0,r = κr, R
ω
0,r = ϑr, H
ω
0,r = φr,
F ω0,r = υr, B
ω
0,r = τr, V
ω
0,r = ϕr, C
ω
0,r = ζr, ∀r ∈ R, ∀ω ∈ Ω, (3.2b)
Sω(j+1),r = S
ω
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j,r, j ∈ J \ {J}, ∀r ∈ R, ∀ω ∈ Ω, (3.2e)




j,r − εrV ωj,r,
j ∈ J \ {J},∀r ∈ R, ∀ω ∈ Ω, (3.2f)
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j ∈ J \ {J},∀r ∈ R, ∀ω ∈ Ω, (3.2h)
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j,r, j ∈ J \ {J},∀r ∈ R, ∀ω ∈ Ω, (3.2o)
Uωj,r ≤ QUBdωj,r, Uωj,r ≥ QLBdωj,r,
Uωj,r ≤ (Cωj,r − T ωj,r)−QLB(1− dωj,r), Uωj,r ≥ (Cωj,r − T ωj,r)−QUB(1− dωj,r),
j ∈ J \ {J},∀r ∈ R, ∀ω ∈ Ω, (3.2p)
W ωj,r ≤ IUB(1− dωj,r), W ωj,r ≥ ILB(1− dωj,r),
W ωj,r ≤ Iωj,r − ILBdωj,r, W ωj,r ≥ Iωj,r − IUBdωj,r
j ∈ J \ {J},∀r ∈ R, ∀ω ∈ Ω, (3.2q)
Oωj,r ≤ Hωj,r, j ∈ J,∀r ∈ R, ∀ω ∈ Ω, (3.2r)∑
r∈R




(Iωj,r − Iωj−1,r + F ωj,r +Hωj,r)− ηωj , j ∈ J,∀ω ∈ Ω, (3.2t)
zωj ≥ 0, j ∈ J,∀ω ∈ Ω, (3.2u)
yωat(n),r − yan,r = 0, I
ω
t(n),r − In,r = 0, Cωt(n),r − Cn,r = 0,
Oωt(n),r −On,r = 0, zωt(n),r − zn,r = 0, ηωt(n) − ηn = 0,




















j ∈ J,∀r ∈ R, ∀ω ∈ Ω, (3.2w)
yωaj,r ∈ {0, 1, 2, . . .}; yωaj,r ≤ Iωj,r,
a ∈ A, j ∈ J \ {J},∀r ∈ R, ∀ω ∈ Ω, (3.2x)
dωj,r ∈ {0, 1}, ∀j ∈ J,∀r ∈ R, ∀ω ∈ Ω. (3.2y)
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The objective function (3.2a) minimizes the total expected number of infected
individuals, funerals, plus the close contacts of infected individuals, plus the
conditional value-at-risk over all scenarios, in all regions throughout the planning
horizon.
Initial Condition Constraints:
Constraints (3.2b) give the initial number of the general community, infected, treated,
recovered, close contacts, funerals, buried, and vaccinated compartments, and the
total ETC capacity, respectively, in each region r at the beginning of the planning
horizon.
Population Dynamics Constraints:
Equations (3.2c)–(3.2j) represent the dynamics of the population in each disease
compartment, which are shown in Figure 3.1. Constraint (3.2c) shows that the
number of susceptible individuals in the community in region r at the end of
period j + 1 under scenario ω is equal to the number of susceptible individuals
from the previous time period minus the number of newly infected individuals,
plus the number of successfully vaccinated individuals who were no longer immune










j,r) represents the number of susceptible individuals
in the community (S) that transfer to close contacts (H) due to the newly infected
individuals (I), where q is the average number of close contacts of each newly infected
individual.
Constraint (3.2d) implies that the number of infected individuals at the end of
period j+1 in region r under scenario ω is equal to the number of infected individuals
from the previous time period plus the net migrated infected individuals, plus newly
infected individuals from the close contacts, general community, and funerals, minus
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died, and treated individuals at the end of period j under scenario ω.
Constraints (3.2e) define the number of close contacts at the end of time period
j + 1, which equals the number of close contacts from the previous time period plus
the net migrated close contacts, minus the number of newly infected individuals from
close contacts, minus the number of successfully vaccinated individuals during period
j, and plus the new close contacts and the close contacts saved by the vaccination.
Constraint (3.2f) ensures that the number of successfully vaccinated individuals at
the end of period j + 1 equals the number of successfully vaccinated individuals from
the previous time period plus the number of new successfully vaccinated individuals
and minus the number of individuals who are not immune to the virus anymore.
Constraint (3.2g) describes the total number of treated individuals in region r at the
end of time period j + 1 under scenario ω, which is equal to the number of treated
individuals at the end of period j plus infected individuals who were admitted to
the hospital for treatment based on the availability of beds minus treated individuals
who died or recovered. Constraint (3.2h) implies that the cumulative number of
individuals who recover in region r at the end of the period j + 1 under scenario ω is
equal to the number of individuals who recover from the previous period plus newly
recovered individuals. Constraint (3.2i) ensures the number of unburied funerals in
region r at the end of time period j + 1 under scenario ω is equal to the sum of
infected and treated individuals who died, minus the buried dead people. Constraint
(3.2j) gives the total number of buried dead bodies at the end of the period j under
scenario ω.
Migration Constraints:
Constraints (3.2k) and (3.2l) formulate the number of net immigrated individuals in
infected and close contact compartments, similar to the spatio-temporal reaction-
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diffusion (RD) models [Kıbış and Büyüktahtakın, 2019]. Specifically, constraints
(3.2k) show the number of infected individuals and close contacts migrating into
region r from region l ∈Mr under scenario ω. Constraints (3.2l) represent the number
of infected individuals and close contacts emigrating from region r into neighboring
region l ∈Mr under scenario ω.
Logistics and Operation Management Constraints:
Constraints (3.2m)–(3.2s) show the restrictions regarding logistics and operations
management. Specifically, the inequality (3.2m) represents the budget constraint on
the sum of the fixed costs of opening ETCs and the variable cost of treating infected
individuals, and the cost of allocating vaccines over all regions r in all periods j
under scenario ω. Constraint (3.2n) denotes the total capacity in region r at the
end of period j under scenario ω. Constraint (3.2o)–(3.2q) are linear constraints
that ensure the number of available beds in ETCs limit the number of hospitalized
individuals in region r. Particularly, linear equations (3.2o)–(3.2q) are equivalent to
the non-linear constraints implying that the number of hospitalized individuals (I)
is equal to the minimum number of infected individuals and the capacity available
at established ETCs after considering currently hospitalized individuals in ETCs (see
Yin and Büyüktahtakın [2021a] for the details of the linearization). Constraint (3.2r)
represents that the number of vaccines supplied to region r at period j under scenario
ω is limited by the number of close contacts in region r at period j under scenario ω.
Constraint (3.2s) ensures that the total number of vaccines allocated over all regions
can not exceed the available supply at each time period.
Risk Measure Constraints:
Constraints (3.2t) and (3.2u) represent the risk measure limitations. Constraint (3.2t)
calculates the difference between the objective function value and the value-at-risk
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for each stage under each scenario. Constraint (3.2u) ensures that the loss value
exceeding the value-at-risk is included in the CVaR calculation, and thus zωj should
be greater than or equal to 0.
Non-anticipativity Constraints:
Constraints (3.2v) are non-anticipativity restrictions stating that if two scenarios
share the same path up to stage j, the corresponding decisions will be the same.
Non-negativity Constraints:
Constraints (3.2w) imply non-negativity restrictions on the number of individuals who
are susceptible, being vaccinated, close contacts, successfully vaccinated, infected,
total treated, recovered, funeral, buried, and treated, respectively, under scenario ω.
Constraints (3.2x) represent the integer requirements on the number of type-a ETCs
to be opened in region r at the end of period j under scenario ω. Additionally, if
the number of infected individuals is less than 1 in a region r, the value of integer
variable corresponding to opening an a-bed ETC is forced to be zero, and thus there
will be no ETC opened in that region.
Constraint (3.2y) represents the binary variable dωj,r, which is 1 when the number
of infected individuals to be hospitalized is restricted by the number of available beds
in the ETCs, and 0 when all infected individuals are hospitalized for treatment in the
ETCs due to the available capacity.
3.4 Case Study and Results
3.4.1 Implementation Details
We apply our model 3.2a–3.2y to the case of the 2018-2020 EVD in the Democratic
Republic of the Congo (DRC). The North Kivu and Ituri provinces of the DRC are
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affected by the EVD. We divided these two provinces into six different sub-regions:
Upper (UNK), middle (MNK), and lower (LNK) North Kivu, and upper (UI), middle
(MI), and lower (LI) Ituri. We describe the case study data used to formulate the
model parameters, including population and migration data, resource cost data, and
epidemiological data in Appendix B.1. The details of the mathematical formulation
used to calculate the migration rates are presented in Appendix B.1.2.
We use a nested risk measure in multi-stage stochastic programming, known as
the E-CVaR, in the stochastic model, as described in Section 3.2. We assume that
the vaccines’ availability impacts the transmission rates in community contact, and
thus uncertain transmission rates depend on the uncertain vaccine supply. Hence the
high (low) availability of vaccines implies the low (high) realization of the uncertain
transmission parameter. We present the value of the vaccine availability and uncertain
transmission parameters under two realizations at each branch of the scenario tree,
as shown in Table B.7 in Appendix B.1.4. We solve the model for a 5-stage time
period, where each stage corresponds to three weeks (from June 25, 2019, to October
8, 2019, in total 15 weeks) with high and low vaccine supply under different budget
levels. Because each node of the scenario tree has two branches, each corresponding
to a possible realization of the random parameters, we have 25 = 32 scenarios for
T = 5 stages.
The mathematical model is solved using CPLEX 12.7 on the desktop running
with Intel i7 CPU and 64.0GB of memory. For each run, the time limitation is set
at 72,000 CPU seconds. In the following subsections, we present results from solving
the mean-risk multi-stage stochastic epidemics-vaccination-logistics model.
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3.4.2 Resource Allocation under Different Budget Levels
We test the formulation for each time period under different budget levels: Very Tight
($40M), Tight ($70M), Medium ($100M), and Ample ($130M). The mean-risk
trade-off coefficient λ is set to be 1, and the confidence level α is set to be 0.5.
Figure 3.2 presents the optimal allocation of resources (budget, capacity
[number of beds], and vaccine) for each region under each budget level. According to
the results, the regions with the highest initial infestation levels receive most of the
budget, as in the case of Upper North Kivu and Middle North Kivu (Figure 3.2a).
When the budget increases from very tight to ample, other regions will also get their
share of the budget depending on their initial infection levels and disease-growth
scenarios in the model.
Similar to the total budget allocation, the total capacity is allocated based on
the initial infection levels (Figure 3.2b). However, different from the total budget
allocation, the majority of the ETCs are assigned in the first stage of the 5-stage
planning horizon. For instance, under the $130M budget level, 1450 beds are allocated
to Upper North Kivu in the first stage, while the total number of beds allocated to
Upper North Kivu only increases by 150 by the end of stage five. Therefore, quick
response in terms of allocating most of the treatment centers at the beginning of
the outbreak will help to slow down the spread of the disease, while the majority of
the budget should be allocated to treat infected people in ETCs and vaccine close
contacts over multiple periods throughout the planning horizon.
When the budget level increases, the number of vaccines allocated to each region
does not always increase (Figure 3.2c). For instance, under the $100M budget level,
Lower North Kivu receives 177 vaccines, while this reduces to 128 vaccines under the
$130M budget level. A possible reason for this is that vaccination can prevent more





Figure 3.2 Budget, capacity (bed), and vaccine allocated to each region (λ = 1
and α = 0.5).
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Thus, the model gives priority to opening new ETCs and treating infected individuals
and then uses the rest of the budget to allocate vaccines.
3.4.3 Analysis of the Risk Trade-off
We perform an analysis of the risk parameters λ and α in terms of their impact
on the objective function values and the resource allocation strategies. Specifically,
under the $70M budget level, we compare four different problems with respect to their
risk-averseness level, adjusting λ and α values accordingly–risk-neutral (λ = 0, α = 0),
weak risk-aversion (λ = 1, α = 0.05), mild risk-aversion (λ = 10, α = 0.5) and strong
risk-aversion (λ = 100, α = 0.95).
Impact, Risk, and Cost under Risk-Neutral and Risk-Averse Policies In
this subsection, we provide insights on the effect of risk parameters λ and α on
the expected impact and expected risk and how those values change as the decision
maker shifts from being risk-neutral to risk-averse at varying risk levels. To analyze
the results with the risk trade-off coefficient, we decompose the objective function
into the expected impact [E(f(x, ω))] and the expected risk [λCVaRα(f(x, ω))], as
demonstrated in Equation (3.1). Specifically, the expected impact represents the
expected value of the total number of infections, funerals, and close contacts of
infected people, and the expected risk corresponds to the expected CV aRα term
in Eq. (3.2a). Table 3.1 presents results for the optimal objective function value
for Eq. (3.2a), expected impact, expected risk, and the expected total cost over the
four different risk-averseness levels described above. We also present values of the
expected impact and expected risk for various combinations of λ = {0, 1, 10, 100} and
α = {0.05, 0.5, 0.95} under the $70M budget level in Table 3.2. In both Tables 3.1
and 3.2, the “Expected Risk” under the risk-neutral model, where λ = 0, is computed
as the expected total number of infections, funerals, and close contacts of infected
people over all periods for the (1− α) worst scenarios.
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Table 3.1 Comparison of Objective Value, Expected Impact, Expected Risk, and
Expected Cost under Various Risk-Averseness Levels
Risk-aversion Risk Neutral Weak Mild Strong
(λ, α) (0, 0.95) (1, 0.05) (10, 0.5) (100, 0.95)
Objective Value a 3,881,046 7,771,744 44,365,553 409,005,446
Expected Impact 3,881,046 3,881,501 3,882,344 3,884,815
Expected Risk b 5,628,125 3,890,243 4,048,321 4,051,206
Expected Cost ($M) 69.70 69.76 69.84 69.85
a The calculation with units is represented as “Expected Impact” + λ * “Expected
Risk”
b The Expected Risk is the CV aRα and does not include preceding λ coefficient
According to Table 3.1, the risk-neutral model has the smallest expected impact
but the largest expected risk compared to all other risk-averseness levels. This
indicates that the risk-neutral model provides the least expected number of infections,
funerals, and close contacts over all scenarios, but once one of the worse-case
scenarios happens, it gives much larger number of infections, funerals, and close
contacts compared to the risk-averse model. When both λ and α increase, the
level of risk-averseness increases. Consequently, the optimal objective function value
significantly increases due to the additional values of risk that are added to the
objective formulation. The expected impact also increases, implying that there is a
price for being risk-averse in terms of the increased number of infections, funerals, and
close contacts under a more risk-averse policy. Moreover, the total cost of allocated
capacity, treatment, and vaccination increase slightly when the risk-averseness level
increases, implying that more budget is needed as the decision maker becomes more
risk-averse.
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Table 3.2 Expected Impact and Expected Risk for Different Risk-averseness Levels
λ\α 0.05 0.5 0.95
Expected Expected Expected Expected Expected Expected
Impact Risk a Impact Risk a Impact Risk a
0 3,881,046 3,957,443 3,881,046 4,512,163 3,881,046 5,628,125
1 3,881,501 3,890,243 3,881,323 4,047,577 3,887,508 4,054,319
10 3,881,053 3,889,802 3,882,344 4,048,321 3,883,418 4,050,082
100 3,883,462 3,892,219 3,881,704 4,047,882 3,884,815 4,051,206
a The Expected Risk is the CV aRα and does not include preceding λ coefficient
Each row of Table 3.2 shows the change of the expected impact and expected
risk when we fix the value of one of the risk parameters (λ = {1, 10, 100} and α =
{0.05, 0.5, 0.95}) and change the other. All optimality gaps for the computational
results in Table 3.2 are between 0.51% and 1.26%. According to the results, the
largest expected risk occurs when λ = 0 for each α value. Similar to Table 3.1,
in Table 3.2 the expected risk is the highest and the expected impact is the lowest
under the risk-neutral model. When we move from risk-neutral (λ = 0) to risk-averse
(λ = {1, 10, 100}), the expected impact always increases. However, changing the λ
parameter have a non-monotonous influence on the expected impact. When fixing the
λ value and increasing the α value, the expected risk increases because we increase
the confidence level for the impact of scenarios that is under the V aR value. When
we increase α from 0.05 to 0.95, the risk-averseness level increases, and the expected
impact also shows an increasing trend for all risk-averse policies (λ ≥ 1).
Resource Allocation under different Risk-Averse Policies Table 3.3 presents
the allocation of the budget over the five stages of the planning horizon. We observe
that the majority of the budget is allocated under stages one, two, and four, while
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as the risk-averseness increases, the budget under stage one is slightly decreased and
moved further into the future to be used later. The total budget used over all stages
increases as the decision-maker becomes more risk-averse.
Table 3.3 The Budget ($M) Allocation at Each Stage over Four Different Risk-
Averseness Levels
Risk-averseness Level Stage 1 Stage 2 Stage 3 Stage 4 Stage 5 Total
Risk-neutral 14.0 20.6 8.9 20.6 5.6 69.7
Weak Risk-aversion 12.1 22.4 9.0 20.6 5.6 69.8
Mild Risk-aversion 13.0 22.0 8.8 20.9 5.3 69.8
Strong Risk-aversion 13.8 20.9 9.0 20.8 5.4 69.9
Figure 3.3 Budget allocation over treatment, ETC capacity, and vaccine for four
different risk-averseness.
Figure 3.3 illustrates the budget allocation of treatment, ETC capacity, and
vaccination for different risk-averseness levels. As shown here, the capacity and
treatment budget shows an increasing trend, and the budget allocated to vaccination
shows a decreasing trend when the risk-averseness level increases. This may imply
107
that as the decision-maker becomes more risk-averse, more investment is made on
treatment rather than vaccination. It helps reduce variability in the set of scenarios
that results in the highest number of infections and deaths.
The optimal allocation of treatment budget, ETC capacity, and vaccine
allocation under different risk-averseness levels is presented in Figure 3.4. When the
risk-averseness level increases, the budget allocated to Upper North Kivu, which has
the highest initial infection level, is decreased by moving the budget to neighboring
locations with a potential risk of getting infections from Upper North Kivu (Figure
3.4a). For example, under the strong risk-averseness level, the budget allocated to
Middle Ituri and Lower Ituri increases because they are geographically close to Upper
North Kivu and thus are under the risk of getting infections through the large migrant
population from Upper North Kivu.
The total capacity allocation of 1700 beds over all regions under the risk-neutral
and weak risk-averseness cases is increased to 1750 beds under the mild and strong
risk-averseness levels to alleviate adverse outcomes under the worst-case scenarios
exceeding the VaR value (Figure 3.4b). As the risk-averseness level increases, the
model allocates more beds to some regions that have low infection levels, considering
their proximity to highly-infected locations and the risk of getting more infections
from those locations. For example, Lower Ituri, right above the Upper North Kivu,
receives an increased number of beds under the strong risk-averseness level.
The number of vaccines allocated to each region varies under different risk-
averseness levels (Figure 3.4c). The total number of allocated vaccines decreases
when the risk-averseness level increases. Regions that initially have zero infections
get zero bed capacity. However, they still get vaccination due to the migration impact
and the expectation of the disease spread under the risk-neutral and all risk-aversion
cases. Thus, in locations where the disease has just started, the model uses the budget





Figure 3.4 Treatment budget, capacity (bed), and vaccine allocation under
different risk-averseness levels.
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3.4.4 Analyzing the Impact of Delay in Vaccination
In this subsection, we compare the number of infections and funerals for each stage
for the 5-stage planning horizon with respect to the delay of the vaccine application
in the first stage (Delay 1), first two stages (Delay 2), first three stages (Delay 3),
first four stages (Delay 4) and five stages (Delay 5) under the $70M budget level.
For example, in “Delay 3”, we fix the number of available vaccines in the first three
stages to zero. In those first three stages, we assume a high transmission rate, which
is equivalent to the low vaccine supply, and thus results presented here provide a
lower bound on the number of infections and deaths. Here, we also consider a mild
risk-averseness level by setting λ at 10 and α at 0.5.
The results of the cumulative number of infections and funerals in each type
of delay in vaccines are shown in Figure 3.5, while Figure 3.6 demonstrates the non-
cumulative infections and funerals for each delay option over no delay of vaccines for
five stages. Both figures indicate that the number of infections and funerals increases
exponentially over time for each delay type. The more the vaccination is delayed, the
larger the infections and funerals are. Furthermore, the difference in the number of
infections and funerals between “Delay 1” and “Delay 3” is larger than the difference
between “Delay 3” and “Delay 5.” A possible reason is that the vaccination at the
initial stages of the disease transmission would decrease the transmission rate faster
and cause fewer infections and funerals than vaccination at later stages. These results
indicate that the vaccines should be supplied as soon as possible once the epidemic
breaks out, given the vaccines’ availability.
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Figure 3.5 Cumulative number of infections and funerals for each stage under
different types of delay (λ = 10 and α = 0.5).
Figure 3.6 Non-cumulative number of infections and funerals for each delay option
over no delay (λ = 10 and α = 0.5).
3.5 Analyzing Vaccine Effectiveness and Acceptance Rates
In this section, we perform the sensitivity analysis on vaccination effectiveness and
acceptance rates. Specifically, we adjust the vaccination effectiveness rate and the
proportion of close contacts who are willing to get vaccinated. In WHO [2019c], the
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vaccination effectiveness rate is estimated as 0.975. In our model, we test vaccination
effectiveness rates varying from 0.7 to 0.975 in increments of 0.05. Specifically,
we change the value of the parameter βr from low to high to simulate the impact
of varying vaccination effectiveness rates on the number and location of vaccines
allocated.
Several papers study the willingness of people to be vaccinated. For instance,
Kpanake et al. [2018] find that 38% of people always choose to be immunized for
the Ebola Virus Disease. Mudatsir et al. [2019] conclude that 74% of the people
who participate in the interview express their acceptance for an Ebola vaccine. In
addition, Ughasoro et al. [2015] suggest that 80% of the respondents accept being
vaccinated with the Ebola vaccine. Therefore, we consider four different vaccine
acceptance rates in the sensitivity analysis, which are 0.01, 0.4, 0.8, and 1. In reality,
the vaccine acceptance rate may not be as low as 0.01. However, considering that
the vaccine supply is quite limited, even under a vaccine acceptance rate of 0.4, the
number of people who are willing to get vaccinated is still more than the upper bound
on the vaccine supply. Thus, we use a vaccine acceptance rate of 0.01 to observe the
changes in the vaccine allocation when the upper bound of vaccine supply is larger
than the number of people who are willing to get vaccinated. In particular, we use
a new parameter f to represent the number of close contacts who are willing to be
vaccinated. Thus, Constraint (3.2r) is replaced by:
Oωj,r ≤ Hωj,rf, j ∈ J,∀r ∈ R, ∀ω ∈ Ω. (3.3)
Constraint (3.3) implies that the number of successfully vaccinated individuals
at stage j in region r under scenario ω should be less than or equal to the number of
close contacts who are willing to be vaccinated.
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In this section, we assume that the amount of available vaccine supply changes
with respect to the time period. For example, in the initial stages of an epidemic
or a vaccine discovery, it is less likely to make sufficient vaccine supply available
to all demand locations. As time progresses, the vaccine supply upper bound will
also increase. In this section’s analysis, the vaccine supply upper bound under each
scenario is set to be 1000 at stage one, 2000 at stage two, 4000 at stage three, 5000
at stage four, and 6000 at stage five. The budget level for each test instance is set
to be an ample level of $130M . Since the number of people who are willing to get
vaccinated at the initial stages is less than the number of available vaccines, the
remaining vaccines can be allocated in the following stages. Thus, in this analysis,











Oωm,r, j ∈ J,∀ω ∈ Ω. (3.4)
Constraint (3.4) ensures that the number of vaccines allocated to region r at
stage j under scenario ω should be less than or equal to the total number of available
vaccines up to stage j minus the total number of vaccines that are allocated to various
regions from stage 1 until the end of stage j − 1.
Figure 3.7 shows the optimal number and location of vaccines allocated under
different vaccination effectiveness rates when the vaccine acceptance rate is fixed at
0.8. For all the cases, the Upper North Kivu has most of the vaccines allocated,
followed by Middle North Kivu. Also, the number of vaccines allocated to these two
regions has a complementary relationship. When Upper North Kivu receives more
(fewer) vaccines, Middle North Kivu will get fewer (more) vaccines allocated. This is
because these two regions suffer from Ebola the most. The total number of infections
and deaths does not fluctuate much if the number of vaccines allocated to these two
regions is in a range of 11,000 to 15,000 for Upper North Kivu and 2,000 to 6,000 for
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Middle North Kivu. In addition, the total number of vaccines allocated under each
case is close to the total supply upper bound of 18,000. Thus, we can conclude that,
as long as the vaccine stays effective, no matter what vaccine effectiveness rate is,
the total number of vaccines allocated will not significantly change under a limited
supply of vaccines.
When the vaccination effectiveness rate increases, we also observe some of the
vaccines that are allocated to regions with high levels of infections are moved to regions
with fewer infections. Specifically, 17,670 vaccines allocated to Upper North Kivu and
Middle North Kivu reduce to 16,113 vaccines when the vaccination effectiveness rate
increases from 0.7 to 0.975. This result implies that the more effective the vaccine
is, the fewer vaccines are needed in highly-impacted areas so that regions with lower
infection could benefit from the remaining vaccines.
Figure 3.7 Vaccine allocation under different vaccine effectiveness rates (λ = 10
and α = 0.95).
Figures 3.8a and 3.8b present the results for the first-stage and total vaccine
allocation over all stages, respectively, under different vaccine acceptance rates when
the vaccine effectiveness rate is fixed at 0.975. When the vaccine acceptance rate
is 0.01, fewer vaccines are allocated in the first stage compared to the number of
vaccines allocated under vaccine acceptance rates of 0.4, 0.8, and 1. Upper North
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Kivu is the only region that receives vaccines at the first stage when the vaccine
acceptance rate equals 0.4, 0.8, and 1 because it has the highest number of initial
infections among all regions. However, under the vaccine acceptance rate of 0.01, the
number of close contacts willing to get vaccinated in Upper North Kivu is less than
the supplied vaccines in the first stage. Thus, some vaccines in hand are allocated to
other regions.
Compared to the first stage vaccine allocation, the total vaccine allocation over
all stages shows a similar trend under different vaccine acceptance rates. This is
because as the number of infections increases in the following stages, the number
of close contacts also significantly increases. Therefore, even under the vaccine
acceptance rate of 0.01, the number of close contacts who are willing to get vaccinated
is more than the vaccine supply upper bound when considering the planning horizon
of five stages. Furthermore, remaining vaccines from previous time stages will be
used in the following stages. The total number of vaccines allocated to Upper North
Kivu under the 0.01 vaccine acceptance rate is less than those in other cases. This
is because more vaccines become available under a quite low vaccine acceptance rate,
and those available vaccines are allocated to other regions with infections lower than
that of Upper North Kivu.
3.6 Discussion and Conclusions
This chapter presents a multi-stage mean-risk epidemics-vaccination-logistics model
to address the optimal resource allocation challenges for epidemic control. We apply
our model to the 2018-2020 EVD case in the Democratic Republic of the Congo
(DRC). Because the information regarding the migration rates between regions in
DRC is limited, we develop a method to estimate the transmission rate between each
considered region. In our multi-stage stochastic programming model formulation, we




Figure 3.8 The first-stage and total vaccine allocation under different vaccine
acceptance rates (λ = 10 and α = 0.95).
116
number of infections, funerals, and close contacts of infected people, and a weighted
risk in a five-stage planning horizon, including 15 weeks.
The results regarding the analysis of risk trade-off show that there is a price for
being prepared for the worst set of disease-growth scenarios. In other words, a risk-
averse decision-maker should expect a possible increase in the number of infections
and deaths while trying to mitigate disastrous outbreak scenarios. Thus, when the
mean-risk trade-off coefficient increases, the confidence level in a risk-averse model will
improve while the expected impact on infections and deaths worsens. Furthermore,
the total cost of treatment and vaccination increases as the decision-maker becomes
more risk-averse.
Allocating the resources fully based on the initial infection level will increase
the risk of experiencing more infections and deaths in some disease scenarios. For
example, the initial infection level of Lower Ituri is not high. Still, the model considers
the possible adverse scenarios that may happen in Lower Ituri and allocates more
resources to Lower Ituri under the case of strong risk-aversion. Thus, the potential
risk associated with the disease growth in regions that have low initial infection levels
but are in close proximity to hot spots of infection should also be considered when
making risk-averse decisions on epidemics resource allocation.
The analysis of resource allocation under different budget levels indicates that
the initial infection level is the key parameter that influences the budget and capacity
allocation among each region. The regions with high initial infection levels get more
resources, similar to the findings in Yin and Büyüktahtakın [2021a]. Different from
the former literature, we study the budget allocation trade-off between treatment
and vaccination while also accounting for the disease transmission dynamics. The
results of vaccine allocation under different budget levels suggest that priority must
be given to treat and isolate infected individuals in ETCs, while vaccination is
supplementary to treatment. This has also been justified by the study of Kucharski
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et al. [2016], which states that ring vaccination might be insufficient to contain the
outbreak if standard measures for controlling the transmission are not working, as in
the EVD case in West Africa in early 2014. In another study, Kretzschmar et al.
[2004] state that ring vaccination can contain the smallpox disease provided the
intervention measures are very useful. Being risk-averse reinforces our findings on
the resource-allocation priority of treatment over vaccination.
Our results also show that as the number of stages with no vaccines supplied
increases, the number of infections, funerals, and close contacts exponentially
increases even under other intervention measures, such as treatment and isolation.
This result implies that vaccination is still quite effective when performed in addition
to standard intervention measures, as shown in the studies of Kretzschmar et al.
[2004], Ajelli et al. [2016], and Merler et al. [2016]. Under the same length of delay,
the delay of the vaccine at the early stages will cause more infections and deaths
compared to the delay in the late stages. This proves that when the vaccines are
limited but available, we should supply them as early as possible to minimize the
number of infections at the beginning of an outbreak. Similarly, Wells et al. [2019]
mention that even modest delays in initiating vaccination could noticeably degrade
the impact of the epidemic control.
Interestingly, the model allocates vaccination to regions that get no treatment
resources under a limited budget because it estimates a disease spread to these
locations due to human mobility. Specifically, the model uses the budget for
vaccination in regions where the disease has just started to curb the growth of the
epidemic, while in regions with high initial infections, the model gives priority to
build new ETCs and treat infected people over vaccination.
The sensitivity analysis on the vaccine effectiveness and acceptance rates
indicates that the number of vaccines supplied to Upper North Kivu and Middle
North Kivu has a complementary relationship. The number of vaccines provided
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to these two regions fluctuates under different vaccine effectiveness rates when the
vaccine acceptance rate is fixed. This fluctuation does not influence the number of
infections significantly.
When the vaccine effectiveness rate is fixed, vaccine acceptance rates affect
vaccine allocation in the initial stages. Specifically, available vaccines are moved from
highly impacted locations to less affected areas under a very low vaccine acceptance
rate. In the early stages of an epidemic, there are fewer infections and close contacts,
and the number of close contacts who are willing to get vaccinated is less than the
number of vaccines supplied when the vaccine acceptance rate is very low. However,
in the subsequent stages of an epidemic, the number of infections increases, thus
significantly increasing close contacts. Therefore, even under a low vaccine acceptance
rate, the number of close contacts who are willing to get vaccinated is much more than
the available vaccine supply as the disease progresses over time. Consequently, those
leftover and newly-supplied vaccines are allocated in the stages following the first
stage to locations with both high and low infection levels. Thus, the total number of
vaccines distributed over the whole planning horizon is similar under different vaccine
acceptance rates.
This study leads to a number of important future directions. For example, the
method we present for calculating the migration rate between each region could be
further improved. Human behavior and social effects could be incorporated into the
calculation of migration rates. For instance, Miami is not a metropolis compared to
New York City. However, a substantial amount of people may travel to Miami for
vacation. In our model, we only chose the metropolis of each region as the center
of movement but did not consider other regions that may also have large short-term
population migrations. This research could be extended by improving our estimation
by considering more complicated environments to formulate the migration-estimation
model.
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In our epidemic-vaccination-logistics model, the term “logistics” represents the
spatial and temporal allocation of ETCs, treatment budget used at ETCs as a
function of T (treated) people, and the number of vaccines in region r at the end of
period j under scenario ω. Here logistics do not involve details, such as distributing
vaccines to certain locations within a region and its transportation specifics. A
future extension of this work could investigate the transportation details of both
vaccination and treatment resources, such as distributing those resources to specified
locations within a region and its associated costs. Future work could also specify the
transmission rate parameter, θ1,r, as a function of the vaccines allocated in region
r, converting the model into a stochastic non-linear mixed-integer program. Both
future directions would require the development of advanced solution algorithms,
such as decomposition methods, global optimization, and cutting plane algorithms,
to tackle the increased complexity of the mathematical model.
In this study, we present a general multi-stage mean-risk epidemics-vaccination-
logistics model. This epidemic model could be adopted, for example, in the case of
the COVID-19 pandemic. In such a model, the susceptible individuals can be divided
into multiple sub-compartments based on their risk, demographics, and behaviors.
For example, susceptible individuals can be divided into different sub-groups, such
as people who wear masks and people under quarantine, with each group having a
different infection rate, depending on the intervention measures applied. We can
also analyze specific groups for vaccination, e.g., doctors, nurses, and volunteers
to be injected. Increasing the number of compartments in a heterogenous-mixing
epidemiological model will further complicate the epidemic-vaccination-logistics
optimization model. Thus, the analysis of multiple specified groups can be studied
in a more detailed agent-based simulation rather than a large-scale meta-population
model as in our case.
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For the pandemic control, we should also consider the international imported
infections for the selected regions. Also, the travel patterns of people during the
pandemic might influence the transmission of the disease. Therefore, our future
research would present new mathematical models that will control a pandemic and
help optimize resource allocation decisions.
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CHAPTER 4
COVID-19: OPTIMAL ALLOCATION OF VENTILATOR SUPPLY
UNDER UNCERTAINTY AND RISK
4.1 Introduction
The world is undergoing a major health crisis, which has now eventually turned into a
pandemic. The Coronavirus Disease 2019 (COVID-19), first detected in Wuhan city
of China at the end of 2019, has been creating havoc on human life and economies
in all parts of the world. Countries worldwide enforce lockdown and quarantine rules
to slow down the spread of the virus. The lockdown, imposing travel restrictions,
and social distancing have severely affected the economy, from small-scale industries
to stock prices and international trading. The virus has such a high transmission
rate, causing more than 104.7 million cases globally, out of which 2.3 million people
have succumbed to death by mid-February 2021 [JHU, 2021]. The continuous increase
seen in coronavirus cases has made a worldwide scarcity of essential resources, such as
ventilators, Intensive Care Unit (ICU) beds, Personal Protective Equipment (PPE),
and masks. Effective, sufficient, and timely delivery of those critical resources to
serve the COVID-19 patients has been a major challenge faced by the world countries
during the pandemic.
COVID-19 is primarily an acute respiratory disease. Ventilator incubation
delivers high oxygen concentrations while removing carbon dioxide and reduces the
risk of hypoxia for COVID-19 patients [Meng et al., 2020]. The standard Acute
Respiratory Distress Syndrome protocol mandates that the most severe COVID-19
patients, who constitute 5% of all COVID-19 patients, should receive ventilator
support [Bein et al., 2016]. As a result, the life of many COVID-19 patients depends on
the use of ventilators. The shortage of supplies and uncertainty in disease transmission
has affected the proper allocation of ventilators, causing immense distress on the
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healthcare system. Due to ventilator shortages worldwide during the pandemic’s peak
times, hospital officials have had to make life-altering resource allocation decisions and
prioritized the care of COVID-19 patients [Ranney et al., 2020]. To tackle ventilator
shortages and reduce the number of COVID-related deaths, studies have come up
with new approaches for ventilator distribution. For example, Ranney et al. [2020]
suggest that the demand for ventilators can be fulfilled by the government by allowing
other industries to come together and help medical industries to cater to the needs of
the ventilators. Another study by Castro et al. [2020] suggests that the government in
Brazil should start thinking about expanding the resource capacity rather than only
focusing on the allocation of the available resources for controlling COVID-19. White
and Lo [2020] develop a framework for the distribution of ICU beds and ventilators
depending on the priority scores using a scale of 1 to 8 based on patients’ likelihood
of survival and ethical considerations.
Operations Research (OR) methods have been widely used to determine optimal
resource allocation strategies to control an epidemic or pandemic. Several studies
have used multi-period OR models to optimize the allocation and redistribution of
ventilators (see, e.g., Mehrotra et al. [2020], Bertsimas et al. [2020], and Blanco et al.
[2020]). Other OR research models that study the epidemic diseases and resource
allocation mainly focus on the logistics and operation management to control the
disease in optimal ways [Büyüktahtakın et al., 2018a, Zaric and Brandeau, 2001, Yin
and Büyüktahtakın, 2021a, Kaplan et al., 2003, Tanner et al., 2008, Coşgun and
Büyüktahtakın, 2018]. We refer the reader to excellent reviews of Dasaklis et al.
[2012] and Queiroz et al. [2020] for a discussion of OR models for epidemic resource
allocation.
While OR has been an extremely useful tool for effective and timely allocation
of resources as a response to epidemics, none of the former work has considered
the ventilator allocation problem using a risk-averse spatio-temporal stochastic
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programming model under uncertainty of asymptomatic infections. People move
between regions, states, and countries, which aggravates the disease transmission
to the other areas. Evaluating undetected or asymptomatic individuals is critical
for determining disease dynamics because asymptomatic individuals move around
and unknowingly infect other individuals [McCrimmon, 2021]. Thus, the short-term
migration of people is a critical factor that needs to be considered to forecast the
transmission of the COVID-19 realistically. However, the short-term migration
rate is hard to predict and is affected by interventions and human behaviors.
Furthermore, disease transmission rates are not constant and rather evolve over time
with government interventions, such as the lockdown or social distancing measures.
This change in the transmission rates also should be considered in a realistic model.
To our knowledge, none of the former OR ventilator allocation models have integrated
the epidemiological aspects of the disease and resource allocation challenges in one
optimization model.
In this chapter, we address the limitation of realistically forecasting the
transmission of COVID-19 and build a risk-averse multi-stage stochastic epidemics-
ventilator-logistics programming model to study the ventilator allocation for the
treatment of severe COVID-19 patients. Our model considers the uncertainty of
untested asymptomatic individuals during the transmission of COVID19 and involves
various pandemic scenarios for the proportion of untested infections during each
time stage of the planning horizon. Our model also incorporates the short-term
migration between the highly-impacted regions while using changing transmission
rates under various non-pharmaceutical intervention measures. The model optimizes
the distribution of ventilators while minimizing the total expected number of infected
and deceased people. We calibrate, validate, and test our epidemiological ventilator
allocation model using COVID-19 data collected during the pandemic’s early stages.
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4.1.1 Key Contributions and Insights
In summary, former stochastic programming approaches on ventilator allocation in
a pandemic situation have involved a time domain of only two stages, and have
not integrated an epidemic model within the stochastic program. Furthermore, the
mathematical models on the forecast of the COVID-19 do not include the uncertainty
of untested asymptomatic infections. They do not incorporate the impact of short-
term migrations on COVID-19 transmission in an epidemiological model. Also, former
studies on the COVID-19 modeling and logistics have omitted the time consistency
of the risk for making decisions over multiple stages of a stochastic program under
extreme pandemic scenarios.
Our modeling and applied contributions to the epidemiology and OR literature
are summarized below.
Modeling contributions: First, to our knowledge, this is the first study
that addresses the optimal distribution of ventilators to control a pandemic in a
multi-stage stochastic mean-Conditional Value at Risk (CVaR) model. Considering
multiple stages is essential to capture uncertain disease dynamic over multiple
time periods. This model includes many realistic effects critical in the COVID-19
pandemic, including untested asymptomatic infections, human movement among
multiple regions, and evolving transmission rates under non-pharmaceutical inter-
vention measures. Second, we consider the uncertainty of the proportion of untested
asymptomatic infections at each stage and integrate this unknown dimension of
the pandemic by generating a multi-stage scenario tree. Third, we present a
new susceptible (S)- tested infected (I)- untested asymptomatic (X)- hospitalized
(H)- ICU (C)- recovered (R)- death (D) compartmental disease model specialized
for the COVID-19, and also incorporate the short-term human migration among
multiple regions into this epidemiological model. Fourth, we derive a new time-
and space-varying disease transmission formulation, which takes into account the
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impact of government interventions on transmission rates. Fifth, we formulate a
budget-constrained ventilator allocation logistics model. Sixth, we incorporate a
time-consistent CVaR risk-measure and the expectation criterion in the objective
function to alleviate the impacts of extreme pandemic scenarios. Lastly, we integrate
all those elements into one epidemics-ventilator-logistics mathematical formulation,
which minimizes the number of infections and deceased individuals under different
intervention strategies while determining the optimal timing and location of resources
(ventilators) allocated. Our model combines the forecast of the transmission of
COVID-19 and the determination of optimal ventilator allocation strategies in one
formulation. Accordingly, the decision-maker can evaluate possible outcomes of
wait-and-see decisions while foreseeing how the disease could progress in each time
period.
Applied Contributions: We apply our general multi-stage mean-risk epidemics-
ventilator-logistics model to the case of controlling the COVID-19 in highly-impacted
counties of New York and New Jersey. We collect real data from various resources and
provide researchers with compact epidemiological, population and logistics-capacity
data for COVID-19. Using this data, we calibrate, validate, and test our model,
which could be used as a decision support tool for fighting against the COVID-19.
Our model can also be adapted to study other similar diseases transmission dynamics
and logistics.
Key Recommendations to Decision Makers. This study provides optimal
risk-averse ventilator allocation policies under different risk levels that the decision-
maker can take to control the COVID-19. Based on our results, we offer the following
recommendations to inform resource allocation policies under a pandemic:
(i) The short-term movement of people influences the number of new infections
even if the disease transmission rate stays the same.
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(ii) The number of treated people in the ICU may stay at the capacity limit under
different intervention strategies because this value depends on the minimum
number of patients who require a ventilator for treatment and the scarce
ventilator supply. There is also a lag time to observe the impacts of government
non-pharmaceutical interventions on the number of hospitalized, ICU and
deceased individuals.
(iii) “Lockdown” is the best strategy to control the COVID-19. However, the “Mask
and Social Distance” intervention following a certain period of “Lockdown” is
the second-best choice, considering the need for opening facilities and businesses.
(iv) The region with a high initial transmission rate and low initial ICU capacity
will have more ventilators allocated under a limited budget and low or high
transmission scenarios. Independent from the budget level, the region with a
low initial transmission rate and low initial ICU capacity gets more ventilators
allocated under a medium transmission scenario.
(v) Under a medium and ample budget level, the model allocates more capacity to
the regions with a higher population and a larger initial number of infections
but with a lower transmission rate. A large-enough budget also provides some
flexibility in delaying ventilator allocation to some regions. In contrast, all of
the ventilators are allocated at the first two stages under a limited budget.
(vi) Considering risk in decision-making improves the confidence level for reducing
the loss of lives under risky pandemic scenarios. However, a risk-averse decision-
maker should also expect a possible increase in the number of infections and
deaths while mitigating disastrous outbreak scenarios.
4.2 Problem Formulation
This section presents the description of the notations, compartmental disease model,
the formulation for transmission rates, uncertainty and scenario tree generation
scheme, specific features and assumptions made in the mathematical model, a brief
description of the CVaR, and the formulation for our epidemics-ventilator-logistics
model.
4.2.1 Model Notation and Formulation
Below we provide notations used for the rest of the paper.
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Sets and Indices:
J : Set of time periods, J =
{0, ..., J}.
R: Set of regions, R = {1, ..., R}.
Ω: Set of scenarios, Ω = {1, ...,Ω}.
N : Set of nodes in the scenario tree,
where n ∈ N .
j: Index for time period, where j ∈
J .
r: Index for region where r ∈ R.
ω: Index for scenario, where ω ∈ Ω.
State Variables:
Sωj,r: Susceptible individuals in
region r at stage j under scenario
ω.
Iωj,r: Tested symptomatic infected
individuals in region r at stage j
under scenario ω.
Xωj,r: Untested asymptomatic
infected individuals in region r at
stage j under scenario ω.
Hωj,r: Hospitalized individuals in
region r at stage j under scenario
ω.
Cωj,r: Individuals treated in the
intensive care unit (ICU) in region
r at stage j under scenario ω.
Rωj,r: Recovered individuals in
region r at stage j under scenario
ω.
F ωj,r: Deceased individuals in region
r at stage j under scenario ω.
Oωj,r: Number of tested
symptomatic infected individuals
admitted to the hospital in region r
at stage j under scenario ω.
I
ω
j,r: Number of tested symptomatic
infected individuals who cannot be
admitted to the hospital due to
limited capacity in region r at stage
j under scenario ω.
C
ω
j,r: Number of individuals
admitted to ICU in region r at stage
j under scenario ω.
Kωj,r: Number of hospitalized
individuals not admitted to the ICU
due to the limited availability of
ventilators in region r at stage j
under scenario ω.
Uωj,r: Number of cumulative venti-
lators (ICU capacity) in region r at
stage j under scenario ω.
Ĭωj,r: Number of infections caused by
short-term migration in region r at
stage j under scenario ω.
Parameters:
λ1: Recovery rate of tested
symptomatic infected individuals in
region r.
λ2: The death rate of tested
symptomatic infected individuals in
region r.
λ3: Hospitalization requirement
rate of tested symptomatic infected
individuals in region r.
λ4: Recovery rate of the hospi-
talized individuals in region r.
λ5: Death rate of hospitalized
individuals in region r.
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λ6: Ventilator requirement rate of
hospitalized individuals in region r.
λ7: Recovery rate of ICU patients
in region r.
λ8: Death rate of ICU patients in
region r.
λ9: Recovery rate of untested
asymptomatic individuals in region
r.
σ1,j,r: Transmission rate of tested
symptomatic infected individuals in
region r at stage j.
σω2,j,r: Proportion of untested
asymptomatic infections in region r
at stage j under scenario ω.
T ωj,r: Hospital capacity in region r at
stage j under scenario ω.
U0,r: Initial number of ventilators
(ICU capacity) in region r.
e1: Cost of each ventilator.
∆: Total budget for ventilators.
Risk parameters:
α: Confidence level of value-at-risk,
where α ∈ [0, 1).
λ: Non-negative risk preference
parameter or mean-risk trade-off
coefficient.
Risk variables:
ηωj : Value at risk for each stage j
under scenario ω.
zωj : Value exceeding the value-at-
risk at the confidence level α at
stage j under scenario ω.
Non-anticipativity parameters:
n: The serial number of nodes in the
scenario tree, where n ∈ N .
t(n): The corresponding stage that
node n marked in the scenario tree.
β(n): The set of scenarios that pass
through node n.
Decision variables:
yωj,r: Number of ventilators
allocated to region r at the end of
stage j under scenario ω.
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4.2.2 Compartmental Disease Model Description
Figure 4.1 One-step COVID-19 compartmental model.
Figure 4.1 shows the transmission dynamics of COVID-19 in each region r at each time
period j for a particular scenario ω. In this figure, susceptible individuals (S) can be
infected and become infected (either symptomatic or asymptomatic). Asymptomatic
infections (X) may have slight or no symptoms throughout the infection period and
will recover with a rate of λ9. Tested symptomatic infections (I) may recover or
die with rates of λ1 and λ2, respectively, if they are not treated in the hospital
(H). Note that Ĭωj,r with an incoming dashed arc to the I compartment represents
the number of infected people coming into the region r at stage j under scenario ω
from neighboring regions. Tested infected individuals (I) move to the hospital (H)
compartment, depending on the number of tested infections (I) and available hospital
capacity. Some of the treated infected people in the hospital (H) will recover with
a rate of λ4. The situations of some patients in the hospital (H) may get worsen,
and thus they may be transferred into the intensive care unit (we use C to represent
ICU), and those individuals need ventilators for the treatment.
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Similar to the case of admittance into the hospital, the number of hospitalized
patients transferred into ICU at each time period is equal to the minimum of the
number of patients who need to be transferred into ICU and the number of available
ventilators. The patients who are not able to receive the treatment in the ICU due
to the limitation on the number of available ventilators may die at a rate of λ5. After
being treated in the ICU, some of the patients may recover with a rate of λ7, while
others may die with a rate of λ8. Different from a typical compartmental model, the
transfer rate from I to H and H to C is not a constant, and it depends on the available
capacity in the H and C compartments, respectively, as discussed previously.
4.2.3 Time- and Space-Varying Transmission Rate
In this subsection, we formulate the transmission rate σ1,j,r as a time- and space-
varying parameter, which depends on the government interventions taken at time j
and region r. Since the onset of the COVID-19, many governments have imposed
different intervention strategies to reduce the transmission rate. At a certain stage,
each intervention has a different impact on the transmission rate for the next stage.
In this chapter, we incorporate three main non-pharmaceutical interventions to






j,r be binary decision variables that correspond to none
(i = 1), mask and social distancing (i = 2), and lockdown (i = 3) interventions,
respectively, taken at stage j and region r. If xij,r takes a value 1, then intervention i
is employed; otherwise, it is not employed, at stage j and region r. The transmission
rate at stage j + 1 in region r is a function of the transmission rate and specific
























j,r ∈ {0, 1} ∀j ∈ J, r ∈ R, (4.3)
where mij,t represents the percent change in the transmission rate with respect to
the binary decision variable xij,r for intervention i = 1, 2, 3 taken at stage j in region
r. Equation (4.1) shows that the transmission rate at stage j + 1 is a function of
the transmission rate at stage j and the intervention strategy i taken at stage j.
Equation (4.2) indicates that only one intervention measure can be taken at each
stage j. Equation (4.3) describes the binary nature of intervention decisions.
The transmission rate in our model is not equal to the basic reproduction
number, R0. It shows how many new tested infections will be caused by the
symptomatic and asymptomatic infections from the previous stage. Since the
number of new asymptomatic infections is uncertain, the number of new infections
(both symptomatic and asymptomatic) changes under different scenarios even if the
transmission rates at each stage j stay the same.
There is a delay in the impact of the government’ interventions on the number
of infections and the reaction to the test results is also slow. Therefore, we calculate
the transmission rate for the first two stages directly using the real data from
JHU [2020], independent from the intervention type. Based on the first two-stage
transmission rates, we calculate the transmission rates from stages three to five using
the formulation (4.1)–(4.3) for each intervention strategy. Also, the values of mij,t
are trained using the real data obtained from JHU [2020]. As an example, the initial
transmission rates for the first two stages in New York and New Jersey and the impacts
of government intervention strategies mij,t are shown in Table 4.5 under Subsection
4.3.2.
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4.2.4 Uncertainty and Multi-period Scenario Tree
Data regarding undetected or untested asymptomatic cases is lacking and uncertain.
Therefore, we model the uncertainty regarding the proportion of untested asymp-
tomatic infections (σω2,r) by generating a set of scenarios ω ∈ Ω, each representing a
specific realization of the uncertain proportion of untested asymptomatic individuals
over multiple time periods. Our scenario generation approach is similar to Alonso-
Ayuso et al. [2018]’s method developed to model the demand uncertainty in forestry
management. Each scenario has a probability of pω and
∑
ω∈Ω
pω = 1. Since data is not
available to describe the probability distribution of the uncertain variable (σω2,r), we
assume that the uncertain parameter follows a normal distribution. The lower and
upper bounds for the proportion of asymptomatic infections are obtained from the
study of Meller [2020]. The lower bound value for the random variable is considered
as the value of 0.001-quantile and the upper bound is considered as the value of
0.999-quantile of the normal distribution.
As an example, Figure 4.2 shows a particular scenario tree for the proportion of
untested asymptomatic infections (σω2,r) for a two-stage problem. We consider three
realizations at each node of the scenario tree by dividing its normal distribution into
three discrete parts [low (L), medium (M), high (H)]. The low and high realizations
have a probability of 0.3, and the medium realization has a probability of 0.4. Each
path from the root node to the leaf node of the scenario tree represents a scenario ω.
The probability of a scenario ω, pω, is calculated as the multiplication of probabilities
on the path for scenario ω. For two stages, 9 (32) scenarios will be generated in
this instance. The non-anticipativity constraints indicate that two scenarios are
inseparable at a stage j if they share the same scenario path up to that stage. This
means that the corresponding decision made at this stage for those two scenarios
should also be the same.
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The value of the proportion of asymptomatic infections has a mean µjr and
standard deviation σjr at stage j. We use Qh to represent the value of h-quantile in
the normal distribution. For each node n in the scenario tree, the mean value of the
low realization is the value of 0.15-quantile (E(µnr,low|Q0.001 ≤ µnr,low ≤ Q0.30) = Q0.15),
the mean value of medium realization is the value of 0.50-quantile (E(µnr,medium|Q0.30 ≤
µnr,medium ≤ Q0.70) = Q0.50), and the mean value of high realization is the value of
0.85-quantile (E(µnr,high|Q0.70 ≤ µnr,high ≤ Q0.999) = Q0.85). For node 0 in our example,
the proportion of untested asymptomatic infections at stage j = 0 has µ0r = 0.26 and
σ0r = 0.05. The low, medium, and high realizations at node 0 in stage j = 0 and nodes
1 and 3 in stage j = 1 are given in Table 4.1 below. According to the distributions
presented in Table 4.1, the proportion of untested asymptomatic infections in stage
1 is realized as 0.21 (Low) at node 1, 0.26 (Medium) at node 2, and 0.31 (High) at
node 3.
Table 4.1 The 0.15-, 0.50-, 0.85-Quantiles of the Normal Distribution at Nodes 0,
1, and 3 of the Scenario Tree in Figure 4.2 and the Associated Node of the Uncertain
Parameter Realization.
Low (realized node) Medium (realized node) High (realized node)
Q0.15 Q0.50 Q0.85
Node 0 0.21 (node 1) 0.26 (node 2) 0.31 (node 3)
Node 1 0.17 (node 4) 0.21 (node 5) 0.25 (node 6)
Node 3 0.12 (node 10) 0.31 (node 11) 0.50 (node 12)
4.2.5 Model Features and Assumptions
Since the transmission of COVID-19 is affected by many factors, data to calibrate
some of the model parameters, such as the impact of human mobility, is either lacking
or inaccurate. Therefore, we incorporate some important features and make some
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Figure 4.2 Multi-stage scenario tree generation example for the uncertain
proportion of untested asymptomatic infections (σω2,r).
assumptions in the model formulation.
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Important features. First, we consider the impact of different intervention
strategies on the disease transmission rate and adjust the short-term migration
population depending on the intervention strategy. For instance, under the lockdown
strategy, we assume that the short-term migration among each county is zero. Under
mask and social distancing strategies, the short-term migration population among
each county is reduced to 60% of the original value, as estimated from the study
of Lee et al. [2020]. Second, we incorporate the cost for purchasing ventilators
to provide a capacity limitation on the total number of ventilators that could be
allocated for treating COVID-19 patients. Since there are significant fluctuations in
the ventilator prices [Glass, 2020], we consider the minimum purchase price for each
ventilator acquired. Third, we train the real data to determine the impact rate of
each intervention strategy on the disease transmission rate. The trained value of the
impact of interventions can only be used in the regions considered in our case study
since all the selected counties in New York and New Jersey are geographically close to
each other, and thus interventions have similar social effects. However, for example,
the impact of intervention strategies in a rural area may be different from those taken
in a city. To estimate the COVID-19 transmission in other regions of the United
States, the model should be re-trained using the associated data.
Assumptions. First, since studied counties in New Jersey and New York are
geographically close to each other, the proportions of untested asymptomatic
infections at each stage j under scenario ω are set to be the same for each region r.
Second, the model considers allocating newly purchased ventilators for the treatment
of COVID-19 patients instead of re-allocating existing ventilators from other counties
or states since the demand for ventilators during the disease’s peak periods is high
for all the counties and states, and there is a lead time for transfer of the ventilators
between the states that are far from each other. Here, we also assume a central
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decision maker entitled to allocate a given supply of ventilators to multiple regions.
Third, the infected individuals who cannot be treated in the hospital (both severe
and less severe) due to the limited capacity have the same death rate as the ICU
patients because some of those infections may worsen without professional treatment.
Fourth, we assume that all symptomatic individuals are tested, and asymptomatic
infected individuals are untested. Fifth, we assume that people react to the pandemic
by anticipating the government’s interventions and may start social distancing and
quarantining days or weeks before an intervention is imposed [Zhang et al., 2020b,
Fischer et al., 2020]. Thus, the transmission rate with either doing nothing or mask
and social distancing shows a decreasing trend in later stages of the pandemic due
to physical distancing among people. Lastly, we use each county’s ICU capacity
from JHU [2020] as the initial ventilator availability. We assume that non-COVID-19
patients use 60% of this capacity [Mehrotra et al., 2020]. Thus, only 40% of the initial
ICUs are available for treating the COVID-19 patients.
4.2.6 Multi-Stage Risk and Time Consistency
The α-quantile of the cumulative distribution of a random variable z, infη{η ∈ R :
Fz(η) ≥ α}, is defined as the value-at-risk (VaR) at the confidence level α ∈ {0, 1}
and denoted by VaRα(z). The conditional expected value that exceeds the VaR at the
confidence level α is called conditional value-at-risk (CVaR), defined as CVaRα(z) =
E(z | z ≥ VaRα(z)). For a minimization problem, VaRα is the α-quantile of the
distribution of the cost, and it provides an upper bound on the cost that is exceeded
only with a small probability of 1 − α. CVaRα measures an expectation of the cost
that is more than VaRα, and can be calculated as an optimization problem as follows







where (a)+ := max(a, 0) for any a ∈ R.
We formulate our model as a mean-risk minimization problem:
min
x∈X
{E(f(x, ω)) + λCVaRα(f(x, ω))}, (4.4)
where E(f(x, ω)) is the expected cost function over the scenarios ω ∈ Ω, CVaRα
represents the conditional value-at-risk at α, and λ ∈ [0, 1] is a non-negative
weighted risk coefficient and it can be adjusted for a trade-off between optimizing
an expectation value and the level of risk taken.
Time Consistency. Time consistency is considered as a critical issue when modeling
a risk-averse multi-stage stochastic program. Time consistency means that if you
solve a multi-stage stochastic programming model today, you should get the same
solution if you resolve the problem tomorrow given the information that is observed
and decided today. We consider a nested risk measure, expected conditional value-at-
risk (E-CVaR), as defined in Homem-de Mello and Pagnoncelli [2016] since it is shown
to satisfy the time consistency of multi-stage stochastic programs. The E-CVaR
can be linearized and formulated as a linear stochastic programming model. In the
following subsection, we will utilize the E-CVaR as a risk measure in our formulation.
4.2.7 Mathematical Model Formulation and Description
The mathematical formulation for our risk-averse multi-stage stochastic epidemics-
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j ∈ J \ {J}, r ∈ R, ∀ω ∈ Ω, (4.5g)









j ∈ J \ {J}, r ∈ R, ∀ω ∈ Ω, (4.5h)
Oωj,r = min{λ3,rIωj,r, T ωj,r −Hωj,r} j ∈ J, r ∈ R, ∀ω ∈ Ω, (4.5i)
C
ω
j,r = min{λ6,rHωj,r, Uωj,r − Cωj,r} j ∈ J, r ∈ R, ∀ω ∈ Ω, (4.5j)
Uωj,r = U0,r +
j∑
l=1
yωl,r, j ∈ J, r ∈ R, ∀ω ∈ Ω, (4.5k)
I
ω
j,r ≥ λ3Iωj,r − (T ωj,r −Hωj,r) j ∈ J, r ∈ R, ∀ω ∈ Ω, (4.5l)
I
ω
j,r ≥ 0 j ∈ J, r ∈ R, ∀ω ∈ Ω, (4.5m)
Kωj,r ≥ λ6Hωj,r − (Uωj,r − Cωj,r) j ∈ J, r ∈ R, ∀ω ∈ Ω, (4.5n)










j,r)− ηωj j ∈ J,∀ω ∈ Ω, (4.5q)
zωj ≥ 0 j ∈ J, r ∈ R, ∀ω ∈ Ω, (4.5r)
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yωt(n),r − yn,r = 0, zωt(n) − zn = 0, ηωt(n) − ηn = 0,




















j ∈ J, r ∈ R, ∀ω ∈ Ω, (4.5t)
yωj,r ∈ {0, 1, 2, . . . ,
∆
e1
} j ∈ J \ {J}, r ∈ R, ∀ω ∈ Ω. (4.5u)
Objective Function (4.5a). The objective function (4.5a) minimizes the total
expected number of tested infected individuals and deaths and the conditional
value-at-risk over all stages j and scenarios ω.
Population Infection Dynamics Constraints (4.5b) - (4.5h). Constraint (4.5b)
represents that the number of susceptible individuals in region r at stage j + 1 under
scenario ω equals the number of susceptible individuals at stage j minus the number of
susceptible individuals who become either tested infected or untested asymptomatic
infected at stage j. In this equation, the number of untested asymptomatic infections
equals the number of tested infections multiplied by the proportion of the untested
asymptomatic infections to the tested infections. Constraint (4.5c) shows that the
number of tested infected individuals in region r at stage j + 1 under scenario
ω equals the number of tested infected individuals at stage j plus the infected
individuals caused by short-term migration, plus the newly tested infections at time
j, minus the recovered and deceased infections of tested individuals at stage j, minus
the hospitalized individuals at stage j. Constraint (4.5d) implies that the number
of untested asymptomatic infections in region r at stage j + 1 under scenario ω
equals the number of untested asymptomatic infections at stage j plus new, untested
asymptomatic infections, minus the recovered untested asymptomatic infections at
stage j. Constraint (4.5e) shows that the hospitalized individuals in region r at
stage j + 1 under scenario ω equals the number of hospitalized individuals at stage j
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plus the newly hospitalized individuals at stage j, minus the recovered and deceased
individuals at stage j, minus the individuals who move to the intensive care unit (ICU)
at stage j. Constraint (4.5f) indicates that the total number of individuals in ICU in
region r at stage j+1 under scenario ω equals the total number of individuals in ICU
at stage j plus the individuals who moved to ICU at stage j, minus the individuals who
are recovered or died at the ICU at stage j. Constraint (4.5g) shows that the number
of recovered individuals in region r at stage j under scenario ω equals the number of
recovered individuals at stage j plus the recovered individuals from tested infected,
untested asymptomatic infected and hospitalized individuals, and ICU patients at
stage j. Constraint (4.5h) indicates that the number of deceased individuals in region
r at stage j + 1 under scenario ω equals the number of deceased individuals at stage
j plus the deceased individuals from tested infected and hospitalized individuals and
ICU patients at stage j.
Ventilator Logistics and Capacity Constraints (4.5i) - (4.5p). Constraint
(4.5i) ensures that the number of individuals admitted to the hospital in region r
at stage j under scenario ω equals the minimum number of individuals who require
hospitalization and the available hospital capacity at stage j. Constraint (4.5j) implies
that the number of individuals admitted to ICU in region r at stage j under scenario
ω equals the minimum number of individuals who require treatment in ICU and
the number of available ventilators at stage j. Constraint (4.5k) represents that the
cumulative number of ICU beds (equivalent to ventilators) in region r at stage j under
scenario ω equals the initial number of ICU beds plus the cumulative number of ICU
beds (new ventilators) allocated from stage 1 to stage j. Constraints (4.5l) - (4.5o)
show that the number of individuals who can not be admitted to the hospital or the
ICU due to limited capacity should be greater than or equal to zero. Constraint (4.5p)
represents that the cost of ventilators allocated over all regions and time stages under
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scenario ω cannot exceed the total budget allocated for ventilators. The budget
here also represents the maximum total ventilator supply that could be available
throughout the planning horizon.
Risk Measure Constraints (4.5q) and (4.5r). Constraint (4.5q) indicates the
difference between the objective function value and the value-at-risk for each stage
j under each scenario ω. Constraint (4.5r) ensures that the loss value exceeding the
value-at-risk is included in the CVaR calculation, and thus zωj should be greater than
or equal to zero.
Non-Anticipativity, Non-Negativity and Integrality Constraints (4.5s) -
(4.5u). Constraint (4.5s) is the non-anticipativity constraint, indicating that the
scenarios that share the same path up to stage j should also have the same
corresponding decisions. Constraint (4.5t) indicates that the number of individuals in
each compartment in region r at stage j under scenario ω should be greater or equal
to zero. Constraint (4.5u) implies that the number of allocated ventilators should be
an integer.
Remark 1. Both (4.5i) and (4.5j) are non-linear, and thus we replace them
with equivalent linear constraints with additional linearization variables, using the
method presented in Yin and Büyüktahtakın [2021a]. Hence, the non-linear multi-
stage stochastic programming epidemics-ventilator-logistics model (4.5a)–(4.5u) is
converted into an equivalent mixed-integer linear programming (MIP) formulation.
We implement this MIP formulation for the rest of the paper.
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4.2.8 Scenario Sub-Problem and Bounds
We implement the scenario sub-problems and lower and upper bounds proposed by
Büyüktahtakın [2020] to reduce the optimality gap of solving our risk-averse multi-
stage stochastic programming problem (4.5a)–(4.5u), while referring to Büyüktahtakın
[2020] for the proofs of those bounds originally driven for the general multi-stage
stochastic programs. The scenario sub-problem and bounds are described below.

















s.t. Constraints (4.5b)− (4.5u). (4.6b)
Specifically, in P ω we minimize the objective function value only under scenario ω
while keeping all the variables and the constraints from the original problem (4.5a)–
(4.5u).
Proposition 1 (Lower Bound) Let Z∗ represent the objective function of the





Proposition 2 (Upper Bound) Let ẋω be the optimal solution of scenario-ω
problem, P ω, and Z(ẋω) be the objective value of original problem (4.5a)–(4.5u) where




4.3 Case Study Data
This section provides the data used to calibrate model parameters and formulate the
model, including population and short-term migration data, transmission parameters,
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as well as the cost of a ventilator. As shown in Figure 4.3, we select eight counties
that are most impacted by the pandemic in the states of New York and New Jersey
for our case study. They are New York County, Kings County, Queens County, Bronx
County, Richmond County, Hudson County, Bergen County, and Essex County. In
our multi-stage model, each stage represents a two-week period. Thus, all the data
regarding the transmission and migration are bi-weekly.
Source: [ESRI, 2020]
Figure 4.3 Counties in New York and New Jersey.
4.3.1 Population and Migration Data
Table 4.2 shows the population data for each considered county in New York and New
Jersey. Population data is obtained from JHU [2020]. The migration rates among
the considered counties, estimated from the data on CENSUS [2020], are presented
in Table 4.3. The blank areas in Table 4.3 represent a zero short-term migration
because the movement among those counties is too small to make an impact on the
model results.
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Table 4.2 Counties and Population Sizes in New York and New Jersey
New York Population New Jersey Population
New York 1,632,480 Hudson 668,631
Kings 2,600,747 Bergen 929,999




Table 4.3 Migration Rate Among Counties in New York and New Jersey
To New York Kings Queens Bronx Richmond Hudson Bergen Essex
From
New York 0.015 0.012 0.009 0.006 0.007 0.007 0.007
Kings 0.192 0.038 0.004 0.004
Queens 0.218 0.044 0.009 0.002
Bronx 0.209 0.014 0.028 0.003 0.003
Richmond 0.105 0.105
Hudson 0.040 0.001 0.040 0.040
Bergen 0.126 0.039 0.039
Essex 0.079 0.001 0.057 0.057
4.3.2 Epidemiological Data
Table 4.4 presents the data values for transmission parameters for the studied
counties in New York and New Jersey. The data contains the proportion of untested
asymptomatic infections, recovery rate, and the death rate for tested infections,
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hospitalized infections, and ICU patients. Table 4.5 shows the transmission rate of
each county at the first two stages and the impacts of applying different intervention
strategies, as discussed in Subsection 4.2.3.
Table 4.4 Transmission Parameters and Bi-weekly Rates for the COVID-19
Parameter Description Data Reference
NY NJ
σ2,r Proportion of untested asymptomatic
infections 0.15-0.4 0.15-0.4 Meller [2020]
λ1 Recovery rate without hospitalization 0.69-0.79 0.69-0.79 Hogan [2020]
λ2 Death rate without hospitalization 0.4 0.4 JHU [2020]
*
λ3 Hospitalization rate 0.21-0.31 0.21-0.31 Hogan [2020]
λ4 Recovery rate with hospitalization 0.88 0.88 Hogan [2020]
λ5 Death rate with hospitalization
(No ventilators) 0.4 0.4 JHU [2020]*
λ6 Ventilator requirement rate of hospitalized 0.12 0.12 Hogan [2020]
λ7 Recovery rate with ventilator 0.643 0.643 Bernstein [2020]
λ8 Death rate with ventilator 0.357 0.357 Bernstein [2020]
λ9 Recovery rate with asymptomatic infections 1 1 Bertsimas et al. [2020]
* Trained using real data.
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Table 4.5 Transmission Rate (σ1,r) in New York and New Jersey and Impact of
Interventions
County Transmission Rate Transmission Rate Impact of Impact of Impact of
at Stage 1 at Stage 2 None Mask Lockdown
New York 4.5 0.9855 1 0.4 0.6
Kings 9 0.9855 1 0.4 0.6
Queens 10 1.095 1 0.4 0.6
Bronx 12 1.314 1 0.4 0.6
Richmond 12 1.314 1 0.4 0.6
Hudson 22 2.409 1 0.3 0.6
Bergen 11 1.408 1 0.3 0.6
Essex 22 2.409 1 0.3 0.6
4.3.3 Initial Infection, Capacity and Cost Data
Table 4.6 shows the initial number of infections, hospital capacity, and ICU capacity
for each county. The data is obtained from JHU [2020].
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Table 4.6 Initial Number of Infections, Hospital Capacity, and ICU Capacity for
Each County
County Initial Initial Initial
Infections Hospital Capacity ICU Capacity
New York 1200 8650 944
Kings 1300 5838 282
Queens 1100 3210 146
Bronx 554 2816 274
Richmond 206 1177 72
Hudson 66 1764 89
Bergen 249 2874 122
Essex 73 3541 226
Ventilator Cost. The cost of each ventilator ranges from $5000 to $50000 [Glass,
2020]. In our case, we consider a cost of $5000 for each ventilator, and different
budget levels are set to impose different upper bounds on the ventilator supply.
4.4 Results
4.4.1 Model Validation
This subsection presents the validation results of the mathematical model in
Equations (4.5a)–(4.5u) as presented in Subsection 4.2.7 for the 8-stage time period
from April 3, 2020, to July 10, 2020. We consider a medium realization of the
uncertain asymptomatic proportions at each stage of the planning horizon and
compare the number of infections forecasted by our model to the real outbreak data.
The government applied a lockdown strategy from April 3, 2020, to July 10,
2020, at those considered locations in New York and New Jersey. Thus, we use the
lockdown strategy and the corresponding transmission rate at each stage in our model
for validation.
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Figure 4.4 Comparison of predicted cases with real outbreak data for new infections
in New York and New Jersey.
Figure 4.4 shows the comparison between the predicted infections and real
outbreak data. The model’s predictions provide a visually good fit for the actual
number of new infections in each region, implying that the model can capture the
disease transmission dynamics under a lockdown intervention strategy. We also
perform a paired-t-test to analyze the difference between the pairs of predicted new
infections and the actual data in each period. As shown in Table 4.7, all p-values
are greater than 0.05, and thus our model provides statistically similar predictions
with the real outbreak data from April 3, 2020, to July 10, 2020, for each considered
county.
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Table 4.7 Statistical Analysis to Compare the Bi-Weekly Predicted New Cases and
Real Outbreak Data
County Mean Two-tailed paired-t-test
Outbreak Predicted t-stat t-critical p-value
New York 7300 7299 0.20 2.36 0.58
Kings 7413 7754 0.41 0.65
Queens 8138 8751 0.21 0.58
Bronx 5956 6214 0.46 0.67
Richmond 1762 2040 0.04 0.51
Hudson 2455 2806 0.16 0.56
Bergen 2444 2656 0.30 0.61
Essex 2366 2948 0.04 0.51
4.4.2 Case Study Implementation Details
We apply our model described in Section 4.2 to the selected counties in New York and
New Jersey. We first solve the risk-neutral model. We incorporate the uncertainty
of the proportion of untested asymptomatic infections as well as the short-term
migration in the disease transmission and forecast the number of new infections,
deceased individuals, hospitalized individuals, and ICU patients under different
intervention strategies. Also, we solve the model to determine the optimal location
and number of ventilators allocated under different budget levels and scenarios to
provide insights into resource allocation over multiple jurisdictions under uncertainty.
Due to the high complexity of the mathematical formulation, we solve it for a 5-stage
time period. Each stage corresponds to two weeks, resulting in a planning horizon of
ten weeks from March 20, 2020, to May 29, 2020. Because each node of the scenario
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tree has three possible realizations of the random parameters, we solved 243 (35)
scenarios simultaneously.
The mathematical model is solved using CPLEX 12.7.1 on a desktop computer
running with Intel i7 CPU and 64.0 GB of memory. We set the time limit at 7200 CPU
seconds to solve each test instance. We extend running time for specific budget levels
($30 Million) and interventions (“Lockdown”) due to the large optimality gap. In
the following subsections, we present results from solving the multi-stage stochastic
epidemics-ventilator-logistics model with an application to the case of COVID-19
using the data presented in Section 4.3.
4.4.3 Transmission Forecast under Different Intervention Strategies
Here, we present results of our formulation for each time period under different
intervention strategies: No intervention (“None”), mask and social distancing for
all stages (“Mask and Social Distance”), lockdown for all stages (“Lockdown”), mask
and social distancing for the first three stages and lockdown for the following two
stages (“Mask + Lockdown”), lockdown for the first three stages and mask and social
distancing for the following two stages (“Lockdown + Mask”). The model is solved
under the $30 million budget level. The model with the “Lockdown” strategy gives a
4.54% optimality gap after a run time of 43,241 CPU seconds, while the model solved
for all other strategies has a zero optimality gap within 7,200 CPU seconds.
Figure 4.5 presents the number of infections and deceased individuals at each
stage under different intervention strategies. According to the results, short-term
migration influences the number of new infections even under constant transmission
rates. As in the first stage, within the same initial transmission rate, the number
of infections under different intervention strategies is different from each other.
When the stage increases, the difference in the number of new infections among
each intervention strategy becomes more and more significant. The “None” strategy
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has the most infections at each stage, followed by the “Mask and Social Distance”
strategy. The “Lockdown” strategy results in the lowest number of new infections
compared to those under other strategies at each stage. The “Lockdown” strategy
provides a little higher number of infections compared to the actual infection data
since our model slightly (but statistically insignificantly) overestimates the number of
infections. Compared to the “Mask + Lockdown” strategy, the “Lockdown + Mask”
intervention leads to fewer infections. This implies that applying the “Lockdown”
strategy immediately at the onset of the pandemic followed by the “Mask and Social
Distance” intervention is a better strategy than enforcing “Mask and Social Distance”
first and delaying the lockdown.
The intervention strategy does not influence the number of deceased individuals
as quickly as it does impact the number of infections, as shown in Figure 4.5. Here,
the number of deceased individuals at the first two stages is much lower than that of
the last three stages. Starting from stage three, the number of deceased individuals
under different intervention strategies shows a similar trend with the number of
new infections. The influence of interventions is further delayed for those confirmed
infections to be treated in the hospital and ICU (Figure 4.6).
To reduce both the number of new infections and deaths, “Lockdown” is the
best strategy. As shown in Figure 4.5b, the “Lockdown” strategy with the optimal
ventilator allocation further reduces the actual number of deaths. Due to the negative
impact of COVID-19 on employment and its economic burden, governments are often
forced to stop the lockdown and reopen businesses. In such cases, applying “Mask
and Social Distance” after a certain period of “Lockdown” will be the best choice.
Figure 4.6 shows the number of hospitalized individuals and ICU patients at
each stage under different intervention strategies. Similar to the number of deceased
individuals, there are delays in the impact of government interventions on the number
of hospitalized individuals and ICU patients. An infected person may have mild
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symptoms for about one week, then worsen rapidly (School [2021]). Thus, it may
take some time for patients to be admitted to the ICU, so the impact of interventions
on the number of ICU patients is delayed one more stage compared to the hospitalized
cases. As shown in Figure 4.6, more number of hospitalized individuals at stage j
will lead to more ICU patients at stage j + 1.
Figure 4.5 Number of new infections and deaths under different intervention
strategies and actual numbers.
For all the stages, the “Lockdown” strategy has the least number of hospitalized
individuals and the ICU patients, followed by the “Lockdown + Mask” intervention.
The ICU patients of “None,” “Mask and Social Distance,” and “Mask + Lockdown”
are almost the same at stages three to five. This is because under those, the need
for ventilators is large, and the number of treated individuals in ICUs depends on
the minimum number of patients who require ventilators and the ventilator supply
in those ICUs. Thus, the number of treated patients in ICUs is limited by the tight
ventilator availability.
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Figure 4.6 Number of hospitalized individuals and ICU patients under different
intervention strategies.
4.4.4 Optimal Ventilator Allocation
Table 4.8 shows the number of ventilators allocated to each region at stages one
and two and the total number of ventilators allocated throughout the planning
horizon under different budget levels and three select scenarios. The “All Low,”
“All Medium,” and “All High” scenarios represent low, medium, and high realization
of the proportion of untested asymptomatic infections at each stage of a five-stage
planning horizon, respectively. To analyze the impact of budget on the optimal
ventilator allocation decisions, we select $10M as the limited budget level, $20M as
the medium budget level, and $30M as the ample budget level. The model has zero
optimality gap under the $10M budget level, 4.54% optimality gap under the $20M
budget level and 7.77% optimality gap under the $30M budget level within two hours
of solution time.
The results in Table 4.8 demonstrate that the location and number of ventilators
allocated depend on several factors, including the initial and evolving disease
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transmission rates, the population and the number of initial infections in a region,
and the existing ventilator capacity. Thus, the optimal ventilator allocation should
be determined case-by-case.
According to the results, the total number of ventilators allocated increases in
the budget level due to the high need for ventilators. As shown in Table 4.8, under the
limited budget level, some regions with many initial infections, e.g., the New York
County, do not receive ventilators. This situation is because the initial ventilator
capacity of those regions is higher than in other counties. Also, results suggest that
more ventilators should be distributed to other areas with a higher initial transmission
rate than the New York County, such as Kings, Hudson, and Essex, under a very
tight budget. Kings, Queens, and Hudson have higher initial transmission rates and
lower initial ICU capacity than New York. Thus, these regions get more ventilators
allocated under a limited budget level and “All Low” scenario. Also, regions with a
relatively smaller population, such as Hudson and Essex in New Jersey, get a large
share of ventilators with a very tight budget under the “All Low” and “All Medium”
scenarios due to their high transmission rates at the beginning of the pandemic.
Independent from the budget level, some regions with low initial infections and
low initial ICU capacity (e.g., Bronx) will get more ventilators allocated under the
“All Medium” scenario. Under this scenario, the number of infections in regions with
a high initial transmission rate (e.g., Kings and Queens) will not significantly increase
even if they receive a smaller number of ventilators. These regions usually have much
more initial ICU capacity for the treatment because of their large population. On
the contrary, the areas with a lower initial transmission rate but less initial ICU
capacity may benefit more if they receive more ventilators. As a comparison with
the “All Medium” scenario, the number of infections in the region with a low initial
transmission rate will be much smaller under the “All Low” scenario, and the number
of infections in the regions with a high initial transmission rate will be much larger
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under the “All High” scenario. The model gives priority to allocate more ventilators
to the regions with high initial transmission rates for both of the “All Low” and “All
High” scenarios because the benefit of giving resources to those regions is higher than
the regions with low initial disease transmission.
Moreover, the model is forced to make difficult decisions, and some of the regions
may not have any ventilator allocated under a limited ventilator supply. When the
budget is too tight, the regions with a high transmission rate gets the priority. As
the budget increases to medium and ample, the model allocates more capacity to
the regions with a higher population and a larger initial number of infections but
with a lower transmission rate. Also, the stage-wise distribution of ventilators has
a high relationship with the available budget. If the budget is tight, all ventilators
are distributed within the first two stages. As we increase the budget, some of the
ventilators are allocated in stages three and four in addition to stages one and two.
Thus, a higher budget level also provides some flexibility in delaying the ventilator
allocation to some regions.
4.4.5 Risk Analysis
In this subsection, we perform an analysis of the risk parameters λ and α in terms
of their impact on the expected number of infected and deceased people as well as
the CVaR of the impact. Specifically, under the $30M budget level, we compare
four different problems with respect to their risk-averseness level, adjusting λ and α
values accordinglyrisk-neutral (λ = 0, α = 0), weak risk-aversion (λ = 1, α = 0.3),
mild risk-aversion (λ = 10, α = 0.6), and strong risk-aversion (λ = 10, α = 0.95). The
model under the mild risk-aversion results in a high optimality gap (13%) within 7200
CPU seconds running time. Therefore, we solve the scenario-ω problems described
in Subsection 4.2.8 and obtain the lower and upper bounds for the original problem.
For our problem, we select five representative scenarios, and add bounds based on
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the results of those select scenarios in the risk-averse model. After implementing the
scenario bounds, the optimality gaps over all of the risk-averseness levels reduce to
less than 9.13%.
We decompose the objective function (4.5a) into the Expected Impact [E(f(x, ω))]
and the Expected Risk [CVaRα(f(x, ω))], as demonstrated in Equation (4.4), to
analyze the impact of risk trade-off on the results. Table 4.9 presents the value
of the objective function (4.5a), expected impact, and expected risk (without λ)
under different risk-averseness levels. Specifically, the expected impact represents
the expected total number of infections and deceased individuals, and the expected
risk corresponds to the expected CVaR term in Equation (4.5a) without the λ value.
According to Table 4.9, when both λ and α increase, the level of risk-averseness and
the expected risk increase. The optimal objective function value increases due to
the additional risk term added into the objective formulation. The expected impact
also increases, implying the cost of being risk-averse, which is the increased number
of infections and deceased individuals while trying to mitigate specific disastrous
scenarios.
Table 4.9 Comparison of Objective Value, Expected Impact, and Expected Risk
under Various Risk-Averseness Levels
Risk Weak Mild Strong
Neutral Risk-aversion Risk-aversion Risk-aversion
(λ = 0, α = 0) (λ = 1, α = 0.3) (λ = 10, α = 0.6) (λ = 10, α = 0.95)
Objective Value 347,395 721,710 3,997,129 4,011,964
Expected Impact 347,395 360,438 362,559 363,526
Expected Risk - 361,272 363,457 364,844
The expected impact and expected risk (without λ) for various combinations of
λ = {0, 1, 10} and α = {0.3, 0.6, 0.95} under the $30M budget level are presented in
Table 4.10. We observe the change of the expected impact and expected risk when
changing one of the risk parameters and fixing all others’ original values. According
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to the results, fixing the α value, both expected impact and expected risk show an
increasing trend due to the increase of λ. When we move from risk-neutral (λ = 0) to
risk-averse (λ = {1, 10}), the expected impact always increases. Similarly, λ = {1, 10}
increases the expected impact compared to the risk-neutral model. Besides, when
fixing the λ value and increasing the α value, the expected risk increases because
we increase the confidence level for reducing the risk of having an extremely large
number of infections and big losses of lives.
Table 4.10 Expected Impact and Risk for Different Risk-Averseness Levels
λ\α 0.3 0.6 0.95
Expected Expected Expected Expected Expected Expected
Impact Risk Impact Risk Impact Risk
0 347,395 0 347,395 0 347,395 0
1 360,438 361,272 361,950 363,251 363,882 365,236
10 360,880 361,341 362,559 363,457 363,526 364,844
4.5 Discussion and Future Directions
In this chapter, we present a general multi-stage mean-risk epidemics-ventilator-
logistics model and apply this model to control the COVID-19 in select counties
of New York and New Jersey. We first explicitly formulate the uncertainty of
the proportion of untested asymptomatic infections at each stage, generating a
multi-stage scenario tree. We then develop a compartmental disease model and
integrate the short-term human movement among multiple regions into this model.
We also derive a time- and space-varying disease transmission formulation and a
logistics sub-model. We then integrate all those components into one mathematical
formulation, which minimizes the number of infections and deceased individuals under
different intervention strategies.
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We solve the epidemics-ventilator-logistics model under different budget levels
to determine the ventilator-distribution optimal timing and location under various
pandemic scenarios. Next, we apply the CVaR in a nested form over a five-stage
planning horizon to minimize the total expected number of infections and deceased
individuals, as well as the weighted risk of the loss. Finally, we solve the scenario
sub-problems under various scenarios to generate the lower and upper bounds for the
original problem, reducing the optimality gap. Our results provide key insights into
the resource-allocation decisions for controlling the COVID-19 and can be adapted
to study the transmission and logistics of other similar diseases.
According to the results, the number of infections, deceased individuals,
hospitalized individuals, and ICU patients indicates that short-term migration
influences the number of infections, even if the transmission rate is constant
over time. The impacts of government interventions on the number of deceased
individuals, hospitalized individuals, and ICU patients are delayed because deaths
and hospitalization have a lag period compared to zero or a small lag phase in the
growth of infections. Furthermore, the number of ICU patients at each time period
depends on the minimum number of patients who require the ICU and the available
ventilators. Thus, the number of ICU patients might be at the capacity limit even
under different intervention strategies at a particular stage. The “Lockdown” strategy
is the best way to control disease transmission. Nevertheless, “Mask and Social
Distance” applied after the several stages of “Lockdown” is the second-best strategy
to optimistically alleviate the pandemic’s economic impacts.
The ventilator allocation under different budget levels and scenarios indicates
that the number of ventilators allocated to each region depends on various factors,
such as the number of initial infections, initial disease transmission rates, initial ICU
capacity, and the population of a geographical location. The region with a high initial
transmission rate and low initial ICU capacity receives more ventilators under a low
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disease transmission scenario and a limited budget level. This is because, under a
low disease transmission scenario, other regions with low initial transmission rates
have fewer infections, even if they have smaller initial ICU capacity. Independent
from the budget level, the area with a low initial transmission rate and low initial
ICU capacity has more ventilators allocated under the medium transmission scenario.
This is because the number of infections in the region with a high initial transmission
rate and high initial ICU capacity does not significantly increase even if they receive
fewer ventilators under a mild disease transmission scenario. Under a medium and
ample budget level, the model allocates more capacity to the regions with a higher
population and a larger initial number of infections but with a lower transmission
rate. Moreover, when the budget is limited, all of the ventilators are allocated at the
first two stages. When the budget becomes ample, decision-makers would have some
flexibility in delaying ventilator allocation to later stages of the planning horizon.
The increase in the mean-risk trade-off coefficients in the risk-averse model
improves the confidence level, reducing the loss in the right tail of the objective
function values (the number of infected and deceased individuals over highly-adverse
scenarios). However, we should expect more infections and deceased individuals on
average considering all possible scenarios when we want to decrease the impact of
adverse scenarios by increasing the risk-averseness level.
This study leads to several future directions for research. For instance, vaccine
allocation is also essential as it can potentially protect people from being infected. The
combination of vaccine allocation and other interventions will provide more flexible
strategies to prevent and control the disease. For example, for the region with a low
transmission rate and high vaccine coverage, decision-makers could consider lifting
the “Lockdown” earlier to stimulate the economy. Furthermore, the mathematical
model cannot allocate ventilators to some regions under a very tight budget, and so
future research could investigate ethical and fair resource allocation strategies during
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a pandemic. Also, some of the assumptions and inferences made in our model could
be updated in a future study as more data are available.
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Table 4.8 Optimal Ventilators Allocated under Different Scenarios for Budget
Levels
Scenario County Stage Stage Total Stage Stage Total Stage Stage Total
1 2 Ventilator 1 2 Ventilator 1 2 Ventilator
(Budget=$10M) (Budget=$20M) (Budget=$30M)
All Low
New York 0 0 0 721 1 802∗ 2100 0 2100
Kings 119 0 119 1734 0 1736∗ 2222 0 2222
Queens 107 1069 1176 0 0 0 0 0 0
Bronx 28 0 28 1016 1 1017 1016 1 1017
Richmond 18 0 18 0 0 0 0 0 0
Hudson 0 250 250 0 0 0 0 0 2∗
Bergen 187 0 187 12 433 445 0 0 165∗
Essex 218 0 218 0 0 0 0 0 174∗
Total 677 1323 2000 3483 435 4000∗ 5338 1 5680∗
All Medium
New York 0 0 0 721 0 721 2100 0 2101∗
Kings 119 0 119 1734 76 1810 2222 1 2223
Queens 107 0 107 0 0 3∗ 0 0 69∗
Bronx 28 809 837 1016 0 1016 1016 0 1017∗
Richmond 18 0 18 0 0 0 0 0 35∗
Hudson 0 250 250 0 0 0 0 0 53∗
Bergen 187 264 451 12 435 447 0 0 0
Essex 218 0 218 0 0 3∗ 0 0 349∗
Total 677 1323 2000 3483 511 4000∗ 5338 1 5847∗
All High
New York 0 0 0 721 0 721 2100 1 2190∗
Kings 119 0 119 1734 0 1734 2222 0 2222
Queens 107 1055 1162 0 0 2∗ 0 0 451∗
Bronx 28 4 32 1016 0 1016 1016 0 1017∗
Richmond 18 0 18 0 0 78∗ 0 0 0
Hudson 0 0 0 0 0 0 0 0 0
Bergen 187 264 451 12 437 449 0 0 93∗
Essex 218 0 218 0 0 0 0 0 27∗
Total 677 1323 2000 3483 437 4000∗ 5338 1 6000∗
∗ Some of the ventilators are allocated at stages three and four.
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CHAPTER 5
AN AGENT-BASED SIMULATION-OPTIMIZATION VACCINE
CENTER LOCATION VACCINE ALLOCATION APPROACH TO
CONTROLLING COVID-19
5.1 Introduction
The Coronavirus Disease 2019 (COVID-19) has caused around 4 million deaths
worldwide by mid-July 2021 [JHU, 2021] and 607 thousand only in the United
States with the largest death toll in the world (15%). Fast disease spread caused
the collapse of the healthcare system in many countries, forcing them to use other
intervention strategies to slow down the virus spread, such as lockdown, quarantine,
and mandatory mask [Zhang et al., 2020a, Eikenberry et al., 2020]. In some countries,
where people can strictly follow the rules, these strategies are very effective, and the
cases have been reduced significantly. However, for some countries where people have
more social activities, these strategies could not lessen the increasing number of cases
and deaths in the long term.
The most effective way to stop this health crisis is to produce effective vaccines
and let most people be vaccinated [Peter Loftus, 2021b]. On March 11, 2020, World
Health Organization (WHO) declared the COVID-19 as a pandemic making it a global
threat. All countries felt the urgency to invest in the research and development of
a vaccine, especially the Group of Twenty (G20), which has the most to lose from
the COVID-19. The Pfizer/BioNTech (Pfizer) vaccine was the first vaccine listed
for WHO Emergency Use Listing (EUL) on December 31, 2020. On February 16,
2021, the SII/Covishield and AstraZeneca vaccines were given EUL. The Janssen
developed by Johnson & Johnson was listed for EUL on March 12, 2021. The Moderna
vaccine was listed for EUL on 30 April 2021. The Sinopharm vaccine is produced by
China National Biotec Group (CNBG) and was listed on May 7, 2021. The Sinovac-
CoronaVac was listed for EUL on June 1, 2021 [WHO, 2021d]. Among these, we
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consider mainly three vaccines used in the United States, PfizerBioNTech, Moderna,
and Johnson & Johnson (Janssen), in our model.
With more and more people getting vaccinated, the number of cases and
deaths decreased significantly. Until July 2021, there were about 332 million doses
administered in the United States. About 55.3% of US people got at least one dose,
and about 47.8% of people were fully vaccinated by July 2021 [CDC, 2021]. Since
December 2020, when people started to get vaccinated, the number of daily deaths in
the United States has decreased from about 4,000 to only 300, and the number of daily
cases has dropped from about 200,000 to 20,000 by July 9, 2021 [JHU, 2020]. The
dramatic drop in both the number of deaths and the total infections shows that the
vaccines are very effective for controlling the epidemic. Despite this, the vaccination
process differs based on the vaccines available, the total budget, and the logistic
processes. This study aims to develop a mathematical model to use the available
resources under different budgets effectively and provide insights into optimal vaccine
allocation achieving the lowest infection rate.
Human behavior has a significant influence on COVID-19 transmission. If we
can model human interactions and disease transmission realistically, we can accurately
estimate how vaccines reduce the infection numbers. This aspect is also quite
essential to decide where to locate vaccination centers and find the optimal vaccine
allocation. Kerr et al. [2021] propose an agent-based model (Covasim) that simulates
person-to-person contact among different communities. In their Covasim project,
each individual has the probability of being infected in a complicated environment
for the agent-based simulation. For instance, the kids of the family may go to school,
and adults may go to work. Both activities give them a chance to contact infected
individuals. People may also spend time together with their family members and
friends in the community and get infected. We extend the Covasim agent-based
model and incorporate it with an optimization model to optimize vaccine allocation.
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In this chapter, we formulate an optimization model to determine the COVID-
19 optimal vaccine allocation strategies under budget and population dynamics
constraints. Our model extends the agent-based simulation presented by Kerr
et al. [2021] to incorporate different types of vaccines with one or two shots. We
incorporate service center location and service decision for each center, including
the nearby regions served by the center in the optimization model, and the number
of vaccines allocated to each region. We integrate all those elements into one
simulation-optimization model. The optimization model uses the simulation results
as input to generate the optimal vaccine allocation decisions and transfers the optimal
decisions into the simulation model, which populates health states, such as the
number of infections, in the following period. We calibrate, validate, and test our
simulation-optimization vaccine allocation model using JHU [2020] COVID-19 data
collected during the middle stages of the pandemic.
5.2 Key Contributions and Insights
The majority of existing studies only use the simulation or optimization model
separately. In addition, most researches only focus on one side of the epidemic control,
either transmission forecasting or optimizing the resource allocation strategies. To
our best knowledge, none of them consider the agent-based simulation of disease
transmission with the optimal vaccination center location and vaccine allocation
problem together. To address the limitation of the resource allocation and logistic
planning problem on epidemic control, we formulate our model with the following
contributions:
(i) We formulate an optimization model to determine the COVID-19 optimal
vaccine allocation strategies. Besides the simulation model, the optimization
model includes the population dynamics constraints on the susceptible individuals,
infections, vaccinated individuals to project disease growth, and impacts of
optimization decisions under a limited budget.
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(ii) We extend the agent-based simulation presented by Kerr et al. [2021] to
incorporate vaccination compartments and different types of vaccines with one
or two shots.
(iii) In the optimization model, we incorporate service center location and service
decision for each center, including the nearby regions served by the center and
the number of vaccines allocated to each region. We use exponential functions
to generate the lower bound of the number of vaccines allocated, and the vaccine
acceptance rate provides the upper bound of vaccine supply.
(iv) We integrate all those elements mentioned above into one simulation-optimization
model. The optimization model applies the simulation results as the inputs to
generate the optimal vaccine allocation decisions. Then the decision results are
imported into the simulation model, which populates very detailed health states,
such as the number of infections, hospitalized, and deaths, in the following
period.
(v) Our results suggest that the vaccine with a lower cost is recommended to be
allocated more under a limited budget level. Under an ample budget level, the
vaccine with a higher efficiency should be administered more. In addition, the
region that has a high population or initial infections should have more vaccines
allocated.
5.3 Model Description
5.3.1 Agent-based Simulation Model
In this section, we discuss the agent-based simulation and optimization models and
their integration in more detail.
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Source: [Kerr et al., 2021]
Figure 5.1 Covasim simulation.
The Covasim agent-based simulation process is presented in Figure 5.1. Here,
individuals interact with each other increasing the probability of being infected. For
instance, the student of the family may go to school and contact their classmate,
and adults may go to workplaces and contact their colleagues. People may also go
to a public place during daily activities or hang out with their family members and
friends in the community. Both behaviors increase the risks of contracting infections
and being sick.
167
Figure 5.2 Compartment model of simulation.
For each individual, the health status can be described in Figure 5.2. In
the Covasim simulation, each individual has the following health statuses: the
Susceptible compartment represents people who can potentially be infected. The
Exposed compartment represents the group of people who are exposed to the virus.
The Asymptomatic compartment denotes the infected people who never develop
symptoms, while the Presymptomatic compartment represents people who are not
yet displaying symptoms of an illness or disease. The Mild compartment indicates
people who have minor symptoms. The Severe compartment means that people have
severe symptoms. The Critical compartment represents people who have even more
severe symptoms and need to be treated in the intensive care unit. The Recovered
compartment shows the recovered people, and the Dead compartment represents
people who are dead from the critical symptoms.
Susceptible individuals can contact the infections and be exposed to the virus.
On the one hand, a proportion of exposed individuals shows no symptoms and
thus become asymptomatic. The asymptomatic infections recover from the disease
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automatically. On the other hand, part of the exposed individuals develops symptoms.
The symptoms can vary from mild to severe and then to critical. The majority of
the people with every degree of symptoms recover. However, some individuals with
critical symptoms may die due to their weak immunity or the delayed treatment
process.
In our model, we extend the compartment model presented by Kerr et al. [2021]
by adding two vaccine compartments. As shown in Figure 5.2, Vaccinated 1 represents
the individuals that have received the first shot of the vaccine, and Vaccinated 2
represents the individuals that have received the second shot of the vaccine. We
incorporate three types of vaccines in the model, which are Pfizer, Moderna, and
Janssen. The Pfizer and Moderna vaccines include two shots, and the Janssen vaccine
only requires one shot. Thus, a proportion of susceptible and recovered individuals
receives the first shot of the vaccine at each period. The individuals who choose
the Pfizer and Moderna vaccines receive the second shot after a few weeks of their
first shot. The people who have received the vaccine can still be infected, but the
probability of being infected is much smaller than the general susceptible individuals.
5.4 Optimization Model Formulation
This section provides the essential features and assumptions of the optimization
model, the notations used in the optimization model, and the mathematical
formulation of the optimization model.
5.4.1 Important Features and Model Assumptions
A few assumptions are made in the formulation of the optimization model. To
begin with, the optimization model includes three types of vaccines, where Pfizer and
Moderna vaccines require two shots and Janssen vaccines come with only one shot.
Second, the Pfizer vaccination center has a 6,000 daily vaccine capacity due to the high
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number of supplies [NJIT, 2021], while the Moderna and Janssen vaccination centers
have 2,000 vaccine capacity [Heffernan, 2021a]. Third, since the human behavior for
the vaccination is hard to predict, we assume the people in each region are served only
by the vaccine centers in the closest nearby region. Fourth, for the new vaccine centers,
we calculate the distribution cost from the warehouse to them. For the existing local
pharmacies and small vaccine sites, since the detailed location and transportation cost
information is limited, we only solve an overall vaccine capacity for each county and do
not specify the vaccine capacity for each small site and the associated transportation
cost. According to the data on Heffernan [2021b], the daily vaccine supply capacity for
local pharmacies and small vaccination sites is set to 10,000, and we assume an ample
total vaccine supply availability at each stage. In addition, we add $1.41 to each of the
vaccines allocated to the local pharmacies and small vaccination sites as a unit cost for
delivery, according to the information obtained from WHO [2021c]. Fifth, the exact
location of the supply warehouse for each type of vaccine is unknown. According to
Pfizer [2021] and Peter Loftus [2021a], the Pfizer and Moderna vaccine manufacturing
center is far from New Jersey. Thus, we assume that the Pfizer and Moderna vaccines
are transported from the manufacturing center to the supply warehouse by air. The
largest port of New Jersey locates in Essex County (Newark Airport), so we assume
the Pfizer and Moderna supply warehouses for New Jersey are in Essex County.
In addition, we observe that the Janssen supply warehouse locates in Somerset
County. Sixth, the vaccine willingness rate is estimated as 0.3% per day using the
information obtained from NJ.GOV [2021]. Seventh, we simulate the compartment
flow in the optimization model in each region at each stage. As shown in Figure 5.3,
S includes the Susceptible compartment in Figure 5.2, which means the susceptible
individuals. People in S can be infected and become infected individuals I, which
includes Asymptomatic and Presymptomatic compartments in Figure 5.2. V1 and
V2 represent the individuals who received the first-dose and second-dose of different
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types of vaccines, which represent Vaccinated 1 and Vaccinated 2 compartments in
Figure 5.2, respectively. The susceptible individuals can be vaccinated and transfer
to V1 and V2. People in both V1 and V2 can transfer to recovered individuals R
depending on the vaccine type. The results for each compartment in each region at
each stage are only used in the optimization model to generate the vaccine center
location and vaccine allocation decisions, and they will not influence the results of
the agent-based simulation.
Figure 5.3 Compartment model of optimization.
5.4.2 Notation
Below we provide the notations used for the rest of the chapter.
Sets and Indices
J : Set of time periods, J = {0, . . . , J}.
R : Set of regions, R = {0, . . . , R}.
P : Set of vaccine supply warehouse, P = {1, 2, 3}.
N : Set of the number of the days between the first and second shot
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of type i vaccine, N = {21, 28}.
j : Index for time period, where j ∈ J .
r : Index for region, where r ∈ R.
i : Index for vaccine, where i ∈ {1, 2, 3}.
p : Index for vaccine supply warehouse, where p ∈ P .
n : Index for the number of the days between the first and second shot
of type i vaccine, n ∈ N .
State Variables
Sj,r : Susceptible individuals in region r at stage j.
Ij,r : Infected individuals including both symptomatic and asymptomatic
individuals in region r at stage j.
V 1j,r : Number of people get the first dose of type i (i ∈ {1, 2}) vaccine
and a single dose of type i (i ∈ {3}) vaccine in region r at stage j.
V 2j,r : Number of people who get the second dose of
type i (i ∈ {1, 2}) vaccine in region r at stage j.
Other Parameters
bir : Cost of building type i vaccination center in region r.
ci : Purchase cost for each type i vaccine.
dr,l : The distance from the highest populated city in region r to the highest
populated city in region l.
dp,r : The distance from vaccine supply warehouse p to the highest populated
city in region r.
t : Unit transportation cost of vaccines with a truck from the vaccine supply
warehouse to a region.
Gij,r : Vaccination capacity for type i vaccination center at stage j in region r.
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H ij : Vaccine supply upper bound for type i vaccine at stage j.
Cij,r : Total existing capacity of the local pharmacies and small vaccination sites
for type i vaccine at stage j in region r.
β1r : The first shot vaccine acceptance rate, i.e., willingness to get vaccinated,
for a two-dose vaccine in region r.
β2r : The lower bound of the second shot vaccine acceptance rate for a
two-dose vaccine in region r.
βr : The vaccine acceptance rate for the one-dose vaccine in region r.
α1,ir : Proportion of individuals who get immunization by the first shot of
type i two-dose vaccine.
α2,ir : Proportion of individuals who get immunization by the second shot of
type i two-dose vaccine.
αr : Proportion of individuals immune by the one-shot vaccines.
nr : The total number of vaccine centers allocated in region r.
e : Euler’s number.
m : Parameter that is used to change the value of equations (5.1q) and (5.1r).
k : Parameter used to change the value of equations (5.1q) and (5.1r).
πr : The initial number of susceptible individuals in region r, inputted from the
simulation model.
$r : The initial number of infections in region r, inputted from
the simulation model.
θir : The initial number of the individuals who have received the first-dose
type i (i ∈ {1, 2}) vaccine shot in region r.
ϑir : The initial number of the individuals who have received the second-dose
type i (i ∈ {1, 2}) vaccine shot in region r.
σir : The initial number of the individuals who have received the first-dose
type i (i ∈ {3}) vaccine shot in region r.
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Decision variables:
xir :Whether to build type i vaccination center in region r (x
i
r ∈ {0, 1}).
yr,l :Whether vaccination center in region r serves people
in region l (yr,l ∈ {0, 1}).
oi,1j,r :Number of type i (i ∈ {1, 2}) first-dose vaccines allocated to region r
at end of period j for a newly established center.
oi,2j,r :Number of type i (i ∈ {1, 2}) second-dose vaccines allocated to
region r at end of period j for a newly established center.
oij,r :Number of type i (i ∈ {3}) vaccines allocated to
region r at end of period j for a newly established center.
zi,1j,r :Number of type i (i ∈ {1, 2}) first-dose vaccines allocated to region r
at end of period j for existing pharmacies and small vaccination sites.
zi,2j,r :Number of type i (i ∈ {1, 2}) second-dose vaccines allocated to region r
at end of period j for existing pharmacies and small vaccination sites.
zij,r :Number of type i (i ∈ {3}) vaccines allocated to region r at end of
period j for existing pharmacies and small vaccination sites.
5.4.3 Optimization Model Formulation







s.t. yr,l ≤ xir r ∈ R, i ∈ {1, 2}, (5.1b)∑
r∈R
yr,l = 1 ∀l ∈ R, (5.1c)
xik + yr,l ≤ 1 ∀k, r, l ∈ R, i ∈ {1, 2}
(s.t. dk,l ≤ dr,l), (5.1d)
3∑
i=1
xir ≤ nr ∀r ∈ R, (5.1e)
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Sω0,r = πr, I
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r ≤ ∆ (5.1v)
xir, yr,l ∈ {0, 1} i ∈ I, j ∈ J, r ∈ R, (5.1w)













i ∈ I,∈ J, r ∈ R. (5.1x)
Objective Function (5.1a). The objective function (5.1a) minimizes the total
number of infections over all the regions throughout the planning horizon.
Vaccination Center Location and Service Constraints (5.1b) - (5.1e).
Constraint (5.1b) ensures that region r cannot serve region l if there is no vaccination
center build in region r. Constraint (5.1c) represents that only one region with a
vaccination center can serve region l. Constraint (5.1d) ensures that the nearest
region with a vaccination center serves region l. Constraint (5.1e) limits the total
number of different types of vaccine centers allocated to region r.
Population Infection Dynamics Constraints (5.1f) - (5.1j). Constraint (5.1f)
gives the initial number of susceptible individuals and infections generated from the
simulation model and the initial number of individuals who have received the first-dose
of type i vaccine, as well as the initial number of individuals who have received the
second-dose of type i (i ∈ {1, 2}) vaccine. Constraint (5.1g) shows that the number
of susceptible individuals in region r at stage j + 1 equals the number of susceptible
individuals from the previous stage minus the number of infected individuals in region
r at stage j and minus the number of susceptible individuals who have received the
first-dose of type i (i ∈ {1, 2}) vaccine in region r at stage j, and minus the number
176
of susceptible individuals who have received a single dose of type i (i ∈ {3}) vaccine
in region r at stage j.
Constraint (5.1h) represents that the number of infected individuals in region r
at stage j + 1 equals the number of infected individuals from the previous stage plus
newly infected individuals, minus the number of individuals saved by the vaccines.
Constraint (5.1i) indicates that the number of people who have received the first-dose
of type i (i ∈ {1, 2, }) vaccine and a single dose of type i (i ∈ {3}) vaccine in region
r at stage j + 1 equals the number of people who have received the first-dose of type
i (i ∈ {1, 2}) vaccine and a single dose of type i (i ∈ {3}) vaccine from the previous
stage plus the newly vaccinated people (first dose and single dose) minus the number
people who have taken the second dose of type i (i ∈ {1, 2, }) vaccine. Constraint
(5.1j) indicates that the number of people who have received the second-dose of type
i (i ∈ {1, 2}) vaccine in region r at stage j + 1 equals the number of people who have
received the second-dose of type i (i ∈ {1, 2}) vaccine from previous stage plus the
newly vaccinated people (second dose).
Vaccines Logistics and Capacity Constraints (5.1k) - (5.1v). Constraints (5.1k)
and (5.1l) ensure that the total number of each type of vaccine allocated to the new
vaccine centers in region r at stage j should be smaller or equal to the vaccine capacity
upper bound of the vaccination center in region r. Constraints (5.1m) and (5.1n)
ensure that the total number of each type of vaccine allocated to local pharmacies
and small vaccine sites in region r at stage j should be smaller than or equal to the
vaccine capacity upper bound (obtained from Heffernan [2021b]). Constraints (5.1o)
and (5.1p) ensure that the total number of each type of vaccine supplied to the new
vaccine centers and local pharmacies (and small vaccination sites) over all regions at
each stage j should be smaller than or equal to the vaccine supply upper bound at
stage j. Constraints (5.1q) and (5.1r) indicate that the total number of each type
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of vaccine supplied to the new vaccine centers and the existed vaccine locations over
all regions at each stage j should be greater than or equal to the vaccination lower
bound at stage j. The vaccination lower bound at each stage j is represented by an
exponential function reaching an asymptote over time. Constraint (5.1s) indicates
that the total number of people who have received the first shot of type i (i ∈ {1, 2})
vaccine should be smaller than or equal to the people who are willing to be vaccinated.
Constraint (5.1t) implies that the total number of people vaccinated by the second
shot of type i (i ∈ {1, 2}) vaccine should be greater than or equal to the lower
bound of the people who are willing to be vaccinated but smaller than or equal to
the people who have received the first shot n (n ∈ N) days before the second shot.
Constraint (5.1u) represents that the total number of people vaccinated by type i
(i ∈ {3}) vaccine should be smaller than or equal to the people who are willing to be
vaccinated.
Constraint (5.1v) represents the budget limitations. Specifically, constraint
(5.1v) ensures that the total vaccination center building cost, plus the cost of vaccines
that are distributed to the newly established vaccine centers and existing pharmacies
and small vaccination sites, plus the logistics distribution cost from the vaccine supply
warehouses to vaccine centers, over all regions throughout the whole planning horizon,
should be smaller than or equal to a certain budget level.
Integrality and Non-Negativity Constraints (5.1w) - (5.1x). Constraints (5.1w)
and (5.1x) are the variable’s restrictions. Specifically, constraint (5.1w) indicates
that xir and yr,l are binary variables. Constraint (5.1x) implies that the number of
susceptible individuals, the vaccine upper bounds, the number of existed infected and
newly infected individuals, the number of each type of vaccine should be greater than
or equals to 0.
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5.4.4 Linearization
Constraint (5.1l) is non-linear. We define two variables U ij,r,l and o
i,UB







j,r is the upper bound of parameter o
i
j,r. Thus, constraint (5.1l) can be
linearized by the following equations:
U ij,r,l ≤ o
i,UB
j,r yr,l j ∈ J, r, l ∈ R, i ∈ {3}, (5.2)
U ij,r,l ≤ oij,r j ∈ J, r, l ∈ R, i ∈ {3}, (5.3)
U ij,r,l ≥ oij,r − o
i,UB
j,r (1− yr,l) j ∈ J, r, l ∈ R, i ∈ {3}, (5.4)
0 ≤ U ij,r,l ≤ o
i,UB
j,r j ∈ J, r, l ∈ R, i ∈ {3}. (5.5)
Constraint (5.1k) can be linearized by using a similar method.
5.4.5 Simulation-Optimization Model
Figure 5.4 The loop of simulation-optimization model.
In this chapter, we introduce a simulation-optimization approach to address the
vaccination facility location and vaccine allocation challenges of the COVID-19. We
extend the Covasim agent-based model of the COVID-19 and incorporate it with
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a new vaccination center and vaccine-allocation optimization model. As shown in
Figure 5.4, the integrated model runs in a loop, where the simulation model forecasts
the disease transmission and import the results into the optimization model. The
optimization model minimizes the total number of infections throughout the planning
horizon by choosing the optimal vaccination center locations and vaccine allocation
among each region and sends the results back to the simulation model to estimate the
number of infections in the future. Specifically, the simulation model uses the number
of initial susceptible and infected individuals to forecast the number of susceptible
and infected individuals, presymptomatic and asymptomatic individuals, as well as
the mild, severe, critical, recovered, and dead individuals for each stage in the current
planning horizon. The forecast numbers of susceptible and infected individuals
are imported into the optimization model. The optimization model incorporates
the available budget, potential vaccine sites in each region, vaccine capacity for
each site, and total available vaccine supply for each vaccine type to generate the
optimal vaccination center location and vaccine allocation while minimizing the total
number of infections in the considered regions. The optimization results include
the number of people that are supposed to be vaccinated in vaccination centers and
local pharmacies (and small vaccination sites) at each future stage in each region.
Then these parameters are fed into the simulation model to simulate the number of
susceptible and infected individuals for the next periods.
We implement our model to the New Jersey state in the United States; each
stage in the model represents a one-day period. We run the simulation optimization
in three steps. In the first step, the number of initial susceptible individuals and
infections from JHU [2020] is imported into the optimization model to generate the
vaccination center locations and vaccine allocations for the first 30-days period. Then
the results are input in the simulation model to simulate the number of susceptible
individuals and infections for the first 30-days period. In the second step, the
180
simulation results of the first 30-days are input into the optimization model, and the
optimization model generates the optimal vaccination center locations and vaccine
allocation decisions for the second 30-days period. The optimization model results
for the second 30-days are combined with the first 30-days together and then imported
into the simulation model to estimate the total number of susceptible individuals and
infections for the first 60-days. In the last step, we repeat the second step and combine
the 90-days vaccine allocation results. Thus, we solve the model for a total 90-days
time period. For step 2 and step 3, the vaccination center allocation variable xir is
fixed to be the same as the solution of step 1. This indicates that the model generates
the vaccine allocation decisions under the same xir values in each loop.
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5.5 Case Study Data
Source: [Aparadinar, 2021]
Figure 5.5 All the counties in New Jersey.
This section presents the data used to formulate and test the model. The data includes
the population for each county in New Jersey State, the number of infections over
time for each county in New Jersey State, the logistics cost, and the cost of vaccines.
In our model, each stage represents a one-day period. In total, we consider a 90-day
planning horizon, which is equal to three months.
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5.5.1 Population and Infection Data
Table 5.1 shows the population and the cumulative number of infections data for each
county in New Jersey state, which is obtained from JHU [2020]. For the number of
infections, we only present three specific days of the total 90 day period, which are
March 1, April 12, and May 24, 2021. The numbers of cumulative infections are
rounded in thousands.
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Table 5.1 Populations and the Number of Infections (in Thousands) for Each
County in New Jersey
County Population March 1, 2021 April 12, 2021 May 24, 2021
Atlantic 274.5 24.9 29.7 31.5
Bergen 905.1 78 96.4 104.1
Burlington 448.7 35.5 41.9 44.1
Camden 513.5 44.3 51.1 55.4
Cape May 97.3 7.3 8.6 9.1
Cumberland 156.6 14.3 15.8 17
Essex 783.9 74 90.1 93.8
Gloucester 288.8 24.2 28.2 30.4
Hudson 634.3 69.6 83.7 87.8
Hunterdon 127.4 7 9 9.8
Mercer 367.5 27.9 32.1 33.8
Middlesex 810.0 72.8 87.8 91.9
Monmouth 630.4 57.2 71.5 75.3
Morris 492.3 37.7 47.4 50
Ocean 576.5 58.9 71.9 75.6
Passaic 501.6 57 67.5 72.7
Salem 66.1 4.7 5.5 6.1
Somerset 323.5 22.9 28.1 30
Sussex 148.9 9.2 12.7 13.9
Union 536.5 57 67.4 71.2
Warren 108.6 7.1 9 9.9
5.5.2 Logistics and Operations Cost Data
Table 5.2 presents the vaccine cost and efficiency data for Pfizer, Moderna, and
Janssen. Table 5.3 shows the logistic and operations cost data. The fixed cost of
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the vaccination center includes planning and coordination cost, training cost, social
mobilization cost, cold chain equipment cost, pharmacovigilance cost, as well as hand
hygiene cost. The recurring cost contains cold chain recurrent cost, vaccination
certificates cost, personal protective equipment (PPE) cost, Hand hygiene cost, and
waste management cost.
Table 5.2 COVID-19 Vaccine Cost ($) and Efficiency [Seladi-Schulman, 2021]
Vaccine Category Cost First Dose Second Dose
per dose Efficiency Efficiency
Pfizer 19.5 80% 95%
Moderna 15 80% 94.1%
Janssen 10 74.4% -
Table 5.3 Logistics Cost ($) for the COVID-19 Vaccines [WHO, 2021c]
Cost Category Fixed Recurring Total
Planning and coordination 30,513 - 30,513
Training 7,629 - 7,629
Social mobilization 137,308 - 137,308
Cold chain equipment 61,026 - 61,026
Cold chain recurrent - 1,447 1,447
Pharmacovigilance 15,257 - 15,257
Vaccination certificates - 4,495 4,495
PPE - 9,745 9,745
Hand hygiene 2,247 13,955 16,202
Waste management - 5,944 5,944
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5.6 Model Validation
In this section, we present the validation results of the simulation-optimization model
shown in Section 5.3. The government set up one Pfizer vaccination center in March
at the New Jersey Institute of Technology in Essex County. The vaccination center
can vaccinate up to 6,000 people each day. Thus, we use this actual vaccination
center location in our model for validation. The number of Pfizer vaccine centers in
our model is set to 1, and the location is in Essex County, while other types of vaccine
centers are set to be 0 in the validation experiments. The optimization model decides
on how many vaccines of each type are allocated to each region and uses these values
as inputs in the simulation model. We present the number of estimated infections
throughout the 90-days planning horizon and compare it with the real outbreak data.
The results of nine counties are shown in Figure 5.6 (the validation results of all the
counties in New Jersey are shown in Figures C.1, C.2, and C.3 in Appendix C).
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Figure 5.6 Model validation against real outbreak data in New Jersey.
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Table 5.4 Statistical Analysis to Compare the Weekly Predicted New Cases and
Real Outbreak Data
County Mean Two-tailed paired-t-test
Outbreak Predicted t-stat t-critical p-value
Atlantic 508 479 0.21 2.20 0.73
Bergen 2008 2030 0.04 0.94
Burlington 662 609 0.28 0.61
Camden 854 860 0.03 0.96
Cape May 138 167 0.60 0.27
Cumberland 208 183 0.46 0.59
Essex 1523 1593 0.14 0.84
Gloucester 477 402 0.69 0.25
Hudson 1400 1391 0.02 0.97
Hunterdon 215 193 0.40 0.56
Mercer 454 449 0.03 0.95
Middlesex 1469 1477 0.02 0.98
Monmouth 1392 1405 0.03 0.96
Morris 946 984 0.14 0.74
Ocean 1285 1318 0.08 0.86
Passaic 1208 1300 0.33 0.62
Salem 108 117 0.40 0.54
Somerset 546 507 0.26 0.64
Sussex 362 484 1.24 0.27
Union 1092 1093 0.00 0.99
Warren 215 188 0.52 0.35
188
According to the results, since the model starts from zero infections, but the
real data is in the middle of the pandemic, the model predicts a greater number of
infections at the beginning of the time period than the predicted number becomes
less than the real data in the later periods. Overall, the estimation fits the real data
well. In addition, we perform a paired-t-test to analyze the difference between the
pairs of predicted new infections and the actual data in each period. As shown in
Table 5.4, all p-values are greater than 0.05, and thus our model provides statistically
similar predictions with the real outbreak data from March 1 to May 30, 2021, for
each considered county.
5.7 Case Study Results
We apply our model described in Section 5.3 to all the counties in New Jersey. We
solve the optimization model to generate the results of the optimal vaccination center
locations and vaccines’ allocation, including Pfizer, Moderna, and Janssen. Then we
use the results generated by the optimization model as the inputs of the simulation
model. We incorporate vaccination in the Covasim model. The vaccination includes
the first and second shots for Pfizer and Moderna vaccines and a single shot for the
Janssen vaccine. We solve the model for a 90-days period, a planning horizon from
March 1, 2021, to May 30, 2021. The optimization model is solved using CPLEX
20.1 on a desktop computer running with Intel i7 CPU and 64.0 GB of memory.
The simulation model is run on the same desktop computer in PyCharm Edu (using
python language).
5.7.1 The Number of Cumulative Infections under Different Budget
Levels
We fix only one Pfizer vaccination center in Essex county, similar to the validation
experiments and test our model under different budget levels (from limited to ample).
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We use $5M as a limited budget level, $10M as a medium budget level, and we do not
put a budget restriction under the ample budget scenario. However, under the ample
budget scenario, the number of people being vaccinated is bounded by the number of
people willing to be vaccinated in each region.
Figure 5.7 shows the number of cumulative infections under different budget
levels for nine counties in New Jersey (the number of cumulative infections under
different budget levels for all the counties in New Jersey are shown in Figures C.4,
C.5, and C.6 in Appendix C). According to the results, the number of cumulative
infections stays the same under different budget levels at the initial stages. This is
because it takes time for people to be exposed and develop symptoms after their being
infected. Thus, the difference in the number of cumulative infections becomes more
significant after a certain time period. For almost all the counties shown in Figure 5.7,
the ample budget level generates the least number of cumulative infections due to the
high number of vaccines allocated, followed by the medium budget level. However, for
some of the counties, the cumulative number of infected individuals under different
budget levels are similar, especially for the medium and ample budget levels. Not
surprisingly, we find that these counties either have high populations or high initial
infections. Thus, the model gives priority to allocate more vaccines to these counties
when the budget is not ample. Therefore, the total number of vaccines that these
counties receive under the medium budget level is similar to the number under the
ample budget level, leading to a similar number of cumulative infections.
We find that some counties do not have the lower number of infections under the
ample budget level (e.g., CapeMay and Salem County). This is because we randomly
vaccinate susceptible and recovered individuals in the agent-based simulation model.
Although more people are vaccinated under the medium and ample budget levels,
more recovered people could be vaccinated than susceptible people. Thus, the
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number of cumulative infections may be higher under medium and ample budget
levels compared with the limited budget level.
Figure 5.7 New Jersey cumulative infections under different budget levels.
5.7.2 The Number of Vaccines Allocated to Each County under Different
Budget Levels
The number of vaccines allocated to each county under different budget levels is
presented in Tables 5.5, 5.6, and 5.7, respectively. Each table presents the population
proportion of each county, the total vaccines allocated to each county, the proportion
of the vaccines allocated to each county, and the number of first and second doses
of each type of vaccine allocated to each county. Figure 5.8 shows the proportion of
each type of vaccine allocated under different budget levels.
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Table 5.5 Vaccine Allocation under Limited Budget Level
County Population Vaccine Total Pfizer Pfizer Moderna Moderna Janssen
Proportion Vaccine First Second First Second
Dose Dose Dose Dose
Atlantic 3.1% 3.6% 38,789 4,500 1,083 6,493 2,676 24,037
Bergen 10.3% 9.5% 103,971 4,500 1,082 12,072 7,138 79,179
Burlington 5.1% 5.1% 56,034 4,502 1,080 6,862 2,970 40,620
Camden 5.8% 5.9% 63,752 4,500 1,080 8,640 4,392 45,140
Cape May 1.1% 1.8% 20,085 4,500 1,080 4,500 1,080 8,925
Cumberland 1.8% 2.4% 25,848 4,500 1,080 4,500 1,080 14,688
Essex 8.9% 7.9% 86,335 4,500 1,080 4,500 1,080 75,175
Gloucester 3.3% 3.6% 38,654 4,500 1,080 4,500 1,080 27,494
Hudson 7.2% 6.6% 71,729 4,500 1,080 4,500 1,080 60,569
Hunterdon 1.4% 2.1% 23,024 4,500 1,080 4,515 1,093 11,836
Mercer 4.2% 4.3% 46,304 4,500 1,080 4,500 1,080 35,144
Middlesex 9.2% 8.2% 88,937 4,500 1,080 4,500 1,080 77,777
Monmouth 7.2% 6.6% 71,448 4,500 1,080 4,500 1,080 60,288
Morris 5.6% 5.3% 58,236 4,500 1,080 4,500 1,080 47,076
Ocean 6.6% 6.1% 66,165 4,500 1,080 4,500 1,080 55,005
Passaic 5.7% 5.4% 59,113 4,500 1,080 4,500 1,080 47,953
Salem 0.8% 1.6% 17,099 4,500 1,080 4,500 1,080 5,939
Somerset 3.7% 4.0% 43,294 4,500 1,080 6,118 2,378 29,218
Sussex 1.7% 2.3% 25,086 4,500 1,080 4,500 1,080 13,926
Union 6.1% 5.8% 63,450 4,500 1,080 5,782 2,106 49,982
Warren 1.2% 2.0% 21,463 4,500 1,080 4,842 1,354 9,687
Total 100.0% 100.0% 1,088,816 94,502 22,685 113,824 38,147 819,658
According to the results, the total number of vaccines allocated increases when
the budget level increases. Under a limited budget level, the majority of the vaccines
are allocated in Janssen, followed by Moderna, while Pfizer has the least number
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of vaccines allocated (Figure 5.8). On the contrary, Pfizer has the highest vaccine
efficiency. This is because the insufficient budget limits the total number of vaccines
purchased. Although Pfizer has the highest efficiency, the cost of each dose of the
Pfizer vaccine is much higher than the others. On the contrary, the Janssen vaccine
has the lowest price, followed by Moderna. Therefore, under the limited budget
level (Table 5.5), the model considers purchasing more doses of vaccines rather than
purchasing the vaccines with the highest efficiency. Thus under a limited budget,
the model chooses to vaccine more people with mainly cheaper vaccines and the
vaccines with a single dose. Compared with the population proportion and vaccine
proportion, the counties with a bigger population are more likely to receive more
vaccines. However, some counties may receive more (or less) vaccines compared with
their population proportion due to their high (or low) number of initial infections.
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Table 5.6 Vaccine Allocation under Medium Budget Level
County Population Vaccine Total Pfizer Pfizer Moderna Moderna Janssen
Proportion Vaccine First Second First Second
Dose Dose Dose Dose
Atlantic 3.1% 3.2% 61,169 4,500 1,080 26,005 13,683 15,901
Bergen 10.3% 9.9% 188,279 4,500 1,080 84,927 47,770 50,002
Burlington 5.1% 5.2% 98,378 4,500 1,080 41,796 22,671 28,331
Camden 5.8% 5.9% 112,200 4,501 1,081 49,253 27,279 30,086
Cape May 1.1% 1.3% 24,961 4,504 1,084 8,905 3,680 6,788
Cumberland 1.8% 1.9% 36,933 4,501 1,080 14,368 6,814 10,170
Essex 8.9% 8.6% 163,455 4,500 1,080 72,965 40,689 44,221
Gloucester 3.3% 3.4% 65,606 4,504 1,084 27,469 14,543 18,006
Hudson 7.2% 7.0% 134,295 4,500 1,080 60,535 33,883 34,297
Hunterdon 1.4% 1.6% 31,162 4,500 1,080 11,837 5,398 8,347
Mercer 4.2% 4.3% 82,226 4,500 1,080 35,112 19,013 22,521
Middlesex 9.2% 9.0% 170,680 4,504 1,084 77,708 43,924 43,460
Monmouth 7.2% 7.0% 133,654 4,500 1,080 60,232 33,703 34,139
Morris 5.6% 5.5% 105,676 4,500 1,080 46,992 25,992 27,112
Ocean 6.6% 6.4% 122,502 4,500 1,080 54,960 30,630 31,332
Passaic 5.7% 5.6% 107,558 4,500 1,080 47,909 26,496 27,573
Salem 0.8% 1.0% 18,657 4,500 1,080 5,932 1,946 5,199
Somerset 3.7% 3.7% 71,320 4,500 1,080 30,800 16,489 18,451
Sussex 1.7% 1.9% 35,542 4,504 1,084 13,902 6,600 9,452
Union 6.1% 6.0% 114,559 4,500 1,080 51,216 28,433 29,330
Warren 1.2% 1.4% 27,316 4,500 1,080 10,020 4,334 7,382
Total 100.0% 100.0% 1,906,128 94,518 22,697 832,843 453,970 502,100
Under the medium budget level (Table 5.6), the total number of Janssen vaccines
allocated is decreased, while more Moderna vaccines are allocated (which is also shown
in Figure 5.8). This is because the model starts to consider the vaccine efficiency when
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the budget increases, and the expected number of people saved by the vaccines with
higher efficiency is more than the number of people saved by the vaccines with lower
efficiency. Nevertheless, since Pfizer is still much more expensive than Moderna and
Janssen, the model allocates more Moderna vaccines instead of Pfizer. Compared with
the population proportion with the vaccine allocation proportion, the counties with
a higher population receive even more vaccines. This is because the total number of
vaccines allocated is still not enough to satisfy the people’s vaccination need, and the
model gives priority to distribute more vaccines to the regions with high population
and initial infections.
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Table 5.7 Vaccine Allocation under Ample Budget Level
County Population Vaccine Total Pfizer Pfizer Moderna Moderna Janssen
Proportion Vaccine First Second First Second
Dose Dose Dose Dose
Atlantic 3.1% 3.1% 88,854 34,143 17,744 29,833 2,634 4,500
Bergen 10.3% 10.3% 294,610 161,094 66,391 58,775 3,850 4,500
Burlington 5.1% 5.1% 145,735 70,577 31,296 36,846 2,514 4,502
Camden 5.8% 5.9% 167,620 104,750 38,124 18,890 1,352 4,504
Cape May 1.1% 1.1% 30,842 13,383 4,596 6,619 1,744 4,500
Cumberland 1.8% 1.8% 50,308 21,690 9,031 13,131 1,956 4,500
Essex 8.9% 8.9% 254,718 136,864 55,362 53,241 4,751 4,500
Gloucester 3.3% 3.3% 93,755 56,344 20,229 11,328 1,352 4,502
Hudson 7.2% 7.2% 205,278 101,315 45,020 51,386 3,057 4,500
Hunterdon 1.4% 1.4% 40,817 18,793 6,749 8,766 2,009 4,500
Mercer 4.2% 4.2% 119,530 56,846 24,608 30,394 3,178 4,504
Middlesex 9.2% 9.3% 264,130 136,834 61,506 59,940 1,350 4,500
Monmouth 7.2% 7.2% 204,867 104,985 42,127 46,883 6,372 4,500
Morris 5.6% 5.6% 160,023 70,210 33,748 47,679 3,886 4,500
Ocean 6.6% 6.5% 186,872 95,527 38,248 42,705 5,892 4,500
Passaic 5.7% 5.7% 162,595 76,867 35,180 43,377 2,671 4,500
Salem 0.8% 0.7% 20,749 6,852 2,420 5,502 1,475 4,500
Somerset 3.7% 3.7% 105,050 47,109 20,604 29,120 3,717 4,500
Sussex 1.7% 1.7% 47,786 19,483 8,233 13,374 2,196 4,500
Union 6.1% 6.1% 174,383 86,554 36,975 42,214 4,140 4,500
Warren 1.2% 1.2% 34,624 13,765 5,579 9,104 1,676 4,500
Total 100.0% 100.0% 2,853,146 1,433,985 603,770 659,107 61,772 94,512
As shown in Table 5.7 and Figure 5.8, the total number of Pfizer vaccines
allocated under the ample budget level increases significantly. Compared with
Moderna and Janssen vaccines, the model gives priority to allocate as many Pfizer
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vaccines as possible. When there is no budget limitation on the vaccine allocation,
vaccine efficiency is the only consideration for the vaccine administration. Thus,
Pfizer vaccines have the priority to be allocated compared with Moderna and Janssen.
Moreover, under the ample budget level, the vaccine allocation proportion is almost
the same as the population proportion. This is because we assume the same vaccine
acceptance rate in each county of New Jersey. Under the ample budget level, the
number of people who receive vaccines reaches the upper bound on the vaccine supply
available. This implies that all the people who are willing to be vaccinated receive the
vaccine shots when the budget is ample and as long as there is sufficient vaccine supply.
Thus, the vaccine allocation proportion is the same as the population proportion for
each county in New Jersey.
Figure 5.8 Proportion of each type of vaccine under different budget levels.
For all the budget levels, the number of the second dose of Pfizer and Moderna
vaccines is much smaller than that of the first dose. This is because when the total
number of vaccine supply is bounded even if the purchasing budget is ample, the
model gives priority to administer as many as the first shots of those vaccines since the
effectiveness of the first shot is high and more people can benefit from the vaccination.
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5.7.3 Vaccination Center Location Decision under Medium Budget Levels
and Number Restrictions
In this subsection, we present the vaccination center location decisions generated
by the model. Specifically, we change the number of vaccine centers that can be
allocated for each type of vaccine and then generate the vaccination center locations
and service decisions for those vaccine centers under medium budget level.
Vaccination Center Locations for Pfizer We fix the Pfizer vaccination center
to one while keeping Moderna and Janssen centers to zero, as shown on the left side
of Figure 5.9. The model allocates the Pfizer center to Essex county, which is the
same decision the government has taken in the real situation.
Figure 5.9 Vaccination center locations for Pfizer.
We then increase the number of Pfizer vaccine centers to two, and the
vaccination center decision is changed. The right side of Figure 5.9 shows that one
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of the vaccination centers is allocated in Essex County, and the other is allocated in
Union County. The vaccination center in Essex County serves Bergen County, Hudson
County, Passaic County, Sussex County, Warren County, and Hunterdon County. The
Union County vaccination center serves the rest of the counties in New Jersey.
Figure 5.10 Vaccination center locations for all types of vaccines.
Vaccination Center Locations for Multiple Types of Vaccines Vaccination
center locations for multiple types of vaccines are studied. Figure 5.10 presents
the vaccination center locations when the numbers of Moderna centers and Janssen
centers are set to one, while the number of Pfizer centers remains to be two. On
the left side of Figure 5.10, we allow each county to have different types of vaccine
centers. On the right side of Figure 5.10, each region can only have one type of vaccine
center. For the first case, Essex County has the Pfizer and Moderna centers allocated,
while Union County has another Pfizer center allocated. This is because the vaccine
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warehouses for Pfizer and Moderna are located in Essex County. Somerset County has
the Janssen vaccination center allocated. When only considering the transportation
cost from the warehouse to the vaccination centers, the distance from the warehouse
to the vaccination centers is the only factor that can influence the vaccination center
locations. Therefore, the model chooses the closest county to the supply warehouse
for each type of vaccine as the corresponding vaccination center. For the second case,
the Moderna vaccination center is moved to Hudson County since each county can
only have one vaccination center and Hudson County is the third closest county to the
warehouse after Essex County and Union County. We do not show the vaccine centers
service decision in Figure 5.10 because the service decision for the Pfizer center is the
same as Figure 5.9. We find that Union County is geographically the closest county
to Essex County, where the Pfizer and Moderna vaccine warehouses are allocated.
Thus, the vaccination center locations for the counties in New Jersey are ordered by
their distance from the warehouse from low to high.
5.7.4 Vaccine Allocation between Vaccination Centers and Local Pharmacies
(and Small Vaccination Sites)
In this subsection, we compare the vaccine allocation between vaccination centers and
local pharmacies (and small vaccination sites) under different budget levels ($5M as
the limited, $10M as the medium, and no budget limitation as to be ample).
Table 5.8 presents the results of vaccine allocation between the vaccination
centers and local pharmacies (and small vaccination sites) when only one Pfizer center
is located. Under the limited budget level, the model allocates all the Pfizer vaccines
to the vaccination centers. This is because vaccines allocated to the vaccination center
cost lower than those allocated to local pharmacies and small vaccination sites. Under
the limited budget level, the model chooses to distribute vaccines to the vaccination
centers because more people benefit from the vaccination. Under the medium budget
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level, the number of vaccines allocated to the vaccination center decreases. However,
the total number of vaccines allocated to the vaccination center is much more than
the local pharmacies and small vaccination sites. Under an ample budget level, the
model allocates the majority of the vaccines to local pharmacies and small vaccination
sites since there is no budget limitation on purchasing vaccines and the vaccination
capacity provided over pharmacies and small vaccination sites in total is larger than
that of the vaccination centers.
Table 5.8 Vaccine Allocation between Vaccination Centers and Local Pharmacies
(and small vaccination sites) with Only One Pfizer Center
Budget Limit Medium Ample
Pfizer
Center 117,180 100.0% 141,959 73.2% 310,134 15.2%
Pharmacy 0 0.0% 51,916 26.8% 1,727,621 84.8%
Total 117,180 100.0% 193,875 100.0% 2,037,755 100.0%
Table 5.9 shows the vaccine allocation results between vaccination centers and
local pharmacies (and small vaccination sites) with different types of vaccination
centers. In this case, the number of Pfizer vaccination centers is fixed to two, and
the number of Moderna and Janssen vaccination centers is set to one each. Similar
to Table 5.8, the number of vaccines allocated to the vaccination centers shows a
decreasing trend for each type of vaccine when the budget is increased from limited
to ample. For the Janssen vaccine, the proportion of the vaccines allocated to the
vaccination center increases under the medium budget level compared with the limited
budget level. One possible reason might be that the total number of Janssen vaccines
allocated decreases significantly under the medium budget level, as we discussed in
Section 5.7.2.
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Table 5.9 Vaccine Allocation between Vaccination Centers and Local Pharmacies
(and small vaccination sites) with Different Types of Vaccination Centers When
Vaccine Center Types and Locations are Fixed a Priori in the Model
Budget Limit Medium Ample
Pfizer
Center 117,180 100.0% 117,173 100.0% 5,310 0.3%
Pharmacy 0 0.0% 19 0.0% 1,657,658 99.7%
Total 117,180 100.0% 117,192 100.0% 1,662,968 100.0%
Moderna
Center 117,180 100.0% 150,834 13.7% 0 0.0%
Pharmacy 0 0.0% 949,523 86.3% 1,098,128 100.0%
Total 117,180 100.0% 1,100,357 100.0% 1,098,128 100.0%
Janssen
Center 120,156 17.9% 122,988 21.4% 0 0.0%
Pharmacy 550,425 82.1% 452,209 78.6% 94,500 100.0%
Total 670,581 100.0% 575,197 100.0% 94,500 100.0%
5.8 Discussion and Future Direction
In this study, we formulate a simulation-optimization model to generate the
vaccination center locations for different types of vaccines and the optimal vaccine
allocation strategies among different regions. We extend the simulation model
presented by Kerr et al. [2021] by adding two vaccination compartments. The
simulation model is able to incorporate the vaccination for the three types of vaccines,
which are the first and second shots for Pfizer and Moderna, and the first shot for
Janssen. The simulation model simulates the number of susceptible individuals and
infections for a certain time period and imports the results into the optimization
model. The optimization model incorporates the available budgets and potential
vaccination center locations as well as the total number of vaccines available to
generate the optimal vaccination center location and vaccine allocation strategies
for each county in the future planning horizon. Then the generated results are used
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as the inputs of the simulation model to estimate the number of infections and various
disease compartmental values with the vaccination strategies for the same period. We
apply our model to the case of vaccine allocation among all the counties in New Jersey
State.
First, we validate our model with the real outbreak data by fixing one Pfizer
vaccination center at Essex County and keep the number of other types of vaccine
centers to zero as in the real-life case. The predicted results fit the real outbreak
data well, and the paired-t-test shows that our predicted results have no significant
difference from the real outbreak data.
We test our model on the cumulative number of infections under different budget
levels. The results indicate that there is at least a month to see the difference in the
number of infections under different budget levels since it takes time for the disease
transmission and infects people. In addition, the county with a high population and
initial infections receives more vaccines allocated.
The number of vaccines allocated to each county under different budget levels
shows that the total number of vaccines allocated increases with the increase in the
available budget. Under a limited budget level, more vaccines with a lower unit cost
should be allocated because the limited budget reduces the number of people being
vaccinated compared with other budget levels. Using a low-cost vaccine, more people
are vaccinated, and the number of infections is minimized. In addition, the counties
with higher population proportions are more likely to have higher vaccine allocation
proportions since the model gives priority to vaccinate people in these regions. Under
the medium budget level, more vaccines with higher costs and higher efficiency are
allocated. The model has the flexibility to allocate those highly efficient vaccines
due to the increased budget, but there is still a limitation on the number of vaccines
distributed since the budget is still not ample enough. The counties with a higher
population will receive even more vaccines due to the high number of infections. Under
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the ample budget level, there is no limitation on the vaccine cost. Two main factors
that can influence vaccine allocation are the vaccine acceptance rate by people and
the available vaccine supply. In this case, the model allocates as many high-efficiency
vaccines as possible to minimize the total number of infections. The population
proportion of each county is almost the same as the vaccine allocation proportion
because the vaccine acceptance rate in our model is the same for each county. The
total number of people being vaccinated under an ample budget level is bounded by
the people who are willing to be vaccinated since the vaccine supply is also relatively
abundant. For all the budget levels, the model allocates more first doses than second
doses for Pfizer and Moderna vaccines. This is because more people benefit from
taking the first shot of the vaccines.
The results of vaccination center locations show that the model gives priority
to allocate vaccine centers to the region that has the closest distance to the vaccine
supply warehouse. When more vaccine centers are included, the centers are located
by order of distance to the vaccine warehouse from the shortest to the longest. When
tightening the center’s location constraint and only allowing one type of vaccination
center allocated in each county, the model prioritizes the type of center with higher
vaccine efficiency and then centers with lower efficiency.
The results of vaccine allocation between the vaccination centers and local
pharmacies (and small vaccination sites) indicate that more vaccines are allocated to
the vaccination centers than local pharmacies under the limited budget level due to
reduced vaccine and logistics costs. When the budget level increases, the proportion
of the vaccines allocated to the local pharmacies and small vaccination sites also
increases to benefit more people from vaccination.
The future work of this model can be described in the following ways. First,
our model considers the potential vaccination center locations and the overall local
pharmacy capacity. The distribution specifics from the warehouse to the local
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pharmacies are not included. In a future study, local pharmacy supply chain can be
incorporated, and the vaccine allocation strategies can be defined with more detailed
information. In addition, our model assumes that the people in each county can only
be served by the vaccine centers located in the closest county. In the real situation,
human behavior is hard to capture, and some of the people may go to further places to
receive the vaccines due to the complex environment. Thus, various human behaviors
on how to take the vaccines could be incorporated into the model. Moreover, we want
to study the specific vaccination strategies in a real application. For instance, one
may fix the number of vaccines but compare vaccination strategies targeting random
people or age-based groups.
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CHAPTER 6
SUMMARY AND FUTURE DIRECTIONS
In summary, this dissertation presents new multi-stage stochastic models and agent-
based simulation-optimization models to simulate the transmission of the disease (e.g.,
Ebola Virus Disease (EVD), COVID-19) and determine the corresponding optimal
resource allocation decisions among different regions of the considered geographical
location. Each integrates models that can simulate the transmission of the disease
and generate the optimal resource allocation over all the regions. In the first study,
we develop a multi-stage stochastic model to simulate the transmission of EVD
and provide corresponding treatment resource allocations. The model considers the
equity of the resource allocation when different budgets are obtained. The second
study extends the previous model to a mean-risk multi-stage stochastic model. The
provided model uses Conditional-value-at-risk to alleviate the impact of the extreme
epidemic scenarios. In addition, the model incorporates the ring vaccination to
prevent people from being infected, which is applied to study the EVD control in
the Democratic Republic of the Congo (DRC). The third study presents a new
compartment model to simulate the transmission of COVID-19 under uncertainty
of untested asymptomatic infections. The proposed multi-stage-mean-risk model
addresses the optimal ventilator allocation during the COVID-19 pandemic. The
fourth study defines a simulation-optimization model to address the location of
vaccine centers and vaccine allocations for the COVID-19 pandemic. The simulation
model estimates the number of infections in the future planning horizon and import
the estimated values into the optimization model. The optimization model generates
the vaccine center location and vaccine allocation decisions and applies them back to
the simulation model to forecast the number of infections for the next period.
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This dissertation opens up many future research directions. The studies on
vaccine allocation provide an overall decision on where to allocate the vaccines to
minimize the total number of infections throughout the planning horizon. When
applying to the vaccine allocations, a more detailed strategy could be performed. For
instance, whether to apply the ring or mass vaccination is dependent on how many
vaccines are allocated to the studied region. Which group of people should be given
priority to vaccinate, and how can we define the group of vaccination candidates (e.g.,
age, sex, and race) is another critical problem in this area.
Moreover, the proposed simulation-optimization model considers the vaccine
center location and local pharmacy capacity, but the distribution of vaccine supply
from the warehouse to the local pharmacy is not included. The transportation of
vaccines to the local pharmacy could contain many problems, including the supply
chain capacity and vehicle routing problem during the supply. Thus, the proposed
model in the last study could be extended to include vaccine distribution specifics. In
addition, the health care problem is not limited to epidemic control but also involves
many treatment processes of different types of diseases. We want to continue our
research on how to optimize the treatment process of those infectious diseases. For
instance, simulating the cells migration of cancer and defining the optimal treatment
process would be one of the future research topics. Last but not least, another topic
could be finding the optimal efficient antibiotics for some diseases. Many diseases have
developed resistance to antibiotics. For example, the gonorrhea treatment process is a
hot topic in recent years. There are different antibiotics that can treat gonorrhea, but
the efficiency of those antibiotics is decreasing over time since the virus has developed
resistance to them. Thus, the treatment of gonorrhea includes the combination of
different antibiotics to alleviate the impact on the virus’s resistance. Therefore,
defining the optimal treatment process of antibiotics on gonorrhea is another example
of potential future directions.
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APPENDIX A
A MULTI-STAGE STOCHASTIC PROGRAMMING APPROACH TO
EPIDEMIC RESOURCE ALLOCATION WITH EQUITY
CONSIDERATIONS
A.1 Non-Anticipativity
Two scenarios should have the same decision variables at a stage j if they share
the same scenario path up to that stage. Corresponding decisions up to stage j
of two inseparable scenarios should be the same. These implications are named as
non-anticipativity constraints, and can be formulated as follows. Consider the node
marked n in the scenario tree, and denote the corresponding stage as t(n). Let the set
of scenarios that pass through node n be β(n). We must ensure that decision variables
at stage t(n) that are associated with node n (for example: xωt(n)) have identical values
for ω ∈ β(n). One way to do this is to add the non-anticipativity constraint as in the
following form:
xωt(n) − xn = 0 ∀ω ∈ β(n).
As an example, consider the first three stages of the multi-stage problem
shown in Figure 2.2. The set of nodes of this scenario tree is given by N =
{0, 1, 2, 3, ..., 13, 14}, where t(0) = 0, t(1) = 1, t(2) = 1, t(3) = 2, t(4) = 2, t(5) =
2, t(6) = 2, t(7) = t(8) = t(9) = t(10) = t(11) = t(12) = t(13) = 3. The set of
scenarios that share node n = 2 is given by β(2) = {5, 6, 7, 8}. Let xωt(2) represent
decision variables for ω ∈ β(2). The non-anticipativity constraint for those variables
can be written as:
xωt(2) − x2 = 0 ∀ω ∈ β(2).
A.2 Linearization
We first linearize the logical constraint that describes the number of hospitalized
individuals in equation (2.1o). Following the method of Kıbış and Büyüktahtakın





j,r − T ωj,r)zωj,r + Iωj,r(1− zωj,r), (A.1)
where zωj,r is a binary variable, which takes the value 1 if the number of infected
individuals to be hospitalized is restricted by the number of available beds in ETCs,
and the value 0 if the number of beds in ETCs is sufficiently large to hospitalize
all infected individuals. In order to ensure that I
ω
j,r takes the minimum value of
(Cωj,r − T ωj,r) and Iωj,r, we should have the following inequalities satisfied for each j ∈
J \ J , r ∈ R, and ω ∈ Ω:
I
ω
j,r ≤ Cωj,r − T ωj,r (A.2a)
I
ω
j,r ≤ Iωj,r. (A.2b)
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However, constraint (A.1) is still non-linear due to quadratic terms. Therefore, two
auxiliary variables Uωj,r and W
ω
j,r are introduced to be substituted with (C
ω
j,r−T ωj,r)zωj,r
and Iωj,r(1 − zωj,r), respectively. In this case, for each j ∈ J \ J , r ∈ R, and ω ∈ Ω,








We then introduce a lower bound (HLB) and upper bound (HUB) for C
ω
j,r−T ωj,r,
such that HLB ≤ Cωj,r − T ωj ≤ HUB and add the following constraints to the model
for each j ∈ J \ J , r ∈ R, and ω ∈ Ω:
Uωj,r ≤ HUBzωj,r (A.4a)
Uωj,r ≥ HLBzωj,r (A.4b)
Uωj,r ≤ (Cωj,r − T ωj,r)−HLB(1− zωj,r) (A.4c)
Uωj,r ≥ (Cωj,r − T ωj,r)−HUB(1− zωj,r). (A.4d)
Similarly, we introduce a lower bound (ILB) and an upper bound (IUB) for I
ω
j,r,
such that ILB ≤ Iωj,r ≤ IUB, and add the following four constraints for each j ∈ J \ J ,
r ∈ R, and ω ∈ Ω to the model:
W ωj,r ≤ IUB(1− zωj,r) (A.5a)
W ωj,r ≥ ILB(1− zωj,r) (A.5b)
W ωj,r ≤ Iωj,r − ILBzωj,r (A.5c)
W ωj,r ≥ Iωj,r − IUBzωj,r. (A.5d)
Thus the constraint (2.1o) can be equivalently linearized by replacing it with
constraints (A.3), (A.4a)-(A.4d) and (A.5a)-(A.5d).
We then linearize the equity constraint given by equation (2.2). By multiplying
the two denominators on the left side of (2.2) by each other and multiplying the right

























































































P ωIωj,r ≥ 0 (A.7b)
Therefore, the constraint (2.2) can be equivalently linearized by replacing it with
constraints (A.7a) and (A.7b).
Similarly, we have replaced the non-linear capacity equity constraint (2.3) with


















































P ωCωj,r ≥ 0 (A.8b)
The non-linear multi-stage stochastic programming epidemiclogistics model
(2.1) is converted into an equivalent MIP formulation by replacing the non-linear
capacity availability constraint (2.1o) with constraints (A.3), (A.4a)-(A.4d) and
(A.5a)-(A.5d), the non-linear infection equity constraint (2.2) with constraints (A.7a)
and (A.7b), and the non-linear capacity equity constraint (2.3) with constraints (A.8a)
and (A.8b). In the next section, we present a case study involving the control of the
20142015 Ebola outbreak in the three most-affected West African countries, Guinea,
Sierra Leone, and Liberia.
A.3 Ebola Case Study Data
This section presents the data used to formulate the model, including population
and migration data, resource cost data, and epidemiological data. All data provided
in this section was collected using literature resources and given bi-weekly. Data
pertaining to the 2014-2015 Ebola outbreak and the deterministic epidemics-logistics
model have been validated by Büyüktahtakın et al. [2018a].
A.3.1 Population and Migration Data
Table A.1 presents the distribution of the population in Guinea, Liberia, and Sierra
Leone, all located in West Africa. We consider six regions: three of them are located
in Guinea (Upper Guinea (UG), Middle Guinea (MG), and Lower Guinea (LG)), two
of them are in Liberia (Northern Liberia (NL) and Southern Liberia (SL)) and the
last one, Sierra Leone, is a county itself (S). Table A.2 shows the total number of
initial infections in each country. Table A.3 gives the migration rates from each of
the five regions (UG,MG,LG,NL,SL) to the other four regions. There is no migration
in Sierra Leone because it is considered as a region by itself. Rapidly after the initial
recognition of the Ebola outbreak, those three countries closed the national borders,
so we only consider the migration within a country.
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Table A.1 Regions, Population Size and Rate in West Africa
Guinea Population Ratio Liberia Population Ratio Sierra Leone Population Ratio
(millions) (millions) (millions)
UG 4,3 0.41 NL 2,2 0.64 S 4,9 1.00
MG 2,7 0.25 SL 1,2 0.36
LG 3,7 0.34
Total 10,7 1.00 3,4 1.00 4,9 1.00
Table A.2 The Number of Infected People at the Beginning of the Planning Horizon
(August 30, 2014) in West Africa
Guinea Sierra Leone Liberia
218 604 685
Table A.3 Bi-weekly Migration Rate between Regions of Guinea and Liberia,
Original Data Acquired from the study of Wesolowski et al. [2014]






A.3.2 Resource Allocation Cost Data
The fixed cost of locating Ebola treatment centers (ETCs) and the per-person cost
of Ebola treatment for either 50 or 100-bed ETC are given below in Table A.4. The
treatment cost includes the fixed cost for establishing each type of ETCs, isolation unit
center, and laboratory diagnosis. Additionally, each facility has a variable running
cost mainly composed of treating infected people and contact tracing of the infected
individuals. There is also a safe burial cost for safely burying infected dead bodies.
Fixed costs are one-time; however, all other costs are given for a 2-week period in
Table A.4. For example, the variable cost of the Ebola treatment center represents
the cost of treating one infected individual over two weeks.
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Table A.4 Summary of Ebola Treatment Cost for 50 (100)-bed ETC
Cost description Fixed Cost Variable cost*
Ebola treatment center $386,000 ($694,800) $8,810
Isolation unit center (IUC) $112,500 $1,133
Laboratory diagnosis $100,000 $540
Subnational technical services $2,250
Contact tracing $1,128
Safe burial
Total $598,500 ($1,077,300) $13,860
* Variable and safe burial costs are bi-weekly.
A.3.3 Epidemiological Data
Table A.5 presents the data values for transmission parameters for each of the three
considered countries in West Africa. The data contains the fatality rate with and
without treatment, recovery rate with and without treatment, safe burial rate, and
transmission rates. Because the transmission rate in the community is an uncertain
parameter, we present its value under each of the two realizations as low and high.
Moreover, we considered the expected value of the transmission rate at a traditional
funeral for each country.






















with treatment WHO E. R. Team [2014]
λ5 Safe burial rate 0.730 0.710 0.740
WHO [2020c]
WHO E. R. Team [2014]
χl1,r
Transmission rate
0.660 0.632 0.560 Camacho et al. [2014]in community (Low)
χh1,r
Transmission rate
0.990 0.940 0.840 Camacho et al. [2014]in community (High)
χ2,r
Transmission rate
1.460 1.420 1.480 Camacho et al. [2014]at traditional funeral
A.4 Analysis of Infection and Prevalence Equity Constraints
The infection equity constraint (2.2) limits the difference between the proportion
of infections in each region over the total number of infections and the proportion
of the population at each region over the total population with a specific k value.
Introducing the infection equity constraint to the mathematical model with 8 stages
increased the average CPU solution time from 7200 seconds to 10 hours when k = 0.2,
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and the average optimality gap from 1% to 29%. Table A.6 gives the run time
specifics regarding the mathematical model (2.1) with eight stages and the infection
equity constraint (2.2). As seen in Table A.6, for k values between 0.2 and 0.4,
the computational complexity significantly increases compared to the case where the
infection equity constraint is relaxed, i.e., k is set to a large number.
Figures A.1 and A.2 show the budget allocation and the total number of
infections and funerals over the three considered countries for different k values.
According to the results, varying k values does not significantly change the optimal
budget allocation and the total number of infections and funerals. Without
introducing the infection equity constraint into the mathematical model (2.1), the
absolute value of the difference between the infection ratio and the population ratio
in Guinea, Sierra Leone, and Liberia is 0.42, 0.04, and 0.38, respectively, based on
the optimal solution value similar to the k values considered here.
Table A.6 Model Run Specifics with the Infection Equity Constraint (2.2)




A large k value
7232 0
(no-equity-constraint case)
Figure A.1 Optimal budget allocation under different k values for an 8-stage
problem with $24M budget.
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Figure A.2 Total number of new infections and funerals under different k values
for an 8-stage problem with $24M budget.
As a comparison, we also test the prevalence equity constraint (2.4) and compare
it to the infection equity constraint (2.2). The prevalence equity constraint bounds
the absolute difference between the regional prevalence (cases per population in a
region) and the country prevalence (cases per population over all regions). Without
the prevalence equity constraint (2.4) constraint, the absolute value of the difference
between the infection ratio over a region and the infection ratio over all regions in
Guinea, Sierra Leone, and Liberia is 4.4×10−4, 8.2×10−5, and 1.2×10−3, respectively,
based on the optimal solution value.
We test the prevalence equity constraint under the $24M budget level. Table
A.7 presents the run-time and optimality gap specifics for each k value in inequality
(2.4) . Figures A.3 and A.4 show the optimal budget allocation and the number of
infections and funerals under different k values, respectively. Note that the k values
used in the prevalence equity constraint (2.4) are much smaller than the k values used
in the infection equity constraint (2.2). Similar to the infection equity constraint,
the optimal budget allocation does not show any significant difference among each
k value, but the number of infections and funerals slightly reduces when we relax
the prevalence equity constraint. These results imply that our model balances the
proportion of infections in each region, even without imposing the infection equity
(2.2) or (2.4) prevalence equity constraints.
Table A.7 Model Run Specifics with the Prevalence Equity Constraint
k value Solution Time (CPU sec) Optimality Gap (%)
3× 10−9 36,041 1
5× 10−9 7,204 1
1× 10−8 7,232 1
2× 10−8 7,231 1




Figure A.3 Optimal budget allocation under different k values for an 8-stage
problem with $24M budget.
Figure A.4 Total number of new infections and funerals under different k values
for an 8-stage problem with $24M budget.
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APPENDIX B
RISK-AVERSE MULTI-STAGE STOCHASTIC PROGRAMMING TO
OPTIMIZING VACCINE ALLOCATION AND TREATMENT
LOGISTICS FOR EFFECTIVE EPIDEMIC RESPONSE
B.1 Ebola Case Study Data
This section presents the data used to formulate the model parameters, including
population and migration data, resource cost data, and epidemiological data, and the
mathematical formulation for estimating the migration rate.
B.1.1 Regional and Population Data
Figure B.1 Region division in North Kivu and Ituri. The map is constructed using
ESRI [2020].
Based on the World Health Organization (WHO) Ebola situation report [WHO,
2020a], we divided North Kivu and Ituri provinces of the Democratic Republic of
Congo that are affected by the EVD into six different sub-regions: Upper (UNK),
middle (MNK), lower (LNK) North Kivu and Upper (UI), middle (MI), lower (LI)
Ituri. In the report of June 25th, 2019, there were almost no cases confirmed in
Upper Ituri and Lower North Kivu; however, in the latest report of December 17th,
2019, some cases were confirmed in these regions. We consider the migration of
people among multiple regions in our model and include these regions to analyze the
influence of immigration on transmitting the disease.
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Table B.1 presents the population as well as the population ratio of each sub-
region presented in Figure B.1, while Table B.2 shows the number of initial infections
in each region on June 25, 2019.
Table B.1 Regions, Population Size, and Rate in West Africa
North Kivu Population Ratio Ituri Population Ratio
(millions) (millions)
UNK 1,9 0.19 UI 2,3 0.42
MNK 2,3 0.23 MI 2,8 0.51
LNK 5,7 0.58 LI 0,4 0.07
Total 9,9 1.00 5,5 1.00
Table B.2 The Number of Infected People at the Beginning of the Planning Horizon
(June 25, 2019)
Upper Middle Lower
North Kivu 380 260 0
Ituri 0 23 74
B.1.2 Migration Estimation Model and Data for Migration Rates
Migration plays a crucial role in disease transmission between regions of a country and
among multiple countries. Because the data regarding the migration of the population
among each region of North Kivu and Ituri is not available, we have driven a new
formula to estimate the rate of movement among multiple regions as described below.
The logical sequence to derive the migration formulation is presented in Figure B.2
and described below.
Figure B.2 Steps of calculating the migration rate.
If no border closure is imposed, some of the infected individuals from the regions
where the disease has originated migrate to other regions during the incubation period
of the virus. When disease symptoms begin to appear, they are discovered as the
first cases in the new region. The Ebola virus average incubation period is around
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2 to 21 days [WHO, 2020c]. Thus, we estimate the migration rate using a cycle
of three weeks, and the migration rate presented below is three-weekly. Let r ∈ R
represents a newly infected region, and l ∈ L = {1, . . . , R̄} stands for the region
where the disease has already existed, and R̄ is the upper bound for the number
of infected regions. Suppose we have a total of six regions as shown in Figure B.1,
r ∈ R = {UNK,MNK,LNK,UI,MI, LI}. For each region r, denote the number
of infections detected in the first period (the first set of infected people) by Ir.
1. Find the First Reported Cases in Region r We first check the WHO case
situation report [WHO, 2020a] and determine the first group of cases discovered in
each defined region.
2. Find Existing Cases in Surrounding Regions at the Same Time Period
We assume that the first group of infected individuals discovered in region r might
have only come from the regions that already have infections at the same time period
or before. Thus, using the WHO situation report [WHO, 2020a], we choose a subset
of regions l ∈ L surrounding region r, which have discovered infections before region
r, as the possible emigration regions, where Il 6= 0. Specifically, since the average
time from infected to either recovered and funeral, with or without treatment, is from
one week to three weeks, we calculate the total confirmed cases in region l within the
three-week interval of the time period where the first infection is seen in region r, Il.
3. Calculate How Many Cases in Region r Might Have Come from Each of
the Surrounding Region In this step, we calculate the distance Drl between each
main region considered in Figure B.1 using Google Maps (Table B.3). We assume that
the number of infected cases migrated from a possible emigration region l to region
r is negatively correlated with Drl. Therefore, we compute the ratio of Drl and the
sum of the distances from region r to all possible emigration regions, and multiply
it with the total migrated infected cases Ir, to calculate the infected population in
region r that resulted from people moving from region l to r, denoted by Îl→r, as





Ir, ∀r ∈ R, ∀l ∈ L. (B.1)
4. Calculate the Proportion of Infected Individuals for Each of the
Surrounding Region In this step, we calculate the infection ratio at region l,
i = Il/Ul, where Ul is the population of area l. We also assume that we should have









where Îl→r represents the infected people who immigrate from region l to region r,
as given in Equation (B.1), and Ûl→r stands for the migration population from l to
r, which is the parameter that we want to estimate to calculate the migration rate.
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5. Calculate the Migration Rate Between Each Region Substituting
Equation (B.1) in Equation (B.2) and re-organizing it, the number of people that









Since we formulate the model based on the short-term migration, we assume that
those migration population is temporary (for business travel, cargo delivery, etc.)
and migrated population will come back to the original region. Thus, the number
of immigrated people from new infection regions r to the emigration regions l is
estimated the same as the number of people moving from emigration regions l to the
new infection regions r, i.e., Ûl→r = Ûr→l.
Finally, the migration rate from region l to region r is calculated by dividing






Because we have Ûl→r = Ûr→l, similar to Equation (B.4), the migration rate from





Additionally, suppose a considered region b ∈ R does not have any existed
infections. In that case, we can estimate the migration rate based on the distance
between region l and region r, for which the migration population from l to r is






Then we can use Equations (B.4) and (B.5) to calculate the migration rate between
region b and region r.
Here, we note that the estimation of the migration rate based on the distance
between each region may not be accurate in some cases due to the popularity of a
region and social effects. For instance, larger short-term migrations occur between
cities rather than a city and a village because of the greater opportunities in urban
locations and the corresponding social behavior. Therefore, to calculate the migration
rates, the locations that have similar social environments should be selected from each
region to minimize the impact of social effects on human mobility. In our case, each
location selected from a region is a metropolitan of that region.
Example. As an example, consider the case of MNK. The WHO report [WHO,
2020a] shows that MNK discovered the first three cases on September 11th, 2018,
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and at this time, only UNK and LI had infected cases. Thus, we assume that newly
infected cases in MNK come from these two regions. The proportion of the distance
from the main cities of UNK and LI to the main city in MNK is 57.5/145. So we
assume that 71.6% (1.86) of the three cases in MNK come from UNK, and 29.4%
(1.14) of them come from LI. The proportion of infections in UNK and LI is 0.00001
(21 over 1861730) and 0.00001 (2 over 148, 387). Using Equation (B.3), the migration
population of UNK and LI to MNK is estimated as ÛUNK→MNK = 164, 896 and
ÛLI→MNK = 84, 581. Then the migration rate from UNK to MNK is calculated
as iUNK→MNK = 0.0886 , and the migration rate from LI to MNK is computed as
iLI→MNK = 0.5700. On the other hand, because we assume that ÛMNK→UNK =
ÛUNK→MNK = 164, 896, the migration rate from MNK to UNK is calculated as
iMNK→UNK = 0.0685, and the migration rate from MNK to LI is given as iMNK→LI =
0.0351.
The estimated migration rates between each region (Figure B.1) are presented
in Table B.4.
Table B.3 Geographical Distance between Regions (KM)
From \ To UNK MNK LNK UI MI LI
UNK 57.5 358 467 202 92.6
MNK 301 523 258 145




Table B.4 Migration Rate between Regions of North Kivu and Ituri
From \ To UNK MNK LNK UI MI LI
UNK 0.0886 0.0012 0.0016 0.0424 0.0345
MNK 0.0685 0.0059 0.0025 0.0851 0.0351
LNK 0.0081 0.0511 0.0935 0.0062 0.0023
UI 0.0138 0.0283 0.1200 0.0795 0.0088
MI 0.1254 0.0735 0.0050 0.0273 0.0167
LI 0.1456 0.5700 0.0044 0.0129 0.0711
B.1.3 Resource Allocation Cost Data
Table B.5 gives the fixed cost of locating Ebola treatment centers (ETCs) and the
variable or per-person cost of the Ebola treatment. The treatment cost includes the
fixed cost for establishing each type of ETCs (either 50 or 100-bed ETC), isolation
unit center, and laboratory diagnosis. Additionally, each facility has a variable
running cost mainly composed of treating infected people and contact tracing of
the infected individuals. Safe burial cost is also included for safely burying infected
dead bodies. Fixed costs are one-time; however, all other cost values given in Table
B.5 are presented for a three-week period. For example, an Ebola treatment center’s
variable cost represents the cost of treating one infected individual over three weeks.
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Table B.5 Summary of Fixed and Variable Treatment Costs in 50 (100)-Bed ETC
Cost description Fixed Cost Variable cost*
Ebola treatment center $386,000 ($694,800) $13,215
Isolation unit center (IUC) $112,500 $1,699
Laboratory diagnosis $100,000 $810
Subnational technical services $3,375
Contact tracing $1,692
Safe burial
Total $598,500 ($1,077,300) $20,791
* Variable and safe burial costs are given for a period of three weeks.
B.1.4 Epidemiological Data
In this subsection, we present the values of the parameters that describe the disease
transmission among compartments of the EVD that were described in Section 3.3.2
in North Kivu and Ituri of DRC.
Table B.6 Transmission Parameters and Three-Weekly Rates for the Ebola
Outbreak
Parameter Description Data Reference
North Kivu Ituri
χ1 Rate of fatality without treatment 0.527 0.372 WHO [2020c],
WHO E. R. Team [2014]
χ2 Rate of fatality with treatment 0.383 0.288 WHO [2020c],
WHO E. R. Team [2014]
χ3 Rate of recovery without treatment 0.695 0.725 WHO [2020c],
WHO E. R. Team [2014]
χ4 Rate of recovery with treatment 0.937 0.98 WHO [2020c],
WHO E. R. Team [2014]
χ5 Safe burial rate 2.22 2.13 WHO [2020c],
WHO E. R. Team [2014]
σr Transmission rate in the community 0.648 0.54 Camacho et al. [2014]
θ2,r Transmission rate at a traditional funeral 2.04 2.19 Camacho et al. [2014]
βr Vaccination effectiveness rate 0.975 0.975 WHO [2019c]
εr Probability of transition from vaccinated
to susceptibles 0.06 0.06 WHO [2018]
Table B.7 Three-Weekly Values for Vaccine Supply Upper-Bound (Gωj ) and the
Uncertain Transmission Rate (θω1,r) for the Ebola Outbreak( High (Low) Realization
for Gωj Implies Low (High) Realization for θ
ω
1,r)





High (4500, 0.948) (4500, 0.84) Camacho et al. [2014],
WHO [2019a]




AN AGENT-BASED VACCINE ALLOCATION MODEL FOR
CONTROLLING COVID-19
Figures C.1, C.2, and C.3 show the results of model validation against the real
outbreak data for all the counties in New Jersey.
Figure C.1 Cumulative infections (thousands) throughout the planning horizon for
New Jersey counties - 1.
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Figure C.2 Cumulative infections (thousands) throughout the planning horizon for
New Jersey counties - 2.
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Figure C.3 Cumulative infections (thousands) throughout the planning horizon for
New Jersey counties - 3.
Figures C.4, C.5, and C.6 show the results of the cumulative number of infections
under different budget levels for all the counties in New Jersey.
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Figure C.4 New Jersey cumulative infections under different budget levels - 1.
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Figure C.5 New Jersey cumulative infections under different budget levels - 2.
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Figure C.6 New Jersey cumulative infections under different budget levels - 3.
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